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 CHAPTER I 
 
INTRODUCTION 
 
Lipoxygenase catalysis: reactions with polyunsaturated fatty acids 
Widely expressed in plants and animals, lipoxygenases (LOX) are a class of non-
heme iron dioxygenases that incorporate a molecule of oxygen into polyunsaturated fatty 
acids with at least one 1Z,4Z-pentadiene unit, yielding fatty acid hydroperoxides (1). The 
hydoperoxide products, being relatively unstable, will often undergo further 
transformation to bioactive molecules such as leukotrienes, which are pro-inflammatory 
lipid mediators in inflammatory diseases such as asthma (2,3).  
Within the LOX family, soybean LOX-1 and rabbit reticulocyte 15-LOX are the 
best studied mechanistically (4,5). The same catalytic mechanism has been proposed for 
the two enzymes (Figure 1). Briefly, the active site Fe3+, together with one of its six 
ligands, a hydroxide ion, abstracts a hydrogen atom from the fatty acid substrate, forming 
a Fe2+-H2O complex and a fatty acid radical. The fatty acid radical then combines with a 
triplet O2 diradical to form a peroxy radical. Finally, the peroxy radical obtains the 
hydrogen atom back from the Fe2+-H2O complex, forming the hydroperoxide product and 
regenerating the ferric enzyme, thus completing a catalytic cycle.  
 
Figure 1: The catalytic cycle of LOX enzymes 
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Molecular oxygen in the atmosphere exists in the triplet state, and triplet oxygen 
does not react with covalently complete hydrocarbon molecules (6). To overcome this 
difficulty, either molecular oxygen or the hydrocarbon substrate has to be activated. LOX 
enzymes employ the latter strategy to activate the polyunsaturated fatty acid substrate to a 
fatty acid radical, which will then readily react with triplet molecular oxygen. The 
chemistry of this substrate activation involves the homolytic cleavage the bisallylic C-H 
bond in the fatty acid substrate by the active site Fe3+-OH complex. The moderately high 
bond dissociation energy (BDE) of the bisallylic C-H bond (e.g., ~ 73 kcal/mol for C11-H 
in linoleic acid (7)) dictates that the redox potential of the active site iron should be 
moderately high for the bond cleavage to occur (6). Indeed, a moderately high redox 
potential, ~ 600 mV, has been demonstrated experimentally in soybean LOX-1 (8).  
A remarkable feature of LOX catalysis is that the incorporation of molecular 
oxygen is often regio- and stereospecific; each LOX usually makes a single optically 
active hydroperoxide. This implies two facets of enzymatic control: 1) only one hydrogen 
atom on the substrate will be abstracted, and 2) on the subsequently formed pentadienyl 
radical, only one side of one reactive carbon will be preferentially accessible to molecular 
oxygen. The first facet can be explained if the substrate adopts a relatively rigid 
conformation in the enzyme active site so that only one of the hydrogens is placed in 
proximity to the iron and thus available for abstraction. As to the second facet, however, 
a considerable debate continues, centering on the means by which oxygen access is 
controlled in the enzyme active site. O2 channels have been proposed (9,10), yet simple 
steric shielding of O2 by amino acid residues within the fatty acid binding cavity is also a 
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possibility (11). It is foreseeable that this conflict of views may eventually be resolved 
when xenon gas is successfully used to probe LOX enzymes in the years to come.  
In 2004, this laboratory made the discovery that the regio- and stereospecificity of 
LOX enzymes is partly controlled by an active site residue, conserved as Gly in R-LOX 
(i.e., LOX enzymes that make products in the R configuration) and Ala in S-LOX (12). 
Swapping the two residues by site-directed mutagenesis almost always results in 
swapping of stereospecificity along with a shift in regiospecificity in the product (13-16); 
for example, the Ala-to-Gly mutation in 8S-LOX leads to a switch of oxygenation 
specificity from 8S to 12R. To explain this, a model has been proposed (Figure 2) (14). 
In essence, this model states that the Ala/Gly residue is aligned with one of the two 
reactive terminal carbons on the activated pentadiene unit, and that whereas the smaller 
Gly allows O2 to react at this site, the bigger Ala blocks the space for O2 thus causing a 
switch of oxygen insertion to the other reactive terminal carbon. Recently, based on a 
high-resolution crystal structure of coral 8R-LOX, Newcomer and colleagues propose a 
new model where the space for O2 is made available by a nearby Leu residue (rather than 
by the Ala/Gly directly), which alternates between two positions. This controls the 
position of O2 within the active site depending on whether the neighboring residue is Ala 
or Gly (17). At present, with no crystal structure of LOX enzymes with bound fatty acid 
substrate available, it is difficult to ascertain which model depicts more accurately the 
role of the Ala/Gly residue in the control of oxygen access. 
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Figure 2: A model to explain the R or S specificity of LOX enzymes. Reproduced from 
(14).  
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Reactions of lipoxygenases with fatty acid hydroperoxides  
In addition to catalyzing oxygenation of polyunsaturated fatty acids, LOX 
enzymes also react with fatty acid hydroperoxides, especially with their own product 
from the oxygenation reaction. One such reaction common to all LOX enzymes occurs at 
the initial stage of LOX-catalyzed oxygenation of polyunsaturated fatty acids, known as 
the activation step. For soybean LOX-1, for example, the ferrous enzyme will be 
transformed by an equimolar amount of 13S-hydroperoxylinoleic acid (13S-HPODE) to a 
ferric species (18), which is the catalytically active form in the oxygenation reaction (19). 
Because the native LOX is usually in the ferrous state, a kinetic lag phase is commonly 
observed in the oxygenation reaction of the native enzyme; the reaction is usually started 
with a trace amount of fatty acid hydroperoxides present in the substrate solution, and 
only when sufficient hydroperoxide product accumulates will the native ferrous enzyme 
be fully activated to the ferric form and reach the maximal rate. Consistent with this, the 
lag phase can be abolished by pre-incubation of the enzyme with an appropriate fatty acid 
hydroperoxide or, conversely, can be prolonged in the presence of a reagent that reduces 
hydroperoxides (e.g., glutathione and glutathione peroxidase or SnCl2) (20).  
 
Fe(II) soybean LOX-1 + 13S-HPODE → Fe(III) soybean LOX-1 + unknown products 
 
It is important to recognize at this point that this type of reaction of LOX with 
fatty acid hydroperoxides is a single turnover event rather than a self-propagating 
catalytic reaction; once the enzyme is oxidized the ferric form, it will no longer react with 
the fatty acid hydroperoxide. Because of this single turnover nature of the reaction, the 
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products are formed in minute amounts and have not been identified. Although 
substantial evidence suggests that an alkoxyl radical is produced (21), the fate of this 
alkoxyl radical is poorly understood.  
Fueled by the potential clinical applications, investigations into LOX inhibitors 
led to the discovery of a novel mechanism of inhibition in the late 1980s and early 1990s 
(22-26). Several antioxidants, including butylated hydroxyanisole (BHA) and 
nordihydroguaiaretic acid (NDGA), are effective LOX inhibitors, yet these antioxidants 
inhibit LOX enzymes by reducing the catalytically active, ferric enzyme to the 
catalytically inactive, ferrous form (27), instead of by scavenging the enzyme-bound 
radicals as originally proposed (4). After one year into the research, I realized that this 
class of redox-based LOX inhibitors would afford an opportunity to obtain the products 
from the LOX activation reaction in large amounts. As shown in Figure 3, whereas the 
fatty acid hydroperoxide oxidizes the ferrous enzyme to the ferric enzyme, a redox-based 
inhibitor such as NDGA will in turn reduce the ferric enzyme back to the ferrous enzyme. 
Thus, a catalytic cycle is established in the presence of NDGA and now the fate of the 
fatty acid hydroperoxide can be easily followed with a catalytic amount of enzyme.  
 
 
 
 
 
Figure 3 LOX-catalyzed redox reaction between a fatty acid hydroperoxide (ROOH) and 
NDGA, a redox-based LOX inhibitor.  
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Under anaerobic conditions, a fatty acid substrate reacts with a LOX the same 
way as does NDGA, i.e., it will effectively reduce the ferric LOX to the ferrous form 
(28). Recall that in the LOX catalytic cycle (Figure 1), O2 enters the reaction pathway 
after the hydrogen abstraction step (29). In the absence of the reacting O2, the fatty acid 
radical formed from hydrogen abstraction will eventually escape from the enzyme active 
site, leaving the enzyme in the ferrous state. If a fatty acid hydroperoxide is also present 
in the incubation, it would in turn oxidize the ferrous enzyme back to the ferric form with 
itself being converted to an alkoxyl radical. Thus, under anaerobic conditions, LOX 
enzymes will catalyze a redox reaction between a fatty acid and a fatty acid 
hydroperoxide (Figure 4). A well-known example is the anaerobic reaction of soybean 
LOX-1 with linoleic acid and 13S-HPODE, which gives a complex mixture of products, 
including fatty acid dimers, ketones and aldehydes (30,31). In analyzing this complexity, 
one should realize that the enzyme generates only two species, the linoleic acid radical 
and the 13S-HPODE-derived alkoxyl radical, and the complexity arises only when these 
two radicals are released into the solution and allowed to react on their own (32).  
 
 
 
 
 
 
Figure 4 LOX-catalyzed redox reaction between a fatty acid hydroperoxide (LOOH) and 
a fatty acid (LH) under anaerobic conditions. 
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A linoleic acid-independent anaerobic reaction of soybean LOX-1 with 13S-
HPODE or 9S-HPODE has also been reported (33). This reaction is ~ 1500 fold slower 
than the linoleic acid-dependent reaction and gives a different set of products, mainly 
epoxyalcohols. A variation of this reaction is the so-called purple enzyme degradation 
(34). The purple enzyme refers to a complex between ferric soybean LOX-1 (or some 
other LOX enzymes such as soybean LOX-3) and 13S-HPODE, formed and 
spectroscopically detected at high concentrations of enzyme (e.g., 100 µM) and 2-3 
higher concentrations of 13S-HPODE (18). The purple color stems from a charge transfer 
complex between the ferric iron and the hydroperoxide anion. This purple enzyme is 
metastable and will revert to the free ferric enzyme concomitant with conversion of 13S-
HPODE to mainly a single epoxyalcohol with 70% retention of both oxygens from the 
hydroperoxide group (Figure 5) (34). It is found that O2 inhibits this degradation process 
(35). Therefore, under aerobic conditions, the degradation occurs with a lag phase during 
which O2 is gradually consumed (and O2 will eventually all be consumed because the 
enzyme and the fatty acid hydroperoxide are both at high concentrations relative to O2, 
i.e., > 240 µM). It is estimated that the specific epoxyalcohol is mostly formed under 
anaerobic conditions (35).   
 
                            
OOH OHO
139  
Figure 5: Formation of a single epoxyalcohol during the purple enzyme decomposition. 
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Epidermal lipoxygenase-3: an atypical lipoxygenase exhibiting a prominent 
hydroperoxide isomerase activity 
Human epidermal lipoxygenase 3 (eLOX3) is phylogenetically related to the LOX 
enzymes, hence “LOX” in its name. Unlike conventional lipoxygenases, however, 
eLOX3 is claimed to be “totally lacking” dioxygenase activity with polyunsaturated fatty 
acids such as arachidonic acid (36,37). It appears that all the well-conserved sequences, 
including the five amino acid ligands of the iron, remain intact in eLOX3. Thus, it is 
unclear why eLOX3 does not react with polyunsaturated fatty acids.  
In 2003, this laboratory discovered in eLOX3 a novel hydroperoxide isomerase 
activity that converts fatty acid hydroperoxides into epoxyalcohols and ketones (36,37). 
This reaction of eLOX3 with fatty acid hydroperoxides exhibits all the hallmarks of true 
enzyme catalysis: speed, substrate selectivity, and product specificity. For example, 
human eLOX3 converts its best substrate, 12R-HPETE (12R-hydroperoxyarachidonic 
acid), to a single epoxyalcohol isomer and a ketone with a turnover number of 5 s-1. Even 
more remarkably, mass spectrometric analysis of the products from the reaction of 
eLOX3 with an 18O-labeled 15S-HPETE indicated that both oxygen atoms in the 
epoxyalcohol product originate from the hydroperoxide group; thus this is truly an 
isomerase activity. By analogy to the hematin-catalyzed conversion of fatty acid 
hydroperoxides (38), a mechanism for eLOX3 catalysis has been proposed (Figure 6). 
First, Fe2+ eLOX3, the proposed active species, homolytically cleaves the hydroperoxide 
substrate into an alkoxyl radical, and a “HO⋅” trapped in the iron center in the form of a 
hydroxide ion (specifically, the Fe2+ donates an electron to the “HO⋅”, forming a Fe3+-OH 
complex) (step 1); the alkoxyl radical may isomerize to an epoxyallylic radical (step 2), 
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which then combines with the trapped “HO⋅” to form the epoxyalcohol product (step 3); 
alternatively, the alkoxyl radical may lose a hydrogen atom, probably to the Fe3+--OH 
complex, forming the ketone product (step 4). 
 
 
 
 
 
 
 
 
 
Figure 6: Proposed mechanism for eLOX3 catalysis. From (37). 
 
Although unprecedented among LOX enzymes, the chemistry of the 
hydroperoxide isomerase activity is not new. As mentioned above, hematin catalyzes 
similar reactions, albeit with no specificity. In fact, the first chemical step (step 1 in 
Figure 5), involving homolytic cleavage of the O-O bond, is a facile reaction of ferrous 
ion (or other transition metals at the lower oxidation state, such as Cu2+), whether it is in 
aqueous solutions, in model complexes or in proteins (39). The ferrous form of typical 
LOX enzymes is no exception; as noted in the previous section, the LOX activation step, 
common to all LOX enzymes, uses the same chemistry to give the same alkoxyl radical 
intermediate. Thus, the difference between eLOX3 and typical LOX enzymes lies in the 
fate of the alkoxyl radical, one resulting in preservation of the ferrous state of the enzyme 
 11 
via the “oxygen rebound” mechanism, the other resulting in oxidation/activation of the 
enzyme via an yet unknown mechanism.  
It may not be merely a coincidence that oxygenase activity is absent while an 
unusual hydroperoxide isomerase activity is present in eLOX3. Conceivably, certain 
steric factors of the enzyme active site may create a local environment that is depleted of 
O2, which may account for both the lack of oxygenase activity and the possession of the 
hydroperoxide isomerase activity, the latter being easily understood by recalling that the 
linoleic acid-independent reaction of soybean LOX-1 with 13S-HPODE under anaerobic 
conditions also gives epoxyalcohols (33,34).  
It is also possible the active site iron of eLOX3 may have a lower than normal 
redox potential (37). As noted earlier, this redox requirement is imposed by the first 
chemical step of the dioxygenase cycle, which involves homolytic cleavage of a bisallylic 
C-H in the fatty acid substrate by the active site Fe3+-OH complex. Therefore, if tuned to 
a lower redox potential, the iron in eLOX3 may not be able to perform hydrogen 
abstraction. It is worth noting that although a lower than normal redox potential may 
explain the lack of dioxygenase activity in eLOX3, it does not explain why the 
hydroperoxide isomerase activity is uniquely present in this enzyme.  
Having read a few textbooks and dozens of papers, I decided in Aug 2007 that I 
should try some experiments on eLOX3. The first experiment was to test the lack of 
active site oxygen hypothesis, by seeing if eLOX3 would react with arachidonic acid in 
the presence of the fatty acid hydroperoxide 12R-HPETE. Since a similar reaction occurs 
with soybean LOX-1 under anaerobic conditions, this should work for eLOX3 if its 
active site is indeed anaerobic. After a trial or two, disappointed by the seemingly 
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negative results, I quickly abandoned the experiment. (When this experiment was 
revisited and more rigorously done in 2010, to my own surprise, positive results were 
obtained).  
My attention then shifted to the low redox potential hypothesis. To test this, I 
questioned whether the unusual fatty acid I studied in my rotation project, 20:3-
9E,11Z,14Z (structure in Figure 7), is a substrate of eLOX3. The organic chemistry 
textbook I had read tells that this fatty acid is easier to oxidize than arachidonic acid, 
because the fatty acid radical derived from it is stabilized by one more resonance 
structure than the corresponding arachidonic acid radical (Figure 7). The reaction 
worked. Thus with this momentum I wrote the proposal, passed the Phase II exam, and 
formally began my dissertation research. (The second part of my research, on the 
physiological function of 12R-LOX and eLOX3, was not yet in the plan at the time.) 
 
 
Figure 7 Resonance structures of the fatty acid radicals derived from arachidonic acid 
and 20:3-9E,11Z,14Z. 
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The physiological role of 12R-LOX and eLOX3 in the skin 
The barrier function of the skin 
Our skin provides a barrier that protects us from dehydration and invasion by 
foreign substances. Without this skin barrier, humans would not survive on dry land. 
With an impaired skin barrier, most often due to genetic mutations, humans would have 
ichthyosis, a heterogeneous group of disorders of dry scaly skin (40). The fish-like scales 
characteristic of ichthyotic skin result from hyperproliferation of skin cells 
(keratinocytes), which is a compensatory response to the impaired barrier function (40).  
The skin can be dissected into epidermis (the outer layer), dermis (the middle 
layer), and subcutaneous tissue (the inner layer). The epidermis can be further divided, 
from the innermost to the outermost, into stratum basale (the basal layer), stratum 
spinosum (the spinous layer), stratum granulosum (the granular layer), and stratum 
corneum (the horny layer) (Figure 8). Though seemingly a static structural tissue, the 
epidermis undergoes constant changes. In the short life span of a keratinocyte (~ one 
month), it will undergo drastic morphological and cellular changes as it migrates through 
the multiple layers towards the surface, will serve the barrier function for a few days 
when arriving at the stratum corneum, and eventually will be shed off from the skin 
surface as it is replaced by a newly arrived, younger cell. To enable this constant self-
renewal, the epidermis in fact stores a large number of stem cells in its basal layer and 
thus is also of interest to researchers studying stem cells (41). Here, however, the focus 
will be given instead to the barrier layer, the stratum corneum. 
 
 14 
 
Figure 8 Anatomy of the skin. From Shier, Butler, & Lewis (1999) Hole’s of Human 
Anatomy & Physiology, 8th edition.  
 
How does the stratum corneum provide the barrier function? This can be 
explained by the “bricks and mortar” model to a satisfactory degree of accuracy (42). In 
this model, “bricks” refer to the cells in the stratum corneum, a.k.a. corneocytes. These 
cells, anucleate and filled with keratin bundles, provide the framework and the required 
mechanical strength of the barrier. The other component, “mortar”, refers to the lipids 
that fill the intercellular spaces, consisting of an approximately equimolar mixture of 
ceramides, cholesterol, and free fatty acids. Notably, phospholipids are not a component. 
These lipids are organized into stacked membrane sheets. These hydrophobic membrane 
sheets confer the essential water impermeable properties of the skin barrier. As we shall 
see later, the skin barrier function is critically dependent on these membrane sheets in the 
correct, ordered, structure, which in turn relies not only on the correct lipid composition, 
but also on the presence of a unique lipid-protein structure at the surface of corneocyte.  
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Formation of the skin barrier 
As mentioned earlier, keratinocyte differentiation involves a complex program of 
morphological and cellular changes. Here we will focus on the final stage of keratinocyte 
differentiation, i.e., the transition from the granular cell to the corneocyte, during which 
the skin barrier is being formed (Figure 9).  
 
 
Figure 9 Skin barrier formation. The barrier properties are mainly conferred by the 
ordered lamellar membranes outside the cell, the cross-linked cornified protein envelope 
beneath the cell surface, and the monolayer of lipid envelope at the cell surface. The 
plasma membrane composed of phospholipids is eventually replaced by the lipid 
envelope composed mainly of ω-hydroxyceramides covalently bound to proteins (not 
shown). From Ref. (43).   
 
The granular cell, as its name implies, is marked by the occurrence of granules in 
the cytoplasm, including lamellar granules. The lamellar granules are secretory organelles 
loaded with lipids that are organized into stacked coin-like disks, together with numerous 
hydrolytic enzymes that will be activated once secreted into the extracellular space. The 
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coin-like disks in the lamellar granules appear to be flattened membrane vesicles 
composed of phospholipids, glucosylceramides, cholesterol, and free fatty acids.  
As the granular cell transforms into the corneocyte, the lamellar granules will 
migrate to the apical side of the cell, and then the bounding membrane of the lamellar 
granules will fuse with the plasma membrane, while the contents, including the 
membrane disks and the hydrolytic enzymes, will be released into the intercellular space. 
Subsequently, several enzymatic reactions will come into play (44). Inside the cell, just 
beneath the plasma membrane, proteins such as involucrin and loricrin will be 
extensively crosslinked by sulfhydryl oxidases and transglutaminase-1, ultimately 
forming a 10 nm- thick protein envelope. Outside the cell, the polar lipids of the extruded 
membrane disks will be processed by the activated hydrolytic enzymes to less polar 
lipids, in particular free fatty acids and ceramides; glycerophospholipids will be all 
degraded to furnish free fatty acids, and glucosylceramides and sphingomyelins will be 
converted into ceramides. At the cell surface, the phospholipids will also be degraded, 
and one major lipid class originating from the bounding membrane of lamellar granules, 
acylglucosylceramides (see below), will be processed to ω-hydroxyceramides which in 
turn will be covalently coupled to the protein envelope via an ester bond between the ω-
hydroxyl groups on the ceramides and glutamine/glutamate side chains on the proteins. 
The covalent coupling is thought be catalyzed by transglutaminase-1 (45). This 
monolayer of covalently bound ω-hydroxy-ceramides is distinct from the original plasma 
membrane, which is a phospholipid bilayer, although both appear in similar dimensions 
(~ 5 nm thick). To distinguish the two, the monolayer of covalently bound ω-hydroxy-
ceramides is given the name corneocyte lipid envelope (CLE).  
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Upon formation of the corneocyte lipid envelope and lipid maturation catalyzed 
by hydrolytic enzymes, the extruded membrane disks in the extracellular space will fuse 
edge-to-edge to form ordered, elongated, lamellar membranes sheets (46), which are 
essential for the structural integrity of the water barrier. It is hypothesized that the lipid 
envelope serves as a scaffold for the deposition of lipids, thereby facilitating the 
formation of ordered, elongated, lamellar membrane sheets (47).  
Essential fatty acids and skin barrier function 
It has been known for 80 years that essential fatty acid deficiency leads to dry 
scaly skin (48,49). The skin phenotype induced by essential fatty acid deficiency, as in 
ichthyosis, reflects an underlying defect in the skin water barrier. Consistent with this, 
essential fatty acid deficient animals, including humans, show significantly increased 
transepidermal water loss compared to their normal counterparts (50-52).  
There was once a debate on which essential fatty acid, arachidonic or linoleic 
acid, is responsible for normal functioning of the skin. Both fatty acids are effective in 
reversing the scaly skin defect from essential fatty acid deficiency, either when fed to the 
animals (53) or when topically applied to the skin (54). The prostaglandin PGE2 derived 
from arachidonic acid was once considered as a mediator of the epidermal effect of 
essential fatty acids, since a group reported that cutaneous application of PGE2 partially 
alleviated the scaliness of the skin of essential fatty acid deficient animals (55). However, 
the involvement of PGE2 in the barrier function was ruled out later, when it was shown 
that the level of transepidermal water loss remains unchanged upon PGE2 application, 
that indomethacin, a potent cyclooxygenase inhibitor, does not inhibit the curative effect 
of arachidonic or linoleic acid, and that columbinic acid (5trans,9cis,12cis-18:3), which 
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cannot be converted to prostaglandins, is equally effective in reversing the scaly skin 
condition (54,56). Even the involvement of PGE2 in preventing keratinocyte 
hyperproliferation (i.e., scaliness) per se has been called into question, since the initial 
result could not be reproduced in a prominent lab studying essential fatty acids (54). The 
lesson here is that scaliness is an effect secondary to the primary barrier defect, and any 
conclusion regarding whether or not a molecule is involved in the barrier function should 
be made only from direct, rigorous, functional assays such as measurement of 
transepidermal water loss.  
A major breakthrough pointing to a role of linoleic acid in skin barrier function 
came when two novel classes of sphingolipids, acylglucosylceramides and 
acylceramides, both of which contain esterified linoleate, were discovered in the granular 
layer and the stratum corneum respectively (Figure 10) (57-63). In essential fatty acid 
deficient animals, the linoleate moiety on the two classes of sphingolipids is substituted 
by oleate (64). When either arachidonic or linoleic acid is fed to essential fatty acid 
deficient rats, a correlation is seen between restoration of transepidermal water loss and 
specific incorporation of linoleic acid, but not arachidonic acid, into 
acylglucosylceramides and acylceramides (53). Further evidence suggests that 
arachidonic acid will be retroconverted into linoleic acid under essential fatty acid 
deficient conditions (65), whereas the reverse conversion from linoleic acid to 
arachidonic acid cannot occur in the skin because the Δ-6 and Δ-5 desaturase enzyme 
activities required for the conversion is absent (66). It is inferred, therefore, that the 
action of essential fatty acids in the skin barrier formation is exerted via the unique 
linoleate-containing acylglucosyceramides and acylceramides.  
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Figure 10 Structure of a typical species of acylglucosylceramide and acylceramide. 
 
It has been demonstrated by Houtsmuller and coworkers that topical application 
of several other n-6cis,n-9cis fatty acids in addition to linoleic and arachidonic acids is 
equally effective in reversing the scaly skin condition of essential fatty acid deficient rats 
(54). These results are best explained if, similar to arachidonic acid, these other effective 
fatty acids are first converted to linoleic acid, which is then incorporated into the 
linoleate-containing acylglucosylceramides and acylceramides to exert the function. The 
only known exception is columbinic acid (5trans,9cis,12cis-18:3), which itself is 
incorporated into acylglucosylceramides and acylceramides to a significant extent (53).  
The exact mechanism through which linoleate-containing acylglucosylceramides 
and acylceramides help establish and maintain the skin barrier, however, is not 
completely understood. Acylglucosylceramides, which are localized to the lamellar 
granules in the granular cells, are proposed to function by promoting the formation of the 
stacked coin-like disk structures in lamellar granules (Figure 11) (58). Consistent with 
this, it is found in vitro that acylglucosylceramides readily induce flattening of 
phospholipid liposomes to membrane disks similar to what is observed in lamellar 
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granules (67). The problem with this hypothesis, however, is that stearate-containing 
acylglucosylceramides are as effective as linoleate-containing acylglucosylceramides in 
in vitro experiments. Acylceramides, formed from deglycosylation of the extruded 
acylglucosylceramides by β-glucocerebrosidase, reside instead in the intercellular space 
of the stratum corneum. Biophysical studies suggest that the presence of acylceramides is 
essential for the correct phase separation of the intercellular lamellar membrane sheets 
(68). Yet oleate-containing acylceramides show only subtle differences from linoleate-
containing acylceramides in this respect (68). Taken together, it appears that a new 
hypothesis is needed to fully explain the specific requirement for linoleate in 
acylglucosylceramide and acylceramides (See below).  
 
Figure 11 Proposed model of acylglucosylceramide function in the flattening and 
stacking of lipid vesicles to generate the double bilayer structure of the internal lamellae 
of lamellar granules. From Ref. (47).  
 
A few years after the discovery of acylglucosylceramides and acylceramides, it 
was realized that in addition to free extractable lipids, there are also covalently bound 
lipids in the stratum corneum (69,70), which can be liberated by mild-alkaline hydrolysis. 
These bound lipids, including ω-hydroxyceramides, ω-hydroxy very long chain fatty 
acids and saturated fatty acids, constitute the corneocyte lipid envelope (71), a unique 
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cellular structure essential for the barrier function (see above). Meanwhile, it was 
observed in pig epidermis that the proportion of acylglucosylceramides among all 
glucosylceramide species, ~50%, is considerably higher than that of acylceramides 
among all ceramides, ~ 10% (72). Since acylceramides in the stratum corneum derive 
exclusively from deglycosylation of the extruded acylglucosylceramides from the 
granular cells (73,74), this observation implies that a fraction of acylceramides is further 
metabolized, possibly to ω-hydroxyceramides that will then be covalently attached to 
proteins. This proposed intermediacy of acylceramides to the bound ω-hydroxyceramides 
is further supported by a study on the time course of lipid synthesis in pig epidermis 
pulsed with [1-14C]-acetate (75), and another study that analyzed the lipids of mouse 
epidermis at different embryonic stages (76). In both studies, the level of 
glucosylacylceramides transiently reaches a peak value at an early time point and then 
declines monotonously, concomitant with an increase in the level of ω-
hydroxyceramides. Acylceramides, as expected from a metabolic intermediate, either 
maintains a steady-state level (75) or declines concomitantly with glucosylacylceramides 
(76).  
As to how acylceramides are converted to the bound ω-hydroxyceramides, it is 
presumed that the linoleate would be cleaved off and recycled (47), or that some 
transesterification reaction would directly couple the ω-hydroxyl group to 
glutamate/glutamine residues on proteins (44). The latter proposition is inherently flawed 
in that for transesterification to occur, invariably one nucleophile (the ω-hydroxyl group 
on acylceramides) has to be replaced by another (which cannot be the electrophilic 
glutamate/glutamine carbonyl group), whereas the electrophile (linoleate) has to remain 
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the same. The former proposition is comparatively more attractive, and it seemingly 
represents an ideal mechanism for the skin to conserve the essential fatty acid, linoleic 
acid. However, it is still a matter of debate whether linoleic acid is recycled or not. On the 
one hand, recycling of linoleic acid is suggested by a study on an organotypic murine 
keratinocyte culture model of the skin (77). On the other hand, extensive oxygenation of 
linoleic acid instead is noted when the fatty acid is topically applied to essential fatty acid 
deficient rats to correct the skin defect (54).  
The extensive oxygenation of linoleic acid noted by Houtsmuller and colleagues 
is consistent with a new hypothesis I will propose in this dissertation, necessitating 
linoleate oxygenation by the two LOX enzymes, 12R-LOX and eLOX3, during the 
conversion of acylceramides to ω-hydroxyceramides. Another piece of evidence relevant 
in the present context is that in the epidermis of essential fatty acid deficient hairless rats, 
where the linoleate moiety in acylceramides is replaced by oleate, the amount of protein-
bound ω-hydroxyceramides is significantly reduced compared to that of normal rats, 
pointing to a defect in the metabolic pathway from acylceramides to bound ω-
hydroxyceramides caused by the fatty acid substitution (78). This stringent structural 
requirement for linoleate in acylceramides can be well explained if LOX enzymes are 
involved in the pathway, because linoleate is a LOX substrate, but oleate is not.  
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12R-LOX and eLOX3 and skin barrier function 
It has long been suspected that the effect of essential fatty acids on skin barrier 
formation might be mediated via LOX enzymes. Since the findings that feeding of 
ETYA, a COX/LOX inhibitor, to rats also induces extremely dry scaly skin similar to that 
seen in essential fatty acid deficiency (79), and that COX/prostaglandins are not involved 
in skin barrier formation (see the previous section), scientists in search of potential 
mediators of the effect of essential fatty acids have naturally shifted their attention to 
LOX enzymes and products.  
In an elegant study in 1985, Nugteren and coworkers demonstrated that when [1-
14C]-linoleic acid was topically applied to the skin of essential fatty acid deficient rats, 
some of the radioactivity was incorporated into a novel class of lipids, polyoxyacyl 
ceramides, which were deduced by the team to be LOX metabolites of the linoleate-
containing acylceramides (80). Furthermore, this conversion was not seen in their 
negative controls using either the LOX inhibitor ETYA or the linoleic acid analogues 
9trans,12cis-18:2, 9cis,12trans-18:2, and 9trans,12trans-18:2, none of which is a LOX 
substrate. Despite these control experiments, questions have been raised over the 
enzymatic nature of the polyoxyacyl ceramide formation (81). It can be argued, for 
example, that ETYA at the high concentrations used in the study serves also as an 
antioxidant, or that 9trans,12cis-18:2 or 9cis,12trans-18:2 is more difficult to autoxidize 
than linoleic acid. This issue would have been resolved if regio- and stereospecificity of 
the conversion could be demonstrated. Unfortunately the structures of the putative LOX 
metabolites, the polyoxyacyl ceramides, were not characterized in detail due to technical 
limitations at that time. Although the polyoxyacyl ceramides appeared to be a mixture on 
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TLC, it is possible that the mixture could result from unintended hydrolysis during the 
workup even if there was only a single LOX metabolite in vivo. Some epoxyalcohols 
would easily hydrolyze to a nonspecific mixture at pH < 3. Thus, to analyze this type of 
products, care should be taken to avoid acid-catalyzed hydrolysis.  
It is also worth mentioning that at the time, in the 1980s, the LOX enzymes in the 
skin were yet to be discovered. It was inferred from product analysis of incubations of 
human or rat epidermis with [1-14C]linoleic or arachidonic acid that there must be a 15-
LOX and a 12-LOX in human or rat epidermis (82), yet-as we will understand later-this 
type of classical biochemical experiment cannot detect LOX enzymes that prefer an ester 
to a free acid as substrate (e.g., murine 12R-LOX) or that do not use fatty acid/ester 
substrates at all (e.g., eLOX3).  
Since the 1990s, when molecular cloning became a commonplace technology, our 
knowledge of mammalian LOX enzymes has expanded exponentially. It is now known 
that all the LOX enzymes (e.g., the six in humans, Figure 12) are expressed in the 
epidermis to various degrees, yet only three of them, 12R-LOX, eLOX3, and 15-LOX-2 
(in humans, the mouse homologue of which is 8S-LOX) are specific to epithelial cells. 
Among these three, 12R-LOX and 15-LOX-2 were cloned, expressed, and characterized 
for the first time in our laboratory (83,84). As noted earlier (Chapter I-2), following its 
discovery eLOX3 immediately presented itself as a puzzle because, unlike other LOX 
enzymes, eLOX3 appeared not to react with polyunsaturated fatty acids. So what is the 
function of this strongly expressed (85) enzyme in the skin if it has no activity? (As we 
will see in Chapter II, the dioxygenase activity of eLOX3 is now uncovered, ten years 
after the enzyme was first cloned and expressed. However, this dioxygenase activity is 
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exhibited only under unusual circumstances, and we suspect that the physiological 
relevance of the enzyme residues in its unusual hydroperoxide isomerase activity.) 
 
 
 
Figure 12 Phylogenetic tree of human LOX enzymes 
 
The next advances towards a better understanding of the LOX enzymes in the 
epidermis came when a group of geneticists made a splendid discovery and proposed an 
unconventional pathway (86), which was then further shown by the former graduate 
student Zheyong Yu in this laboratory to be biochemically sound and feasible (37). In the 
human genetic study, mutations in 12R-LOX (ALOX12B) and eLOX3 (ALOXE3) were 
identified in non-bullous congenital ichthyosiform erythroderma (NCIE). The authors 
concluded that “it seems likely that the product of one of these enzymes may be the 
substrate of the other, and that they belong to the same metabolic pathway”. This 
suggestion by the geneticists led to the discovery in this laboratory of a new type of 
activity in eLOX3; instead of incorporating molecular oxygen into fatty acids, eLOX3 
shows a prominent hydroperoxide isomerase activity that converts fatty acid 
hydroperoxides into epoxyalcohols and ketones. Notably, the 12R-LOX metabolite of 
arachidonic acid, 12R-HPETE, was by far the best substrate among all the HPETEs 
examined. Thus, the genetic and biochemical evidence agree with each other, suggesting 
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a novel metabolic/signaling pathway in which 12R-LOX and eLOX3 work in tandem in 
the epidermis.  
More recent findings over the five years reinforced the importance of the 12R-
LOX/eLOX3 pathway for a competent skin barrier function. More inactivating mutations 
in 12R-LOX or eLOX3 in humans have now been identified, and the scope of affected 
patients has been extended to autosomal recessive congenital ichthyosis (ARCI), of 
which NCIE is a subtype (87,88). Knockout mouse models of both 12R-LOX and eLOX3 
have been generated (89,90). Both the 12R-LOX -/- and eLOX3 -/- mice die soon after 
birth due to excessive transepidermal water loss. A 12R-LOX functional knockout mouse 
has also been identified in an ENU genetic screen, which showed an identical phenotype 
(91). The more severe phenotype in the mice than in the patients is probably because 
mice have a larger surface area-to-volume ratio, or because mice have an inherently 
weaker barrier than humans.  
The arachidonate-derived hepoxilin connection in the epidermis? 
Since the discovery of the 12R-LOX/eLOX3 pathway in the skin, it was assumed 
that arachidonic acid is the natural substrate of this pathway, being converted via 12R-
HPETE to 8R-hydroxy-11R,12R-epoxyeicosa-5Z,9E,14Z-trienoic acid, one of the isomers 
of hepoxilin A3. [The name hepoxilin refers to two general classes of epoxyalcohols, 
hepoxilin A-type and hepoxilin B-type (Figure 13) (92)]. This assumption apparently 
agrees with the observation that a large amount of 12R-HETE is produced in human 
psoriatic scales (93). Yet psoriasis is an inflammatory, pathological condition that is not 
caused by an underlying barrier defect, and 12R-HETE or the hepoxilin A3 isomer has 
never been detected in normal skin.  
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Following the discovery of the hepoxilin A3 produced by the combined action of 
12R-LOX and eLOX3 on arachidonic acid, it was shown that this compound at µM 
concentrations activates PPARα in vitro (94). However, if this is the 12R-LOX/eLOX3 
pathway in the skin, the PPARα-/- mice should show the same phenotype as the 12R-
LOX-/- or eLOX3-/- mice. However, in the PPARα-/- mice, a normal permeability 
barrier is formed at a late embryonic stage despite an initial delay (95).  
 
Figure 13 General structures of hepoxilin A-type and B-type. Nonenzymic 
transformation from racemic hydroperoxide could lead to formation of all the individual 
isomers shown (plus the corresponding cis-epoxides, not shown). 12R-LOX and eLOX3 
form exclusively the 8R-OH-11R,12R-epoxy-hepoxilin A3 (boxed). From ref. (96).  
 
A major problem for the arachidonate-derived hepoxilin hypothesis is that mouse 
12R-LOX does not use free fatty acids (including arachidonic acid) as substrate, with the 
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long chain ω-3 fatty acid DHA being the only known exception (97). Instead, the enzyme 
prefers fatty esters. It was once postulated 8S-LOX might take the place of 12R-LOX in 
the hepoxilin pathway in mouse skin (98). This hypothesis is now rejected as the 12R-
LOX -/- mouse model clearly demonstrates the indispensable role of mouse 12R-LOX in 
skin barrier formation (89).  
A new hypothesis on the role of 12R-LOX and eLOX3 in the skin 
While there is little doubt that 12R-LOX and eLOX3 function in tandem in the 
same pathway in the skin, in this dissertation I am challenging the assumption that 
arachidonic acid is the responsible fatty acid substrate of 12R-LOX in the pathway. Also, 
since 12R-LOX and eLOX3 are expressed at precisely the moment when the skin barrier 
is about to form (89), I consider it more likely that these two enzymes play a role in 
building the barrier rather than in signaling for further cell differentiation.  
As noted earlier, linoleic acid is generally accepted as the essential fatty acid in 
the skin. In the barrier layer, stratum corneum, and its immediate precursor, the granular 
layer, linoleic acid is largely esterified into two classes of sphingolipids, acylceramides 
and acylglucosylceramides, respectively. In normal skin, the esterified fatty acid is almost 
exclusively linoleic acid. In essential fatty acid deficiency, the linoleate moiety is 
replaced by oleate, or the trans double bond isomers of linoleate, 9trans,13cis-18:2, 
9cis,13trans-18:2 or 9trans,13trans-18:2, if these fatty acids are topically applied (and 
these trans fatty acids cannot reverse the essential fatty acid deficient state) (64,80). 
Since neither oleate nor any of the trans double bond isomers of linoleate is a LOX 
substrate, this specific requirement for linoleic acid in acylceramides and 
acylglucosylceramides for skin barrier function can be explained if acylceramides and/or 
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acylglucosylceramides are to be metabolized by LOX enzymes, as originally proposed by 
Nugteren and colleagues in 1985 (80).  
If so, I questioned further, what functions would LOX metabolites of 
acylceramides and acylglucosylceramides provide? A possible answer can be deduced 
from two recent developments in studies of essential fatty acid deficiency and the 12R-
LOX-/- mouse model respectively. As noted earlier, in essential fatty acid deficient skin, 
where the linoleate moiety of acylceramides and acylglucosylceramides is replaced by 
oleate, the covalently bound ω-ceramides that are a major component of the corneocyte 
lipid envelope are significantly decreased compared to those in normal skin (78). 
Coincidentally, in 12R-LOX-/- mouse skin the covalently bound ω-ceramides also 
appeared to be absent (89). Combining these two lines of evidence and considering that 
the bound ω-ceramides derive from acylceramides and/or acylglucosylceramides, I 
propose that the metabolites of 12R-LOX and eLOX3 are obligatory intermediates in the 
conversion of acylceramides and/or acylglucosylceramides to covalently bound ω-
ceramides. In other words, the action of 12R-LOX and eLOX3 on the linoleate moiety 
makes possible the cleavage of the ester bond between the carboxyl of linoleate and the 
ω-hydroxyl of the very long chain fatty acid on the ceramides, thus freeing the ω-
hydroxyl group for covalent coupling to the proteins of the cornified protein envelope. 
This new hypothesis is summarized in Figure 14.  
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Figure 14 12R-LOX/eLOX3 pathway in the epidermis proposed in this 
dissertation.  
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CHAPTER II 
 
DIOXYGENASE ACTIVITY OF ELOX3 UNVEILED: TYPICAL AND 
ATYPICAL FEATURES 
 
Introduction 
 Epidermal lipoxygenase-3 (eLOX3) is one of the two lipoxygenases (LOX) 
involved in skin barrier formation (96,99). Inactivating mutations in either the gene 
encoding human eLOX3 or the gene encoding 12R-LOX lead to impaired skin barrier 
function that manifests itself in the disease, autosomal recessive congenital ichthyosis 
(86,100). The scaly skin phenotype of this disease is a compensatory response to the 
fundamental defect in the barrier function (40). Targeted gene knockouts in mice confirm 
the role of these two LOX enzymes, and in both cases the mice die soon after birth due to 
severe transepidermal water loss (89,90). 
 In addition to its involvement in skin barrier formation, eLOX3 also attracts 
attention because of its unusual enzymology. It is classified as a LOX based on its amino 
acid sequence (e.g. 58% identity to 12R-LOX) yet its name eLOX3 lacks the usual 
designation such as 5-, 12- or 15-LOX. The reason is the enzyme appears to be devoid of 
typical dioxygenase activity with polyunsaturated fatty acid substrates such as 
arachidonic acid (37,101). Instead, it displays a novel hydroperoxide isomerase activity 
that efficiently converts fatty acid hydroperoxides, the usual LOX products, to 
epoxyalcohols and ketones (37). This hydroperoxide isomerase activity, acting on a 
hydroperoxide product of 12R-LOX, has been proposed to be the physiological function 
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of eLOX3 (96).  
 The non-heme iron in the active site of LOX enzymes exists in two oxidation 
states, ferrous and ferric. Native LOX are usually in the ferrous state, yet only the ferric 
enzyme is catalytically active as a dioxygenase (19). Therefore, to enter the catalytic 
cycle the ferrous enzyme has to be oxidized to the ferric form first, usually by one 
equivalent of their own hydroperoxide product. This process, commonly known as the 
activation step, accounts for the initial lag phase in the progress curve of LOX reactions 
(20,102). Because the reaction between typical LOX and fatty acid hydroperoxides is 
only a single turnover event, no significant products would accumulate unless an iron 
reducing agent such as nordihydroguaiaretic acid (NDGA) is given to regenerate the 
ferrous enzyme (27) (Figure 15A). 
 Unlike typical LOX, eLOX3 does not require iron reducing agents for its 
hydroperoxide isomerase activity. That this reaction is catalysis, rather than a single 
turnover, implies that the ferrous state of eLOX3 is largely preserved. However, NDGA 
does speed up the reaction (37), suggesting that the enzyme can be oxidized by fatty acid 
hydroperoxides to some extent. I reasoned that the activation step of the LOX activity in 
eLOX3, if it does occur, would be very inefficient, requiring many molecules of fatty 
acid hydroperoxide to oxidize one molecule of eLOX3 (Figure 15B). In other words, 
higher than usual concentrations of fatty acid hydroperoxide might be required to activate 
eLOX3. This inefficiency in the activation step of eLOX3 could potentially account for 
its apparent lack of dioxygenase activity, which must be performed by the activated, 
ferric enzyme.  
 An additional explanation for the lack of dioxygenase activity in eLOX3 might be 
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that the active site iron has a low redox potential. This redox requirement is imposed by 
the first chemical step of the dioxygenase cycle, which involves homolytic cleavage of a 
bisallylic C-H bond in the fatty acid substrate by the active site Fe(III)-OH complex (29). 
The moderately high bond dissociation energy (BDE) of this C-H bond (e.g., ~ 73 
kcal/mol for C7-H, C10-H or C13-H in arachidonic acid (7)) dictates that the redox 
potential of the active site iron should also be moderately high for the bond cleavage to 
occur (6). Indeed, a moderately high redox potential of ~ 600 mV has been demonstrated 
experimentally in the prototypical LOX, soybean LOX-1 (8). Unfortunately, a direct test 
of this hypothesis, by measuring the redox potential of eLOX3 for comparison with 
soybean LOX-1, is not yet possible due to difficulties in preparing multi-milligrams of 
purified eLOX3 for EPR spectroscopy.  
 In this study, I set out to test indirectly the redox potential hypothesis by 
incubating eLOX3 with a panel of synthetic fatty acids with extended conjugation. 
Because of the extended conjugation, these fatty acids are easier to oxidize than typical 
polyunsaturated fatty acids such as arachidonic acid (7) and thus might be accepted by 
eLOX3 as substrate. The study on this panel of synthetic fatty acids revealed some 
unusual characteristics of eLOX3 that prompted me to consider the other possibility that 
eLOX3 does not react with natural fatty acids because it is deficient in the activation step. 
To further test this possibility, I reexamined the reaction of eLOX3 with arachidonic acid 
using high concentrations of hydroperoxide activator. I also studied the effect of an Ala-
to-Gly mutation in the active site that is known to affect oxygenation specificity (12,14) 
and investigated the effect of substrate orientation on product specificity using the large 
ester arachidonoyl-lysophosphatidic acid (AA/lyso PA). The Discussion section ties the 
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findings together and proposes a model with mechanistic relevance to the understanding 
of LOX enzymes in general.  
 
Figure 15: Comparison of typical LOX and eLOX3 reactions with fatty acid 
hydroperoxide (ROOH). (A) For typical LOX, one equivalent of ROOH oxidizes the Fe2+ 
enzyme to the Fe3+ form, via the Fe3+ enzyme-alkoxyl radical (RO•) intermediate. NDGA 
reduces the Fe3+ enzyme back to Fe2+ and thus inhibits dioxygenase activity. (B) For 
eLOX3, more than one equivalent of ROOH is required to oxidize the Fe2+ enzyme, 
because the Fe3+ enzyme-RO• intermediate usually undergoes hydroperoxidase isomerase 
cycling with formation of epoxyalcohols and ketones. Occasionally, the Fe3+ enzyme-
RO• intermediate converts to the free Fe3+ enzyme. NDGA reduces the Fe3+ enzyme and 
thus stimulates hydroperoxide isomerase activity. 
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Experimental procedures 
 
Materials  
Arachidonic acids were purchased from NuChek Prep Inc. (Elysian, MN). 15S-
HPETE or 13S-HPODE was synthesized by reacting soybean LOX-1 with arachidonic 
acid or linoleic acid at pH 9 followed by SP-HPLC purification (103). 12R-HPETE was 
synthesized by autoxidation (37). 4-Hydroxy TEMPO was purchased from Sigma 
Aldrich (St. Louis, MO). AA/lyso PA was purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL).  
Chemical synthesis of conjugated fatty acids  
9E,11Z,14Z-20:3ω6 was synthesized by Dr. Jin K. Cha at Wayne State 
University, as previously described (16).  8Ζ,11Ζ,13Ε−20:3ω7 was a kind gift from Dr. 
K. C. Nicolaou at the Scripps Research Institute. 11Z,14Z,16E-20:3ω4 and 12Ε,14Ζ,17Ζ-
20:3ω3 were synthesized by alkaline isomerization (104) of 11Z,14Z,17Z-20:3ω3 
(NuChek Prep Inc., Elysian, MN), and 9Z,12Z,14E-18:3ω4 by alkaline isomerization of 
α-linolenic acid (NuChek Prep Inc., Elysian, MN)). Briefly, 10 mg of the precursor fatty 
acid was dissolved in 1 ml of 1 N KOH in ethylene glycol, flushed with argon, and 
placed in an oven at 144 °C. The extent of the reaction was monitored every 10 minutes 
by UV spectrophotometry assay of an aliquot, and the reaction was stopped when UV 
absorbance at 235 nm ceased to increase (The total reaction time was about 20 to 30 
minutes). The reaction mixture was then acidified by 1 N HCl to pH 3 and extracted by 
methylene chloride. The extract was analyzed by silver ion chromatography and the two 
desired products were identified based on their UV (identical to that of 9E,11Z,14Z-
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20:3ω6) and 1H and 1H,1H-COSY NMR spectra.  
Expression and purification of human eLOX3 
The cDNA of human eLOX3 with an N-terminal His tag was subcloned into the 
pCW vector, and the protein was expressed and purified according to a previously 
published protocol (105). Flat-bottomed 500-ml flasks, which were found to give a higher 
yield of eLOX3 than baffled flasks, were used for the 50-ml cultures.   
Reaction incubations 
The room temperature reaction with 9E,11Z,14Z-20:3ω6 was monitored by UV 
spectrophotometry. By contrast, 0 °C reactions and the room temperature reaction with 
arachidonic acid were not monitored under UV. For the latter, incubation was typically 
conducted in a 5-ml reactivial. First, the fatty acid substrate and the auxillary components 
to be investigated (e.g., hydroperoxide activators, 4-hydroxy TEMPO) were added to an 
empty vial and then taken to dryness under a stream of N2. Next, 2 ml of 100 mM sodium 
phosphate buffer pH 7.5 was added, the vial capped and subjected to vortex mixing. 
Next, enzyme was added to start reaction. Finally, reaction was quenched by the addition 
of methanol (usually 1 ml). For time course experiments with arachidonic acid, at 
specified time points, an aliquot (usually 150-200 µl) of the incubation mixture was taken 
out and immediately added to a separate vial containing 833 ng of 9E,11Z,14Z-
20:3ω6, the internal standard, in 0.5 ml of methanol. The 0 °C reaction with AA/lyso PA 
was performed under the same conditions as the 0 °C reaction with arachidonic acid. The 
lyso phospholipid was chosen for this study because of its better solubility in aqueous 
solutions than those of diacyl phospholipids (106).  
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Extraction of reaction products 
The incubation mixture was acidified to pH 5 using 1 N HCl, treated with more 
than one molar equivalent of SnCl2 on ice for 10 minutes, and then extracted by an Oasis 
HLB cartridge (Waters Corp.).  
HPLC analysis 
For reaction with 9E,11Z,14Z-20:3ω6, straight phase HPLC analysis used a 
Beckman silica column (0.46 × 25 cm), a solvent system of hexane/isopropyl 
alcohol/acetic acid (100:1.5:0.1, by volume), and a flow rate of 1 ml/min. Chiral phase 
HPLC analysis used a Daicel Chiralpak AD column (0.46 × 25 cm), a solvent system of 
hexane/ethanol/acetic acid (100:5:0.05), and a flow rate of 1 ml/min.  
For reaction with arachidonic acid, reversed phase HPLC analysis of HETE 
products was performed using a Waters Symmetry C18 column (0.46 × 25 cm), a solvent 
system of methanol/water/acetic acid (80/20/0.01), and a flow rate of 1 ml/min. For time 
course experiments, reversed phase HPLC analysis used the same column, 
methanol/water/acetic acid (95/5/0.01), and 1 ml/min. The remaining arachidonic acid 
substrate and accumulated 9- and 5-HPETE products in the time course experiments were 
quantified by comparison of their corresponding peak area with that of the internal 
standard, 9E,11Z,14Z-20:3ω6. To avoid rearrangement of bisallylic HETEs, which may 
occur under even mildly acidic conditions (107), HPLC analyses with no acid-containing 
solvent systems were also performed on reaction extract pre-treated with ethereal 
diazomethane, which converts free acids to methyl esters. 7-HETE and 11-HETE methyl 
esters were separated using a Beckman silica column (0.46 × 25 cm), an isocratic solvent 
system of hexane/isopropyl alcohol (100:2, by volume), and a flow rate of 1 ml/min. The 
 38 
relative abundance of each HETE product was estimated based on the 205 nm 
absorbance. (This is justified by a previous study showing that the radioactive trace of [1-
14C]HETEs matches well with the corresponding UV trace at 205 nm (107).) Chiral 
analysis used a Daicel Chiralpak AD column (0.46 × 25 cm), isocratic solvent of 
hexane/methanol (100:1.5, v/v), and a flow rate of 1ml/min. The stereo-configuration of 
methyl 7-HETE enantiomers on chiral HPLC was deduced based on the finding that 
bisallylic HETEs would undergo mainly “suprafacial” rearrangement upon mild acid 
treatment (107). Briefly, the two enantiomers (1-2 µg) were purified by chiral HPLC, 
repeatedly (4-5 cycles) treated with 1 ml of methanol/water/acetic acid (75:25:1) 
followed by evaporation under N2, and then subjected to chiral HPLC analysis. For 
example, the second peak of 7-HETE methyl ester on chiral HPLC was found to 
rearrange mainly to 5S-HETE and 9R-HETE methyl esters and was thus deduced to be 
7R, since 7R hydroxyl sits on the same face of the double bond system in the fully 
extended configuration as does 5S or 9R hydroxyl.  
For reaction with AA/lyso PA, the products were transmethylated after extraction 
using a previously published protocol (108), followed by reversed phase HPLC analysis 
using a Waters Symmetry C18 column (0.46 × 25 cm), an isocratic solvent system of 
methanol/water (80/20), and a flow rate of 1 ml/min.  
Derivatization and GC-MS analysis 
Catalytic hydrogenations were performed in 100 µl of ethanol using about 1 mg 
of palladium on alumina and bubbling with hydrogen for 2 min at room temperature. The 
hydrogenated products were recovered by the addition of water and extraction with ethyl 
acetate. TMS ether derivatives were prepared by treatment with bis(trimethylsilyl)-
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trifluoracetamide (10 µl) and pyridine (2 µl) at room temperature for 2 hr. Subsequently, 
the reagents were evaporated under a stream of nitrogen and the samples were dissolved 
in hexane for GC-MS.  
Analysis of the methyl ester trimethylsilyl ether derivatives of the products was 
carried out in the positive ion electron impact mode (70 eV) using a Thermo Finnigan 
Trace DSQ ion trap GC-MS with the Xcalibur data system. Samples were injected at 150 
°C, and after 1 min the temperature was programmed to 300 °C at 20 °C/min. Spectra 
collected during elution of the GC peak (typically about 20 spectra) were averaged for 
calculation of the isotopic compositions. 
 
RESULTS 
 
Dioxygenase activity of eLOX3 with 9E,11Z,14Z-20:3ω6  
To examine the potential oxygenase activity of eLOX3, we tested eLOX3 with a 
series of synthetic fatty acids with extended conjugation (their structures shown in Figure 
16). Among these fatty acids, only 9E,11Z,14Z-20:3ω6  turned out to be a good substrate. 
The initial reactions of eLOX3 (0.1 µM) with 9E,11Z,14Z-20:3ω6 (18 µM) were 
conducted at room temperature and monitored by scanning UV spectrometry. The 
substrate contains a conjugated diene chromophore and absorbs strongly at 235 nm 
(Figure 17A, dotted line). Upon addition of enzyme, the UV absorbance of the substrate 
gradually decreased while a new chromophore typical of conjugated trienes came to 
prominence (λmax ~ 270 nm, Figure 17A). Monitoring of the rate of reaction at 235 nm 
revealed a pronounced lag phase of ~ 5 min during which time no significant reaction is 
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apparent (Figure 17B); addition of exogenous hydroperoxide activator (1 µM 13S-
HPODE) almost eliminated the lag phase. Kinetic measurements of initial rates over a 
range of substrate concentrations gave estimates of Km and kcat as 50 µM and 1.6 s-1, 
respectively (Figure 17C).  
Figure 16: Tested synthetic fatty acids with extended conjugation.  
 
Products of the 9E,11Z,14Z-20:3ω6 reaction at room temperature 
Straight phase and reversed phase HPLC analyses revealed a complex product 
pattern including at least four products with λmax at 270 nm, four at 235 nm and four at 
320 nm (data not shown). We reasoned that the substrate was first oxygenated to 
conjugated triene hydroperoxides (λmax 270 nm), which were then further converted by 
the hydroperoxide isomerase activity of eLOX3 to epoxyalcohols and ketones (λmax 235 
nm and 320 nm). The fact that the epoxyalcohol products also absorb at 235 nm explains 
why a substantial UV absorbance at 235 nm remained upon completion of the reaction 
(Figure 17A). 
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Figure 17: Dioxygenase activity of eLOX3 with 9E,11Z,14Z-20:3ω6. (Α)   UV scans of the 
room temperature reaction of eLOX3 (0.1 µM) with 9E,11Z,14Z-20:3ω6 (18 µM). To 1 ml of 
phosphate pH 7.5 buffer, the substrate was added and a UV scan taken (dotted line). After the 
enzyme was added and mixed (for ~15 s), a second scan was taken. Further scans shown were 
taken after 3 min, 4 min, 5 min, 6 min, 7 min and 8 min. (B) Progress curves of the reaction in the 
absence or presence of 13S-HPODE, monitored at 235 nm. The reaction conditions are the same 
as in panel A. (C) Dependence of maximal rate on substrate concentration. Maximal rates were 
taken from the steepest part of progress curves. (D) Straight phase-HPLC analysis of the primary 
products. Here, the reaction of eLOX3 (0.13 µM) with 9E,11Z,14Z-20:3ω6 (33 µM) was 
performed at 0 °C, in the presence of 15S-HPETE (150 µM) and 4-hydroxy TEMPO (1.5 mM). 
The reaction was completed within 30 minutes. (E) UV spectra (in straight phase solvent) of 
products 1, 2 and 3, as designated in panel D. (F) Chiral HPLC analysis of product 3.  
 42 
Trapping of the primary products 
To focus on the primary LOX reaction, we identified three key factors that almost 
eliminated secondary product formation: (i) incubation at 0 °C preferentially reduces 
hydroperoxide isomerase activity compared to dioxygenase activity (109-112); (ii) an 
excess of 15S-HPETE included in the incubation competes with the conjugated triene 
hydroperoxide products for the hydroperoxide isomerase activity, and the excess 15S-
HPETE helps keep the enzyme in the ferric state (see below); and (iii), addition of 4-
hydroxy-TEMPO (1.5 mM), a water-soluble antioxidant, prevents non-enzymatic lipid 
peroxidation without causing significant enzyme inhibition (113). At the end of the 
incubation, SnCl2 was added to convert hydroperoxides to the more stable alcohols and 
the products were extracted and analyzed by SP-HPLC with a diode-array detector 
(Figure 17D and 17E). By comparison with authentic standards obtained in a previous 
study (16) and by GC-MS analysis, the major peak 3 (76%) was identified as 9-hydroxy-
10E,12E,14Z-eicosatrienoic acid, and the two minor products 1 and 2 as positional and 
geometric isomers of 3. (1 and 2 both have a 15-hydroxyl group, but differ in double 
bond configuration, data not shown). Chiral phase HPLC resolved product 3 into the R 
and S isomers with a ratio of 6:94 (Figure 17F). Thus, 9E,11Z,14Z-20:3ω6  was 
oxygenated by eLOX3 in a regio- and stereospecific fashion to its 9S-hydroperoxy 
derivative, 9S-hydroperoxy-10E,12E,14Z-eicosatrienoic acid. The 9S-oxygenation occurs 
four carbons removed from the site of bis-allylic hydrogen abstraction at C-13. None of 
the other conjugated fatty acids tested were significantly oxygenated, indicating substrate 
selectivity of eLOX3. 
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Dioxygenase activity of eLOX3 with arachidonic acid 
The pronounced lag phase seen with 9E,11Z,14Z-20:3ω6 led us to question 
whether there might be an even longer lag phase with arachidonic acid, which might be 
overcome using fatty acid hydroperoxide activator. As shown in Figure 18A, in the 
absence of fatty acid hydroperoxides, eLOX3 (0.4 µM) showed only weak, slow activity 
with arachidonic acid (42 µM) as monitored by RP-HPLC assay of the remaining 
substrate. In the presence of high concentrations of fatty acid hydroperoxides, however, 
the rate of conversion of arachidonic acid was greatly accelerated, more so in the 
presence of 13S-HPODE than in the presence of 12R-HPETE. Also, the effect of fatty 
acid hydroperoxides is concentration-dependent, as 65 µM 13S-HPODE proved to be 
more effective than 27 µM 13S-HPODE. In fact, the reaction initiated with 27 µM 13S-
HPODE was found to stall when 13S-HPODE was fully consumed and resume only after 
a second dose of 13S-HPODE (58 µM) was given. Therefore, the reaction of eLOX3 with 
arachidonic acid coincided with and was likely driven by its reaction with fatty acid 
hydroperoxides.  
Dioxygenase activity of Ala451Gly eLOX3 with arachidonic acid  
The stereospecificity of oxygenation in LOX enzymes is partly controlled by an 
active site residue conserved as Ala in S-LOX and Gly in R-LOX (14). eLOX3 has Ala in 
this position. Recently Oliw and colleagues reported that mutation of the natural Gly to 
Ala in Mn-LOX strongly augments hydroperoxide isomerase activity (114). Accordingly, 
it was of interest to examine whether changing Ala451 to Gly in eLOX3 would produce 
the opposite effect, i.e., a switch from hydroperoxide isomerase to dioxygenase activity. 
Therefore, we mutated Ala451 to Gly and incubated the mutant enzyme (0.5 µM) with 
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arachidonic acid (42 µM). Unlike wild-type eLOX3, Ala451Gly eLOX3 reacted well 
with arachidonic acid even in the absence of fatty acid hydroperoxides, yet only after an 
unusually long lag phase of ~ 20 minutes (Figure 18B). This lag phase could be 
eliminated by addition of 11 µM 13S-HPODE at the beginning of the reaction (Figure 
18B). 
 
 
Figure 18: Effect of fatty acid hydroperoxide on dioxygenase activity of wild-type eLOX3 (0.4 
µΜ) (panel A) or Ala451Gly eLOX3 (0.5 µΜ) (panel B) with arachidonic acid (42 µΜ) at room 
temperature. Arachidonic acid and fatty acid hydroperoxides were added first to phosphate pH 
7.5 buffer, and then addition of enzyme started the reactions. At specified time points, an aliquot 
was taken and the unreacted arachidonic acid substrate was quantified by reversed phase HPLC.  
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Effect of temperature on accumulation of HPETE products 
In the room temperature reactions mentioned above, the expected HPETE 
products occurred only as transient intermediates with either the wild-type or Ala451Gly 
eLOX3 (Figure 19A and 19C); the primary hydroperoxide products are further 
converted to epoxyalcohols and ketones by the hydroperoxide isomerase activity of 
eLOX3 (results not shown). However, similar to the observations with 9E,11Z,14Z-
20:3ω6, when reaction with arachidonic acid was performed at 0 °C and in the presence 
of excess 13S-HPODE, the HPETE products continued to accumulate during the entire 
course of the reaction (Figure 19B and 19D) and the epoxyalcohol and ketone secondary 
products were formed only in negligible amounts.  
Identification of the HPETE products 
After the reaction, the HPETE products from the 0°C incubation were reduced 
with SnCl2, extracted using a C18 cartridge, and subjected to RP- and SP-HPLC analyses. 
As shown in Figure 20A, the products consisted of predominantly 7-, 9-, and 5-
H(P)ETEs (25%, 29%, and 22%, respectively) that resulted from C-7 hydrogen 
abstraction, followed by 15- and 11-H(P)ETEs (8% and 9% respectively) from C-13 
hydrogen abstraction. 12- and 8-H(P)ETEs were formed only in minor amounts (less than 
3% each). The identity of the unusual bis-allylic 7-H(P)ETE product was unequivocally 
established by GC-MS analysis of its methyl ester TMS ether derivative, before and after 
catalytic hydrogenation (Figure 21 and Figure 20C).  
Consistent with this lack of positional specificity, further analysis by chiral HPLC 
indicated no remarkable stereospecificity in any of the positional isomers (Figure 22A, 
22C, 22E). Among the three major products, 7-H(P)ETE showed the highest degree of  
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Figure 19: Effect of temperature on accumulation of HPETE products in the reaction of wild-
type eLOX3 (0.4 µΜ) or Ala451Gly eLOX3 (0.5 µΜ) with arachidonic acid (42µM). 5-HPETE 
and 9-HPETE shown on the plots represented over 50% of the total products and could be readily 
quantified by reversed phase HPLC analysis. (A) Wild-type eLOX3 reaction at room temperature 
in the presence of 65 µM 13S-HPODE. (B) Wild-type eLOX3 reaction at 0 °C in the presence of 
108 µM 13S-HPODE. (C) Ala451Gly eLOX3 reaction at room temperature in the presence of 11 
µM 13S-HPODE. (D) Ala451Gly eLOX3 reaction at 0 °C in the presence of 22 µM 13S-
HPODE.  
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Figure 20: Identification of products from reactions of wild-type eLOX3 and Ala451Gly 
eLOX3 with arachidonic acid. The incubation conditions were the same as in Fig. 19B and 19D. 
(A) & (B) Reversed phase-HPLC analysis of products from wild-type and Ala451Gly eLOX3 
respectively. (C) GC-MS analysis of TMS ether methyl ester derivative of hydrogenated 7-HETE 
product. Before hydrogenation and derivatization, the 7-HETE product had been further purified 
by SP-HPLC.  
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48: GC-MS analysis of TMS ether methyl ester derivative of the 7-HETE product. 
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stereospecificity, being 73% 7R. The 5-H(P)ETE product ranked the second, being 62% 
5R, and the 9-H(P)ETE product was essentially racemic. 
The active site Ala-Gly substitution in other LOX enzymes can lead to relatively 
dramatic changes in product profile (13,14,16) or mainly to changes in stereochemistry 
(115). The most noticeable effect of the Ala451Gly mutation in eLOX3 was a switch 
towards more 9-H(P)ETE, increased from 28.9 ± 1.4% (mean ± s.e.m., n = 4) to 38.5 ± 
1.0%, seemingly at the expense of 5-H(P)ETE, decreased from 21.7 ± 0.8% to 11.6 ± 
1.0%  (cf. Figure 20A, 20B). These differences were statistically significant (p < 0.01) 
for both wild-type and mutant eLOX3. Chiral HPLC analysis further revealed that the 9-
H(P)ETE in the Ala451Gly eLOX3 reaction was 67% 9R (Figure 22F), an improvement 
in stereospecificity compared to the racemic 9-H(P)ETE product of wild-type eLOX3 
(Figure 22E).  
Dioxygenase activity of eLOX3 with AA/lyso PA 
Experiments using AA/lyso PA as substrate, a molecule with a bulky ester on the 
arachidonate carboxyl, were used to gain insight into the possible “tail first” or “head-
first” substrate binding orientation (11,116). Reaction occurred at less than 0.1% of the 
rate with free arachidonic acid and products arising mainly from C-13 hydrogen 
abstraction were formed (Figure 23). These results strongly suggest that the “tail first” 
orientation of substrate binding is mainly associated with H-13 abstraction in the reaction 
of wild-type or Ala451Gly eLOX3 with AA/lyso PA. It can be further inferred that the 
“head first” orientation is associated with H-7 abstraction and is the preferred orientation 
in the reaction of eLOX3 with free arachidonic acid. 
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Figure 22: Chiral HPLC analysis of individual HETE products from reactions of wild-type 
eLOX3 and Ala451Gly eLOX3 with arachidonic acid. (A) Wild-type eLOX3, 5-HETE methyl 
ester. (B) Ala451Gly eLOX3, 5-HETE methyl ester. (C) Wild-type eLOX3, 7-HETE methyl 
ester. (D) Ala451Gly eLOX3, 7-HETE methyl ester. (E) Wild-type eLOX3, 9-HETE methyl 
ester. (F) Ala451Gly eLOX3, 9-HETE methyl ester.  
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Figure 23: Identification of products from reactions of wild-type eLOX3 and Ala451Gly 
eLOX3 with AA/lyso PA. Note that whereas AA/lyso PA usually implies a tail-first 
orientation, the orientation of a free fatty acid substrate could be influenced by pH (117). 
(A) & (B) Reversed phase-HPLC analysis of trans-methylated products from wild-type 
and Ala451Gly eLOX3 respectively. (C) GC-MS analysis of TMS ether methyl ester 
derivative of hydrogenated 13-HETE product. ∗ The slight UV absorbance at 235 nm was 
caused by an unknown 235 nm-absorbing compound that co-chromatographed with 13-
HETE methyl ester.  
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DISCUSSION 
 
Discovery of dioxygenase activity in eLOX3  
This study demonstrates that eLOX3 in its active form is capable of oxygenating 
polyunsaturated fatty acids to the fatty acid hydroperoxides. As summarized in Figure 
24, eLOX3 oxygenates 9E,11Z,14Z-20:3ω6 in a regio- and stereospecific fashion to give 
the 9S hydroperoxide. Although the reaction with arachidonic acid is much slower and 
exhibits considerably less specificity (Figure 24), the enzymatic nature of this reaction is 
confirmed by the formation of 7-HPETE, which cannot be formed non-enzymatically 
under the conditions used in this study. Such bis-allylic hydroperoxides are formed from 
the corresponding peroxyl radical only in the presence of a highly efficient hydrogen 
atom donor (118,119), which in this case is not present in the incubation buffer and thus 
must be part of the enzyme machinery, most likely the Fe(II)-H2O complex. eLOX3 joins 
Mn-LOX (120) and the recently characterized mini-LOX from cyanobacterium 
Cyanothece sp. (121) in the ability to make a bis-allylic hydroperoxide. 
Unusual aspects of eLOX3 and reasons for its elusive dioxygenase activity 
Our study also reveals aspects of eLOX3 that may explain why its dioxygenase 
activity has remained undetected for years: (i) With fatty acid substrate alone, the 
reaction shows an unusually long lag phase. This ranged from 4-5 min with 9E,11Z,14Z-
20:3ω6 (Figure 17B) to over 1 hour with arachidonic acid (Figure 18A). (ii) Compared 
to typical LOX reactions, high concentrations of fatty acid hydroperoxide are required to 
abolish the lag phase. (iii) As known with other LOX enzymes (122-124), not every fatty 
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acid hydroperoxide is equally effective in the enzyme activation. The best substrate for 
the hydroperoxide isomerase activity of eLOX3, 12R-HPETE, turns out to be only  
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Figure 24: Dioxygenase activity of eLOX3.  
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marginally effective. This is not a coincidence, as 12R-HPETE allows for efficient 
hydroperoxide isomerase cycling of eLOX3. (iv) At room temperature (as opposed to at 0 
°C), the primary oxygenation products occur only as transient intermediates, i.e., they 
will be further converted to epoxyalcohols and ketones by the hydroperoxide isomerase 
activity. Therefore, the reaction gives no signal with the usual spectrophotometric (UV 
235 nm) or HPLC-UV assays. 
Our interpretations of the unusual aspects 
The evidence points to a deficiency in the activation of eLOX3. Whereas one 
equivalent of fatty acid hydroperoxide activator is sufficient in the activation step of 
typical LOX, many equivalents are required in the activation step of eLOX3, hence the 
pronounced lag phase and the requirement for high concentrations of a fatty acid 
hydroperoxide activator. At room temperature, the concurrent hydroperoxide isomerase 
activity producing epoxyalcohols and ketones from the primary hydroperoxide products 
implies that a significant fraction of eLOX3 exists in the ferrous state even after the lag 
phase. This is probably because, during the dioxygenase cycling of eLOX3, a significant 
fraction of the free radical intermediates escape from the enzyme active site, leaving the 
enzyme in the ferrous state. 
The deficiency in the activation step of eLOX3 is somewhat relieved by the 
Ala451Gly mutation. Ala451Gly eLOX3 appears to stand at the midpoint between wild-
type eLOX3 and typical LOX. On the one hand, Ala451Gly eLOX3 still shows a 
pronounced lag phase in its reactions with arachidonic acid in the absence of fatty acid 
hydroperoxides. On the other hand, the lag phase of Ala451Gly eLOX3 is much shorter 
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than that of wild-type eLOX3 and can be eventually overcome by only trace amounts of 
fatty acid hydroperoxide present in the substrate preparation. 
Explaining the difference between eLOX3 and typical LOX  
When the hydroperoxide isomerase activity of eLOX3 was originally 
characterized, our group had speculated that the enzyme fails to oxygenate natural fatty 
acids because the active site iron has a lower redox potential than the iron in typical LOX 
(37). As already outlined in the Introduction, hydrogen abstraction on typical fatty acid 
substrates, which is the first step of LOX catalysis, calls for a moderately high redox 
potential, and conceivably the redox potential could be exceptionally low in eLOX3 due 
to some unfavorable protein environment of the enzyme active site. However, this is not 
immediately evident on inspection of the protein sequence, as all the typical conserved 
features of LOX enzymes including the conserved amino acid ligands to the iron are 
retained in eLOX3. Most importantly, this issue is now addressed as we have 
demonstrated in this study that arachidonic acid can be oxidized by eLOX3 (with H-7 
preferentially abstracted by the iron complex) thus definitively ruling out this low redox 
potential possibility.  
To account for the atypical dioxygenase activity of eLOX3, we invoke an 
alternative explanation, that oxygen access is limited in the enzyme active site. Since 
molecular oxygen is one of the two substrates in LOX catalysis, limited oxygen access to 
the reacting fatty acid radical intermediate would undoubtedly impede catalysis. In the 
extreme scenario, when molecular oxygen is not available at all either because oxygen 
access is completely blocked or because the atmosphere is rendered anaerobic, even 
though the initial C-H bond cleavage step may proceed normally, the fatty acid radical 
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thus produced would eventually escape from the enzyme active site in the absence of 
reacting molecular oxygen, leaving the enzyme in the inactive ferrous state (Figure 25). 
Such a single turnover event would be undetectable in typical enzyme assays. Under such 
circumstances, redox cycling can occur only if the ferrous enzyme is re-oxidized by 
hydroperoxide back to the ferric form (Figure 25, dotted line), as seen classically in the 
anaerobic reaction of soybean LOX with linoleic acid and 13S-HPODE (30,125). 
However, under the usual aerobic conditions, such an extreme scenario hardly applies to 
typical LOX, indicating that molecular oxygen is readily accessible to the reacting fatty 
acid radical in their active site. For example, it is estimated that free radical leakage 
occurs only once per hundred turnovers in the reaction of soybean LOX-1 with linoleic 
acid (102). We suggest that limited oxygen access is the actual case in eLOX3, based on 
the following interpretations of the evidence: 
(i) Carbon radicals escape from the active site during dioxygenase cycling - In 
the transformation of arachidonic acid at room temperature, the hydroperoxide isomerase 
activity is persistent throughout the reaction and HPETE products fail to accumulate (cf. 
Figure 19, panel A and C), indicating that the ferrous enzyme is constantly produced. 
Also, the reaction of eLOX3 with arachidonic acid is clearly driven by 13S-HPODE, 
(Figure 18A, the curve with two doses of 13S-HPODE), just as the anaerobic conversion 
of linoleic acid by soybean LOX-1 is driven by 13S-HPODE. These observations can be 
explained if a significant portion of fatty acid carbon radical intermediates escapes from 
the active site, which could be the result of lack of reacting oxygen (cf. Figure 25). 
Although leakage of peroxyl radical instead of carbon radical is also conceptually 
plausible, we consider this rather unlikely, because the subsequent trapping of peroxyl 
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radical by the enzyme is remarkably efficient as indicated by formation of the bis-allylic 
product, 7-HPETE. 
(ii) Lack of regio- and stereo-specificity within the active site - The lack of 
oxygenation specificity with arachidonic acid is not entirely due to radical leakage and 
subsequent non-enzymatic oxygenation in solution. This is indicated by the appearance of 
7-HPETE, which must be generated entirely within the enzyme active site. The R/S ratio 
of 73/27 in 7-HPETE must reflect a combination of the differences in oxygen supply to 
the two faces of C-7 and in trapping efficiency of the respective 7R and 7S peroxyl 
radicals. Indeed, it is likely that oxygen is added non-selectively to every reacting site on 
the delocalized pentadienyl radical (e.g., C-5, C-7 and C-9 when H-7 is abstracted), 
suggesting that oxygen supply is similarly low in every reacting site. 
(iii) The Ala451Gly mutation augments dioxygenase activity - Ala451Gly eLOX3 
shows “improved” specificity in its reaction with arachidonic acid compared to wild-type 
eLOX3, in that both the proportion of 9-HPETE among all isomers and its R/S ratio 
increase considerably. We deduce that the Ala-to-Gly mutation opens up space and 
introduces an oxygen “pocket” that is aligned with the “9R” site on arachidonic acid. 
(iv) eLOX3 readily oxygenates 9E,11Z,14Z-20:3ω6 − This synthetic fatty acid 
with extended conjugation is  a much better substrate than arachidonic acid, and is 
oxygenated regio- and stereospecifically to the 9S hydroperoxide. This is consistent with 
the availability of an oxygen pocket in this unusual 9S position, which is four carbons 
removed from the site of hydrogen abstraction at C-13. Obviously, such a pocket or 
channel would play no role in the oxygenation of typical pentadienyl fatty acids that  
 
 58 
 
require oxygen to be delivered to sites that are two carbons removed from the site of 
hydrogen abstraction.  
The connection between oxygen access and enzyme activation 
The natural question at this point is how our proposed difference of eLOX3 from 
typical LOX, i.e., limited oxygen access, would lead to a deficiency in the enzyme 
activation step. A kinetic study of rabbit reticulocyte 15-LOX-1 suggests that molecular 
oxygen is in fact directly involved in the LOX activation step (126). We have evidence 
from comparison of soybean LOX-1 and eLOX3 that agrees with this proposition and 
further suggests that molecular oxygen is actually a driving force in the activation step. 
Therefore, it is not surprising that the activation step would be impaired when oxygen 
access in the active site becomes limited. 
Concluding remarks 
In this study we have unveiled dioxygenase activity of eLOX3 with fatty acids 
and investigated both the usual and unusual aspects. The usual aspects suggest that the 
basic machinery for LOX catalysis is fully functional in eLOX3, whereas the unusual 
aspects of eLOX3 point to the possibility that eLOX3 has limited oxygen access in the 
active site. It may be useful to consider a spectrum of activities among LOX enzymes that 
are partly dependent on the availability of molecular oxygen within the respective 
enzyme active sites. At one end of the spectrum are the conventional LOX, exemplified 
by soybean LOX-1, in which dioxygenase activity is dominant. Towards the other end of 
the spectrum, with limited access to molecular oxygen and radical leakage from the 
active sites, are atypical LOX enzymes such as eLOX3, plant type-2 lipoxygenases 
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(127,128), moss and maize LOX with hydroperoxide isomerase and lyase activities 
(129,130). 
As noted at the beginning of the Introduction, eLOX3 performs a vital function in 
epidermal barrier formation. Where do our new findings stand in relation to this 
physiological role, and what is their importance? When the hydroperoxide isomerase 
activity of eLOX3 was discovered originally, it was presumed that this atypical isomerase 
activity, acting on a hydroperoxide product of its partner 12R-LOX, represents the 
function of eLOX3 in vivo. As the evidence stands at present, we continue to favor this 
interpretation, although whether this dioxygenase activity in eLOX3 is physiologically 
relevant should be considered in future studies. In our view the latent dioxygenase 
activity of eLOX3 is a reflection of mechanistic issues biasing eLOX3 towards 
hydroperoxide isomerase activity. 
 
 
Figure 25: LOX catalytic cycle. Solid lines: when oxygen access is not limited. Dotted 
lines: when oxygen access is limited. 
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CHAPTER III 
 
COMPARISON AND CONTRAST OF ELOX3 WITH SOYBEAN LOX-1: 
ELUCIDATION OF THE ROLE OF MOLECULAR OXYGEN IN LOX 
ACTIVATION  
 
Introduction 
 
Lipoxygenases (LOX) are a class of non-heme iron dioxygenases that incorporate 
molecular oxygen into polyunsaturated fatty acids to give fatty acid hydroperoxides (11). 
Widely expressed in animals and plants, and also in some bacteria and fungi, LOX 
enzymes participate in diverse physiological and pathological processes. Mammalian 
12R-LOX and epidermal lipoxygenase-3 (eLOX3), for example, play an indispensable 
role in skin barrier formation (96,99), whereas plant LOX enzymes are involved in stress 
responses and development (131). A distinctive characteristic of LOX enzymes in general 
is that the resting enzyme requires activation before catalytic reactions with fatty acids 
and molecular oxygen can begin (4,5,132). 
Mechanistically, soybean LOX-1 is the most extensively studied and generally 
considered as the prototypical LOX enzyme. The non-heme iron of soybean LOX-1 
exists in two oxidation states, ferric and ferrous. The ferric enzyme is responsible for the 
catalytic activity (19) and preferentially oxygenates polyunsaturated fatty acids (PUFA) 
with an ω6 and ω9 pentadiene unit at the “S” face of the ω6 carbon, e.g., to convert 
linoleic acid to 13S-hydroperoxy-octadecadienoic acid (13S-HPODE). The ferrous 
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enzyme is inactive with fatty acids but can react with fatty acid hydroperoxides such as 
13S-HPODE to become the ferric enzyme (102,133). Since the newly isolated enzyme is 
usually in the ferrous state, such a reaction with fatty acid hydroperoxides is required for 
the enzyme to enter the catalytic cycle, hence being known as the LOX activation step. In 
this activation process, as the proportion of ferric enzyme gradually increases, the rate of 
fatty acid oxygenation will also increase, manifesting itself in the progress curve of fatty 
acid oxygenation as a lag phase (20). A distinctive feature of LOX activation is that it is a 
single turnover event; once the enzyme is oxidized to the ferric form, it will no longer 
react with fatty acid hydroperoxides (18). Because of this single-turnover nature of the 
reaction, the products from LOX activation are formed in minute amounts and have not 
been identified. Although substantial evidence suggests that an alkoxyl radical is 
produced in LOX activation (134), the fate of this alkoxyl radical is poorly understood. 
Figure 26 illustrates transformation of a fatty acid hydroperoxide to an alkoxyl radical as 
well as subsequent reactions and rearrangement discussed throughout the paper.  
eLOX3, on the other hand, is an atypical LOX with a prominent hydroperoxide 
isomerase activity (37). Using this hydroperoxide isomerase activity, ferrous eLOX3 
converts fatty acid hydroperoxides via an alkoxyl radical intermediate to epoxyalcohols 
and ketones  (Figure 26). Unlike the single-turnover LOX activation step, this 
hydroperoxide isomerase activity fulfills a catalytic cycle so that the free ferrous enzyme 
will be regenerated upon product release. Although previously unknown, the dioxygenase 
activity of eLOX3 has recently been reexamined and uncovered in this laboratory (135). 
Using this dioxygenase activity, ferric eLOX3 oxygenates the synthetic fatty acid, 
9E,11Z,11Z-20:3ω6, to the specific 9S-hydroperoxide, and oxygenates arachidonic acid 
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to a mixture of HPETEs including the bis-allylic 7-HPETE. However, we have found this 
dioxygenase activity unusual in exhibiting a very pronounced lag phase, which points to a 
deficiency in eLOX3 activation by fatty acid hydroperoxides. We have also found that 
this long lag phase is partially alleviated by introduction of an Ala-to-Gly mutation at a 
conserved residue (Ala451) that has been implicated in the control of O2 access in LOX 
active site (13-16,115,136).  
An alkoxyl radical is postulated as a common intermediate in both the hydroperoxide 
isomerase cycling pathway and the single turnover LOX activation step (Figure 26). O2 
is not involved in hydroperoxide isomerase cycling, but I questioned whether O2 might be 
directly involved in LOX activation. Oxygen uptake has been observed in aerobic 
incubations of soybean LOX-1 with fatty acid hydroperoxides (137). The participation of 
O2 in LOX activation has also been suggested in a kinetic study of rabbit reticulocyte 15-
LOX (126). If O2 is involved in activation, I postulated further, a lack of or limited O2 
access in the enzyme active site could be the explanation for both the prominent 
hydroperoxide isomerase activity and the inefficient enzyme activation observed in 
eLOX3. To explore these ideas, here using kinetic and analytical chemical approaches I 
compared and contrasted the rates and the products of reactions of soybean LOX-1, the 
Ala451Gly eLOX3 and wild-type eLOX3 with fatty acid hydroperoxides at various 
oxygen concentrations.  
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Figure 26: Comparison and contrast of LOX activation and hydroperoxide isomerase 
activity 
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Experimental Procedures 
 
Materials 
Arachidonic and linoleic acids and methyl esters were purchased from NuChek 
Prep Inc. (Elysian, MN). 15S-HPETE or 13S-HPODE was synthesized by reacting 
soybean LOX-1 with arachidonic acid or linoleic acid at pH 9 followed by SP-HPLC 
purification (103). Nordihydroguaiaretic acid (NDGA) was purchased from Cayman 
Chemical, Co Inc (Ann arbor, MI). Triphenylphosphine (TPP) was purchased from 
Sigma-Aldrich (St. Louis, MO). Soybean LOX-1 was purchased from Sigma-Aldrich (St. 
Louis, MO) and Cayman Chemical, Co Inc (Ann arbor, MI), labeled as type V and P1 
purified respectively. The enzyme from both sources gave identical products, although in 
our hands the Sigma enzyme was about ten times as active as the Cayman purified 
enzyme (138). The concentration label in the current manuscript refers to the Sigma 
enzyme assuming 80% purity of the preparation.  
Expression and purification of human eLOX3 
The cDNA of human eLOX3 with an N-terminal His6 tag was subcloned into the 
pCW vector, and the protein was expressed in E. coli and purified according to a 
previously published protocol (105). The Ala451Gly mutagenesis in eLOX3 was 
performed using QuikChangeTM Site-Directed Mutagenesis Kit. The mutation was 
verified by DNA sequencing. Then the Ala451Gly eLOX3 was expressed and purified as 
the wild-type eLOX3.  
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Reaction incubations and extraction 
Initial incubations were conducted on an analytical scale in 100 mM sodium 
phosphate buffer pH 7.5 at various O2 concentrations at room temperature and were 
monitored using a Perkin-Elmer spectrophotometer. The typical reaction volume is 1 ml. 
O2-saturated buffer was made by bubbling ~ 40 ml buffer in a 50-ml conical tube with O2 
for 30 minutes. The O2-saturated buffer was used for the incubations only when the 
buffer temperature reverted to room temperature. For the anaerobic incubations, the 
buffer was rendered anaerobic using an oxygen-consuming system consisting of glucose, 
glucose oxidase and catalase according to a previously published protocol (138). To 
verify the results, each anaerobic reaction was also repeated in N2-saturated phosphate 
buffer inside a N2-inflated glovebag in the absence of the glucose-glucose oxidase-
catalase system (138), and identical results were found. If methyl arachidonate is one of 
the substrates, sodium deoxycholate (final concentration 1-2 mM) was used to help 
solubilize the methyl ester. The incubation mixture was acidified to pH 5 and then 
extracted using an Oasis HLB cartridge (Waters Corp.).  
For structural identification of the products of LOX activation by 13S-HPODE, 
large-scale incubations of Cayman unpurified soybean LOX-1 (250 µl of the commercial 
preparation, Catalog No. 60712) with 13S-HPODE (66 µM) in the presence of NDGA 
(80 µM) was performed in 60 ml of air-saturated 50 mM sodium borate pH 10 buffer for 
15 minutes. Although borate would form a complex with NDGA and thus reduce the 
reaction efficiency (27), we found the reaction was largely complete under the used 
conditions. (Other buffers can be used to eliminate this problem.) In addition, 20 µl of 
bovine liver catalase (the commercial preparation, Sigma-Aldrich, C3155) was added to 
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the incubation to eliminate hydrogen peroxide generated from NDGA autoxidation. The 
reaction mixture was acidified to ~ pH 4 and extracted by methylene chloride.  
HPLC-diode array analysis 
RP-HPLC analysis generally used a Waters Symmetry C18 column (0.46 cm × 25 
cm), a flow rate of 1 ml/min, and a solvent system of methanol/water/acetic acid 
(80:20:0.01, by volume). For better resolution of the epoxyalcohol or epoxyallylic 
hydroperoxide products, we performed SP-HPLC analysis using a Beckman Silica 
Ultrasphere column (0.46 cm × 25 cm), a flow rate of 1 ml/min and a solvent system of 
hexane/isopropyl alcohol/acetic acid (100:2:0.02 v/v/v). The monomeric and dimeric 
products from the anaerobic reaction of soybean LOX-1 or Ala451Gly eLOX3 can be 
conveniently separated using a Waters Symmetry C18 column (0.46 cm × 25 cm), a flow 
rate of 1 ml/min and a solvent system of methanol/water/acetic acid (95:5:0.01, by 
volume) (data not shown in the Results). 
Derivatization and GC-MS analysis 
Free fatty acid products were dissolved in a small volume of methanol and then 
converted to the methyl ester by adding ethereal diazomethane. TMS ether derivatives 
were prepared by treatment with bis(trimethylsilyl)-trifluoracetamide (10 µl) and pyridine 
(2 µl) at room temperature for 2 h. Subsequently, the reagents were evaporated under a 
stream of nitrogen and the samples were dissolved in hexane for GC-MS.  
Analysis of the methyl ester trimethylsilyl ether derivatives of the products was 
carried out in the positive ion electron impact mode (70 eV) using a Thermo Finnigan 
Trace DSQ ion trap GC-MS with the Xcalibur data system. Samples were injected at 150 
°C, and after 1 min the temperature was programmed to 300 °C at 20 °C/min. Spectra 
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collected during elution of the GC peak (typically about 10 spectra) were averaged for 
calculation of the isotopic compositions. 
ESI-LC-MS 
ESI-LC-MS was performed using a Thermo Finnigan LC Quantum or LTQ 
instrument. For analysis of the aerobic reactions of soybean LOX-1 or Ala451Gly 
eLOX3 with 13S-HPODE or 15S-HPETE in the presence of NDGA, a Waters Symmetry 
C18 column (0.2 × 15 cm) was eluted with acetonitrile/water/ammonium acetate 
(50:50:10 mM) at 0.2 ml/min. Mass spectra were acquired over the mass range m/z 200-
500 at 2 s per scan under the negative ion mode. For analysis of monomer products from 
the anaerobic reactions of soybean LOX-1 or Ala451Gly eLOX3 with 13S-HPODE and 
arachidonic acid, we used a Phenomenex C18 column (2.6 µm, 0.3 cm × 10 cm), 
methanol/water/ammonium acetate (80:20:10 mM) and a flow rate of 0.3 ml/min. These 
conditions were held for 5 minutes and a gradient started from the weak solvent to pure 
methanol during which the remaining arachidonic acid substrate and dimer products were 
eluted. Mass spectra were acquired over the mass range m/z 200-700 at 2 s per scan 
under the negative ion mode. For detailed analysis of the dimer products, we used a 
Phenomenex C18 column (2.6 µm, 0.3 cm × 10 cm), a flow rate of 0.3 ml/min and a 
solvent system of methanol/water/ammonium acetate (90:10:10 mM), with MS detecting 
negative ions in the range from m/z 500 to m/z 650. HPLC-diode array analysis was also 
performed for each reaction under identical LC conditions.  
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NMR- 1H and 1H,1H-COSY NMR spectra were recorded on a Bruker DXR 600 MHz 
spectrometer at 298K. The ppm values are reported relative to residual non-deuterated 
solvent (δ = 7.16 ppm for C6H6). 
 
Results 
 
Effect of O2 concentration or the Ala451Gly mutation on the lag phase of eLOX3 
Our previous study showed that eLOX3 is capable of oxygenating the synthetic 
fatty acid, 9E,11Z,14Z-20:3ω6 to a specific hydroperoxide, and that the reaction exhibits 
a pronounced lag phase during which the enzyme is slowly activated by trace amounts of 
fatty acid hydroperoxides (135). As known with other LOX enzymes (4,5,132), this lag 
phase can be eliminated using exogenous fatty acid hydroperoxide activators such as 13S-
HPODE (135). To elucidate the role of O2 in eLOX3 activation, first we compared the 
reactions of eLOX3 with 9E,11Z,14Z-20:3ω6 in air- and O2-saturated buffer ([O2] ~240 
µM and ~1.2 mM respectively). We found a consistently shorter lag phase in O2-
saturated buffer than in air-saturated buffer (Figure 27). Only the duration of the lag 
phase, not the maximal oxygenation rate, was affected. Thus, O2 appeared to promote 
eLOX3 activation. We also found that the eLOX3 mutant, Ala451Gly eLOX3, shows a 
shorter lag phase than wild-type eLOX3 (Figure 27). Mutation of Ala to Gly in this 
position is implicated in oxygenation control in many other LOX enzymes (13-
16,115,136) and the result in Figure 1 is consistent with this mutation in eLOX3 
improving the access of O2 within the enzyme active site.  
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Figure 27: Increased O2 concentration or the Ala451Gly mutation shortened the lag phase in the 
reaction of eLOX3 with 9E,11Z,14Z-20:3ω6. A, reaction progress curves monitored at 235 nm. 
Reaction was conducted in sodium phosphate pH 7.5 buffer at room temperature and was started 
by addition of enzyme. Wild-type eLOX3 concentration: 0.10 µM. Ala451Gly eLOX3 
concentration: 0.13 µM. 9E,11Z,11Z-20:3 ω6 concentration: 18-20 µM. B, statistical bar 
representation of the lag phase duration of the reactions in A. The lag phase duration is defined as 
the time axis intercept of a straight line through the portion of the reaction progress curve where 
the rate is maximal. The data are presented as the mean ± the standard deviation. Each of the 
reactions of wild-type eLOX3 in air- and O2-saturated buffer: n=4. The reaction of Ala451Gly 
eLOX3 in air-saturated buffer: n=3. P < 0.01 for every pair of reactions.  
 
 70 
Effect of O2 concentration or the Ala451Gly mutation on the rate of reaction of eLOX3 
with 13S-HPODE  
Fatty acid hydroperoxide activators of LOX-catalyzed oxygenation of 
polyunsaturated substrates are consumed in the activation process (123). This also occurs 
in 13S-HPODE activated eLOX3-catalyzed oxygenations, as we demonstrated previously 
(135). Here we studied the influence of O2 concentration or the Ala451Gly mutation on 
the consumption of 13S-HPODE when incubated by itself with the enzyme. We observed 
an increased rate of 13S-HPODE disappearance on shifting from O2-saturated buffer to 
normoxic buffer, and a further dramatic ~9 fold increase in rate under anaerobic 
conditions (Figure 28, curves a, b, and c). Thus, the initial rate of reaction with 13S-
HPODE was inversely related to the oxygen concentration. We also found that compared 
to wild-type eLOX3 in air-saturated buffer, Ala451Gly eLOX3 reacted very slowly with 
13S-HPODE (Figure 28, curves b and d), a result compatible with improved access to O2 
within the Ala451Gly mutant active site.  
Although counterintuitive, this inhibitory effect of O2 or the Ala451Gly mutation 
on the rate of 13S-HPODE consumption (Figure 28) is in fact consistent with its 
stimulatory effect on eLOX3 activation (Figure 27). Because O2 or the Ala451Gly 
mutation promotes eLOX3 activation, i.e., the single turnover reaction of ferrous eLOX3 
with 13S-HPODE to give ferric eLOX3, it will necessarily impede the ferrous enzyme 
cycling pathway, i.e., the far more productive pathway of 13S-HPODE consumption (cf. 
Figure 26).  
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Figure 28: Increased O2 concentration or the Ala451Gly mutation decreased the rate of the 
reaction of eLOX3 with 13S-HPODE. A, reaction progress curves monitored at 235 nm. Reaction 
was conducted in sodium phosphate buffer pH7.5 at room temperature and was started by 
addition of enzyme. Wild-type eLOX3 concentration: 0.25 µM. Ala451Gly eLOX3 
concentration: 0.32 µM. Note that the oxygenation rate of wild-type eLOX3 at 0.25 µM is similar 
to the oxygenation rate of Ala451Gly eLOX3 at 0.32 µM (Figure 1). 13S-HPODE concentration: 
52-55 µM. B, statistical bar representation of the initial rate of the reactions in A. The data are 
presented as the mean ± the standard deviation. Each of the reactions of wild-type eLOX3 in air- 
and O2-saturated buffer: n=4. The reaction of wild-type eLOX3 under anaerobic conditions: n=3. 
The reaction of Ala451Gly eLOX3 in air-saturated buffer: n=3. P < 0.01 for every pair of 
reactions.  
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Identification of the products in LOX activation by 13S-HPODE 
As noted in the Introduction, for LOX enzymes such as soybean LOX-1 that are 
efficiently activated to the ferric state, the activation process is a single turnover event 
that produces only traces of hydroperoxide-derived products. NDGA affords an 
opportunity to obtain the products in LOX activation in large amounts, since it helps 
regenerate the ferrous enzyme and thus accelerates transformation of the activating 
hydroperoxide (27), in our experiments 13S-HPODE (Figure 33A). Hence, we incubated 
soybean LOX-1 with 13S-HPODE in the presence of NDGA and identified the products 
by RP- and SP-HPLC, LC- and GC-MS, and NMR. The keto derivative 13-KODE 
(product 3 in Figure 29E) was only a minor product. The major products (1 and 2 in 
Figure 29E) showed end absorbance at 205 nm and similar retentions times on RP-
HPLC to C18 epoxyalcohol standards. On SP-HPLC, 1 and 2 were further resolved into 
four products (I and II, 23% and 58% respectively (a ratio of 28:72), and Ia and IIa 6% 
and 13% respectively Figure 29J). Upon TPP reduction, I and II were converted to Ia 
and IIa respectively. LC-MS showed that products Ia and IIa both have the relative 
molecular mass of 312, consistent with the structure of a linoleic acid-derived 
epoxyalcohol, and that product I and II both have the relative molecular mass of 328, 
which, together with the TPP reduction experiment, suggests that I and II are 
hydroperoxide counterparts of Ia and IIa, i.e., epoxyallylic hydroperoxides. GC-MS 
analysis indicated that both Ia and IIa are stereoisomers of 9-hydroxy-12,13S-
epoxyoctadecenoic acid (Figure 30A, 30B). 1H and 1H,1H-COSY NMR analysis 
confirmed such a structure and further revealed that both Ia and IIa contain a trans 
epoxide between C-12 and C-13 (J = 2.0 Hz) and a trans double bond between C-10 and 
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Figure 29: RP- and SP-HPLC analysis of the products from the reactions with 13S-
HPODE.  Analysis of wild-type eLOX3 (panels A, B, C and panels F, G, H), Ala451Gly 
eLOX3 (panels D and I) and soybean LOX-1 following reaction with 13S-HPODE 
(panels E and J). For wild-type eLOX3, O2 concentration was varied in the incubation, 
from 0 (panel A and F) to 240 µM (panel B and G) to 1.2 mM (panel C and H). For 
Ala451Gly eLOX3 and soybean LOX-1, NDGA was included in the incubation. RP-
HPLC analysis used a Water Symmetry C18 column (0.46 cm × 25 cm), a flow rate of 1 
ml/min and a solvent system of methanol/water/acetic acid (80:20:0.01, by volume). SP-
HPLC analysis used a Beckman Silica Ultrasphere column (0.46 cm × 25 cm), a flow rate 
of 1 ml/min and a solvent system of hexane/isopropyl alcohol/acetic acid (100:2:0.02). ∗ 
Control experiments indicated that this peak was not an enzymatic product.  
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Figure 30: GC-MS analysis of products I and II. Mass spectra of the TMS ether methyl ester 
derivative of the TPP-reduced major products (product I and II in figure 3) from the reaction of 
soybean LOX-1 or Ala451Gly eLOX3 with 13S-HPODE in the presence of NDGA. A, product I. 
B, product II.  
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 C-11 (J = 15.5 Hz) (Figure 31). Finally, the stereochemistry of the 9-hydroxyl in Ia and 
IIa was assigned as 9S and 9R respectively based on their order of elution on silica SP-
HPLC (139). Thus, the major products in the activation of soybean LOX-1 by 13S-
HPODE, I and II, are 9S and 9R-hydroperoxy-12S,13S-trans-epoxyoctadec-10E-enoic 
acid respectively (Figure 32).  
Similarly to soybean LOX-1, Ala451Gly eLOX3 barely reacted with 13S-HPODE 
alone and NDGA stimulated this reaction by ~90 fold (Figure 33B). As the reaction 
proceeded, the enzyme was quickly and irreversibly inactivated (Figure 33B). This type 
of LOX inactivation has been documented for soybean LOX-1 and is partly ascribed to 
hydrogen peroxide generated from reaction of NDGA-derived radical intermediates with 
O2 (27). RP-HPLC, SP-HPLC, LC-MS analyses and also TPP reduction of the products 
from the reaction of Ala451Gly eLOX3 in the presence of NDGA revealed that 13S-
HPODE was converted to the same major products I and II as in the reaction of soybean 
LOX-1, albeit with a different ratio of 42:58 (Figure 29D, 29I, Figure 32). On prolonged 
incubations with an excess of enzyme, the epoxyallylic hydroperoxide products I and II 
were further converted by Ala451Gly eLOX3 to an epoxyketone compound (9-keto-
12S,13S-trans-epoxyoctadec-10E-enoic acid), the structure of which was identified by 
1H-NMR and 1H,1H-COSY NMR and NaBH4 reduction (data not shown). 
For the reaction of wild-type eLOX3 with 13S-HPODE, a considerable 
stimulation (~23 fold) was also observed in the presence of NDGA (Figure 33C). 
However, whether NDGA was present or not, 13S-HPODE was converted to a different 
set of products, among which the two most prominent were 13-KODE (product 3 in 
Figure 29) and one stereoisomer of 11-hydroxy-12,13S-epoxy-octadec-9Z-enoic acid  
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Figure 31A 
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Figure 31B 
 
 
Figure 31 (A) 1H and 1H,1H-COSY NMR spectra of TPP-reduced product I (Figure 29) 
in C6D6. (B) 1H and 1H,1H-COSY NMR spectra of TPP-reduced product II (Figure 29) in 
C6D6.  
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Figure 32: The major products formed in LOX activation by 13S-HPODE. 
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Figure 33: Effect of NDGA on the rates of reaction with 13S-HPODE. NDGA (20 µM) 
stimulated the reaction of soybean LOX-1 (0.06 µM panel A), Ala451Gly eLOX3 (0.32 
µM, panel B), or wild-type eLOX3 (0.25 µM, panel C) with 13S-HPODE (55 µM). The 
incubations were performed in sodium phosphate buffer pH 7.5 and initiated by addition 
of enzyme. NDGA was added at the indicated point. For the reaction of Ala451Gly 
eLOX3 or soybean LOX-1, a second equal aliquot of enzyme was added at the indicated 
point. 
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(product III in Figure 29, identified by GC-MS in Figure 34). Despite this, careful 
examination revealed that the epoxyallylic hydroperoxides I and II were also present as 
minor products. On TPP reduction, these two products were converted to the 
epoxyalcohols Ia and IIa. Importantly, the production of I and II by wild-type eLOX3 
was O2-dependent: under anaerobic conditions, I and II were absent and only 13-KODE 
and epoxyalcohols were produced (Figure 29F); in air-saturated buffer, I and II 
constituted 7% of total products (Figure 29G); in O2-saturated buffer, the yield of I and 
II was increased to 11% (Figure 29H).  
Identification of the products in LOX activation by 15S-HPETE  
Similarly, soybean LOX-1 or Ala451Gly eLOX3 reacted with 15S-HPETE in air-
saturated buffer in the presence of NDGA to give a non-specific mixture consisted of 
mainly epoxyallylic hydroperoxides (Figure 35A, 35B, Figure 36). Wild-type eLOX3, 
on the other hand, gave a specific epoxyalcohol, threo-13R-hydroxy-14S,15S-trans-
epoxyeicosa-5Z,8Z,11Z-trienoic acid followed by 15-KETE (Figure 35C and ref. (37)).  
Reaction of soybean LOX-1 or Ala451Gly eLOX3 with 13S-HPODE under anaerobic 
conditions  
As already demonstrated for wild-type eLOX3, the conversion of 13S-HPODE by 
wild-type eLOX3 was dramatically accelerated under anaerobic conditions giving 
exclusively epoxyalcohols and 13-KODE (Figures 28, 29A and 29F). I questioned 
whether the same applies to soybean LOX-1 and Ala451Gly eLOX3. The anaerobic 
reaction of soybean LOX-1 with 13S-HPODE has been extensively investigated 
(30,31,33) and these findings were confirmed in the present study. The anaerobic  
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Figure 34: GC-MS analysis of the TMS ether methyl ester derivative of the major 
product (product III in Figure 29) from the reaction of wild-type eLOX3 with 13S-
HPODE.  
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Figure 35: RP-HPLC analysis of the products from the reactions with 15S-HPETE. Products 
from reaction of 15S-HPETE with Ala451Gly eLOX3 (panel A), soybean LOX-1 (panel B), and 
wild-type eLOX3 (panel C). RP-HPLC analysis used a Waters Symmetry C18 column (0.46 cm × 
25 cm), a flow rate of 1 ml/min and a solvent system of methanol/water/acetic acid (80:20:0.01, 
by volume). 
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Figure 36: SP-HPLC analysis of the products from the aerobic reactions of Ala451Gly 
eLOX3 and soybean LOX-1 with 15S-HPETE before and after TPP reduction. (A) 
Ala451Gly eLOX3, before TPP reduction. (B) Soybean LOX-1, before TPP reduction. 
(C) Ala451Gly eLOX3, after TPP reduction. (D) Soybean LOX-1, after TPP reduction. 
SP-HPLC analysis used a Beckman Silica Ultrasphere column (0.46 cm × 25 cm), a flow 
rate of 1 ml/min and a solvent system of hexane/isopropyl alcohol/acetic acid 
(100:2:0.02). The epoxyalcohol products were identified by comparison with authentic 
standards (140). 
 84 
conditions afforded only a mild stimulation on the reaction of soybean LOX-1 with 13S-
HPODE alone (33,137); at sub-micromolar enzyme concentrations, the rate of 
consumption of 13S-HPODE by soybean LOX-1 was negligible even under anaerobic 
conditions compared to wild-type eLOX3. When further stimulated by linoleic acid or 
arachidonic acid (which serves as a LOX reducing agent under anaerobic conditions), the 
reaction yielded not only epoxyalcohols and 13-KODE, but also significant amounts of 
C13 aldehydes and fatty acid dimers. 
Although considered later in Discussion, it might be helpful to note at this stage 
that both the anaerobic and aerobic behavior of soybean LOX-1 and Ala451Gly eLOX3 
is consistent with the concept that their reaction with hydroperoxides is often followed by 
dissociation of the fatty acid radicals produced, leaving the enzyme in the activated ferric 
state and thus able to oxygenate polyunsaturated substrates, while unable to further react 
with hydroperoxides. 
Consistent with this, we found that Ala451Gly eLOX3 also required a LOX 
reducing agent in order to react with 13S-HPODE under anaerobic conditions (Figure 
37) and gave products qualitatively similar to those from soybean LOX-1 yet with one 
notable exception. In addition to epoxyalcohols, 13-KODE, C13 aldehydes and fatty acid 
dimers, the reaction of Ala451Gly eLOX3 with 13S-HPODE and arachidonic acid or 
methyl arachidonate unexpectedly gave considerable amounts of (methyl) HETEs 
(Figure 38, Figure 39, Figure 40). These were hydroxy products, not hydroperoxides. 
The relative amounts of these HETE products (5-HETE + 9-HETE > 15-HETE + 11-
HETE > 8-HETE + 12-HETE) were consistent with the preference of this enzyme in  
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Figure 37: Progress curves of the anaerobic reactions of Ala451Gly eLOX3 (0.23 µΜ) 
with 13S-HPODE (90 µM). Reactions were conducted in the absence or presence of fatty 
acids (arachidonic acid or methyl arachidonate, 70 µΜ) in sodium phosphate buffer pH 
7.5, were started by addition of enzyme, and were monitored at 280 nm. The anaerobic 
conditions are described in the Materials and Methods. 
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Figure 38: RP-HPLC analysis of the monomeric products from the anaerobic reaction of 
Ala451Gly eLOX3 with 13S-HPODE and arachidonic acid. RP-HPLC analysis used a 
Waters Symmetry C18 column (0.46 cm × 25 cm), a flow rate of 1 ml/min and a solvent 
system of methanol/water/acetic acid (80:20:0.01, by volume). 
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Figure 39: RP-HPLC-UV and LC-ESI-MS analysis of the dimer products from the 
anaerobic reaction of Ala451Gly eLOX3 with 13S-HPODE and arachidonic acid. RP-
HPLC analysis used a Phenomenex C18 column (2.6 µm, 0.3 cm × 10 cm), a flow rate of 
0.3 ml/min and a solvent system of methanol/water (90:10 by volume) containing 10 mM 
ammonium acetate. MS analysis detected negative ions in the range from m/z 500 to m/z 
650. Under these conditions, arachidonic acid eluted at 3.0 min (data not shown).  
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Figure 40: LC-ESI-MS analysis of the products from the anaerobic reaction of 
Ala451Gly eLOX3 with 13S-HPODE and arachidonic acid. The RP-HPLC used a 
Phenomenex C18 column (2.6 µm, 0.3 cm × 10 cm), a flow rate of 0.3 ml/min and 
initially an isocratic solvent system of methanol/water/ammonium acetate (90:10:10 mM) 
for 5 minutes followed by a gradient elution from the weak solvent to pure methanol. MS 
analysis detected negative ions in the range from m/z 200 to m/z 700.  
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hydrogen abstraction under aerobic conditions (H-7 > H-13 > H-10) (135), pointing to a 
similar hydrogen abstraction step during this anaerobic HETE synthesis. Incubations with 
[18O]-13S-HPODE or in H218O followed by LC-MS analysis led to the unexpected 
finding that the hydroxyl of these HETE products was derived exclusively from water 
(Figure 41). The mechanism of formation of these HETE products is considered in the 
Discussion. As to the leading question, we concluded that for soybean LOX-1 or 
Ala451Gly eLOX3, epoxyalcohols and ketone are formed from 13S-HPODE in better 
yields anaerobically than aerobically, yet the synthesis of these compounds is prevented 
by other factors from being the only mechanism in operation. Their formation may be 
hindered by spontaneous dissociation of the radical intermediates from the enzyme, see 
Discussion. 
As a control, incubation of wild-type eLOX3 with both 13S-HPODE and methyl 
arachidonate under identical anaerobic conditions showed that 13S-HPODE was 
converted to the same set of epoxyalcohols and 13-KODE as in the absence of methyl 
arachidonate, whereas methyl arachidonate remained unconverted. This can be explained 
if wild-type eLOX3 reacts with 13S-HPODE strictly through the cycling pathway under 
anaerobic conditions and thus remains in the ferrous state when in the free enzyme form, 
which is inactive towards methyl arachidonate. Similarly, Ala451Gly eLOX3 failed to 
metabolize methyl arachidonate when 12R-HPETE instead of 13S-HPODE was co-
incubated under anaerobic conditions. Unlike 13S-HPODE, 12R-HPETE was converted 
by Ala451Gly eLOX3 to epoxyalcohol and ketone products (8R-hydroxy-11R,12R-
epoxyeicosa-5Z,9E,14Z-trienoic acid and 12-KETE) whether O2 is present or not,  
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Figure 41: Mass spectra of 15-HETE formed in the reaction of Ala451Gly eLOX3 with 
13S-HPODE and arachidonic acid. A, the reaction with [16O]-13S-HPODE in H216O. B, 
the reaction with [18O]-13S-HPODE in H216O. C, the reaction with [16O]-13S-HPODE in 
83% H218O. The mass spectra were obtained in LC-ESI-MS analysis using a Phenomenex 
C18 column (2.6 µm, 0.3 cm × 10 cm), a flow rate of 0.3 ml/min and a solvent system of 
methanol/water (80:20, by volume), containing 10 mM ammonium acetate. MS analysis 
detected negative ions in the range from m/z 200 to m/z 700. 
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implying that with 12R-HPETE the hydroperoxide isomerase activity of Ala451Gly 
eLOX3 is dominant. Taken together, these results emphasized the importance of the 
enzyme shuttling between the two oxidation states during the synergistic conversion of 
(methyl) arachidonate and 13S-HPODE by Ala451Gly eLOX3 or soybean LOX-1.  
Reaction of soybean LOX-1 or Ala451Gly eLOX3 with 15S-HPETE under anaerobic 
conditions 
When 15S-HPETE alone was used as substrate, significant conversion by either 
soybean LOX-1 or Ala451Gly eLOX3 did occur under anaerobic conditions. Part of the 
reason could be that 15S-HPETE itself serves as a reducing agent to stimulate the 
reaction, due to the presence of the C5-C9 and C8-C12 pentadiene systems on the 
molecule. Strikingly, for both soybean LOX-1 and Ala451Gly eLOX3, the major product 
(>50% yield) is the single epoxyalcohol threo-13R-hydroxy-14S,15S-trans-epoxyeicosa-
5Z,8Z,11Z-trienoic acid (product IV, Figure 42A and 42B), the same molecule as found 
in the reaction of wild-type eLOX3 with 15S-HPETE either aerobically or anaerobically 
(Figure 35C and Figure 42C). (The identification of product IV has been described in 
detail in Ref. (138)). Yet unlike in wild-type eLOX3 reaction, besides the epoxyalcohol 
and 15-KETE (product V), other products were also present, including C15 aldehydes 
(product I), leukotriene-type 8,15-diols (product II and III), and for soybean LOX-1, two 
unusual 5,15-diols (138). Thus, for soybean LOX-1 and Ala451Gly eLOX3, anaerobic 
conditions promoted specific epoxyalcohol synthesis from 15S-HPETE, yet the 
“perfected” epoxyalcohol synthesis as catalyzed by wild-type eLOX3 was still not 
achieved.  
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Figure 42. RP-HPLC analysis of the products from anaerobic reactions with 15S-
HPETE. A, Ala451Gly eLOX3. B, soybean LOX-1. C, wild-type eLOX3. RP-HPLC 
analysis used a Waters Symmetry C18 column (0.46 cm × 25 cm), a flow rate of 1 
ml/min and a solvent system of methanol/water/acetic acid (80:20:0.01, by volume). 
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Discussion 
 
In this study, we have demonstrated that O2 is involved in LOX activation, a 
central piece of evidence being that O2 itself is incorporated into the products from LOX 
activation. Our study also demonstrates that for eLOX3, the enzyme activation and the 
hydroperoxide isomerase activity are in competition and are reciprocally regulated by O2. 
To explain the preponderance of the hydroperoxide isomerase activity over the enzyme 
activation in eLOX3 under normoxic conditions, we propose a model of limited O2 access 
in its enzyme active site. For soybean LOX-1, although complexity arises to suggest that 
the enzyme activation may occur to some extent even under anaerobic conditions, O2 if 
present will penetrate into the enzyme active site and help maximize the efficiency of 
enzyme activation. In a context of enzyme evolution, we suggest that restricting O2 access 
to the enzyme active site is one crucial mechanism that enables eLOX3 to develop the 
unique hydroperoxide isomerase activity that distinguishes itself from soybean LOX-1 
and other typical LOX enzymes.   
A chemical model of LOX activation 
It has long been recognized that ferrous ion, whether in aqueous solutions, in 
model complexes or in proteins, readily induces homolytic cleavage of the peroxide bond 
in an alkyl hydroperoxide to give an alkoxyl radical and a hydroxide, with itself being 
converted to the ferric ion (38,39,141-143). A PUFA-derived alkoxyl radical usually 
exists in equilibrium with an epoxyallylic radical and the fate of such an 
alkoxyl/epoxyallylic radical is usually one of the following: 1) combination of the 
epoxyallylic radical with other radicals, favored in the presence of an efficient radical 
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trap; 2) loss of the β-hydrogen from the alkoxyl radical to become a ketone, favored in 
the presence of a strong oxidant that helps abstract the β-hydrogen; 3) carbon-carbon 
chain cleavage resulting in an aldehyde and an alkyl radical, favored if a γ double bond 
exists to help stabilize the alkyl radical fragment (144,145). Despite these complexities, 
the pioneering work led by Gardner and colleagues suggests that in a simple system such 
as aqueous ferrous ion, cysteine, and 13S-HPODE, the major route of the 
alkoxyl/epoxyallylic radical under aerobic conditions is the combination of the 
epoxyallylic radical with O2, an efficient radical trap, followed by hydrogen abstraction 
to give epoxyallylic hydroperoxides, which, in the cysteine/Fe2+ system, will be further 
converted to epoxyketones (141,146-148).  
The mechanism of LOX activation 
Based on the above chemical precedence, we suggest for LOX activation a similar 
mechanism from an alkoxyl radical to the epoxyallylic hydroperoxide products, with O2 
playing the central role as a radical trap. Yet it merits attention that the ratio of the two 
epoxyallylic hydroperoxide products from soybean LOX-1 epimeric at C-9 (28:72, 
Figure 29J) is clearly deviated from the ratio of 50:50 as predicted in the chemical 
system. We surmise that in LOX activation, the combination of the epoxyallylic radical 
with O2 occurs largely under the enzymatic control, i.e., within the enzyme active site 
where oxygen supplies to the two faces of the molecule are often unequal. Once 
produced, these epoxyallylic peroxyl radicals will then be released into the solution, 
leaving the enzyme in the activated ferric state and free to react with polyunsaturated 
fatty acid substrates. 
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Up to this point, the enzyme activation is complete yet the fate of the epoxyallylic 
peroxyl radical in the solution is uncertain. It is often suggested in the literature that two 
such epoxyallylic peroxyl radicals in solution would combine by the Russell mechanism 
to give epoxyketone, epoxyalcohol and singlet oxygen (143), or that the epoxyallylic 
peroxyl radical would transfer an oxygen atom to certain susceptible compounds (e.g., to 
epoxidize a double bond) with itself being converted to an epoxyalcohol (21,149). 
Although we cannot exclude these possibilities, here we have demonstrated, in agreement 
with the chemical model, that the major route for an epoxyallylic peroxyl radical in 
solution is to abstract a hydrogen atom from certain source to become an epoxyallylic 
hydroperoxide. It might be argued that this could be an artifact brought by NDGA we 
used in the study to regenerate the enzyme and thus to amplify the reaction, since NDGA 
is also a free radical scavenger. However, we consider this rather unlikely, because we 
found in an analogous reaction of Anabaena LOX that when a large quantity of purified 
enzyme instead of NDGA was used, the product pattern of the Anabaena LOX activation 
by 9R-HPODE remained largely unchanged (although in this case, the epoxyallylic 
hydroperoxides were further dehydrated to epoxyketones as in the chemical model, 
Zheng and Brash, unpublished observations). The chemical transformations involved in 
LOX activation are summarized in Scheme 32.  
Is O2 required for LOX activation? 
It is natural to ask whether the observed incorporation of O2 into the products is 
necessary for LOX activation/oxidation. An alternative scenario is that the alkoxyl radical 
is produced in the enzyme active site and then simply released into the solution resulting 
in LOX activation. The present study unexpectedly provides two different answers to this 
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question for the two enzymes, eLOX3 and soybean LOX-1, suggesting variability within 
the LOX family.  
For eLOX3, O2 is required for the enzyme activation, as suggested by three lines 
of evidence. First, increasing O2 concentration promotes the enzyme activation in the 
oxygenation of 9E,11Z,14Z-20:3ω6 (Figure 27). Second, the anaerobic incubation of 
eLOX3 with 13S-HPODE and methyl arachidonate results in the production of 
exclusively epoxyalcohols and 13-KODE from 13S-HPODE with no conversion of 
methyl arachidonate, the latter suggesting that the enzyme is never activated to the ferric 
form under anaerobic conditions. From a different perspective, for eLOX3, the 
hydroperoxide isomerase activity with 13S-HPODE operates at full speed only when the 
competing enzyme activation pathway is fully suppressed under the anaerobic conditions 
(Figure 28). Third, in sharp contrast to the second point, in the presence of O2, eLOX3 
will be activated by 13S-HPODE and will then convert (methyl) arachidonate into a 
mixture of (methyl) HPETEs (135). Given this stringent O2 requirement, we further 
deduce that the relative low efficiency of eLOX3 activation is a consequence of limited 
oxygen access in the enzyme active site. 
For soybean LOX-1, however, O2 seems only to help maximize the efficiency of 
enzyme activation. Although the hydroperoxide isomerase activity as indicated by 
epoxyalcohol and ketone synthesis is indeed promoted by the anaerobic conditions, it is 
not the only mechanism in operation. That the enzyme activation/oxidation occurs to 
some extent even in the absence of O2 is suggested by the observations that linoleic or 
arachidonic acid is converted via the corresponding fatty acid radical to fatty acid dimers 
in the presence of 13S-HPODE under anaerobic condition or that 15S-HPETE is 
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converted via either C-7 or C-10 centered radicals to allylic epoxides such as 14,15-LTA4 
(Figure 42B), both of which have been ascribed to the ferric enzyme form (28,125,138). 
This O2-independent enzyme activation is best explained if a fraction of the 
alkoxyl/epoxyallylic radical intermediate is released into the solution, probably due to a 
low affinity of the enzyme for this radical intermediate, leaving the enzyme in the 
activated, ferric state. Indeed, some of the released alkoxyl/epoxyallylic radicals are 
subsequently trapped in fatty acid dimers, which have been shown to form in the solution 
as opposed to in the enzyme active site (32). Nevertheless, it is beyond doubt that the 
efficiency of enzyme activation will be maximized under aerobic conditions, when the 
fatty acid hydroperoxide is efficiently utilized for enzyme activation with minimal 
conversion to epoxyalcohols and ketones.  
The effect of the Ala451Gly mutation on eLOX3 activation 
Strikingly, the single amino acid substitution Ala451Gly causes eLOX3 to switch 
from the hydroperoxide isomerase cycling pathway to the single turnover enzyme 
activation pathway in the reaction with 13S-HPODE or 15S-HPETE. The close 
resemblance of Ala451Gly eLOX3 to soybean LOX-1 in the chemistry of enzyme 
activation by 13S-HPODE or 15S-HPETE is evident either under aerobic conditions or 
under anaerobic conditions. To explain this effect of the Ala451Gly mutation, we have 
considered two possibilities not mutually exclusive. In the first possibility, this mutation 
opens up space either directly or indirectly, thereby allowing O2 to react with the 
epoxyallylic radical intermediate in the enzyme active site. Consistent with this 
possibility is the finding by Oliw and colleagues that the opposite mutation in the fungal 
Mn LOX, Gly316Ala, produces the opposite effect, i.e., a switch from dioxygenase to 
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hydroperoxide isomerase activity (114). Presumably, O2 is barred from reacting with the 
epoxyallylic radical intermedate when Gly316 is replaced with Ala in Mn LOX.  
In the second possibility, the Ala451Gly mutation results in a lower affinity of the 
enzyme for the alkoxyl/epoxyallylic radical intermediate, which once released will also 
lead to enzyme activation. This will not be unexpected since this residue lies on the 
surface of the active site and may be directly involved in the 
substrate/intermediate/product binding. Consistent with this possibility, the two 
epoxyallylic hydroperoxide products from 13S-HPODE are in a ratio of 42:58 (cf. 28:72 
in soybean LOX-1) and thus may derive comparatively more from combination of the 
epoxyallylic radical with O2 in the solution. Also, as already explained for soybean LOX-
1, the formation of dimers containing an epoxyallylic structure in the anaerobic reaction 
of Ala451Gly eLOX3 with 13S-HPODE and arachidonic acid (Figure 39) is strong 
evidence for the occurrence of the alkoxyl/epoxyallylic radical leakage.  
It should be emphasized, however, that this switch to the enzyme activation 
pathway does not apply to every fatty acid hydroperoxide. 12R-HPETE, for example, is 
still predominantly converted to an epoxyalcohol and 12-KETE by Ala451Gly eLOX3. 
This probably explains why this mutation only partially alleviates the pronounced lag 
phase exhibited by wild-type eLOX3 in fatty acid oxygenation (Figure 27 and (135)).  
A novel mechanism of HETE synthesis  
In this study, the anaerobic reaction of Ala451Gly eLOX3 with 13S-HPODE and 
(methyl) arachidonate unexpectedly gives significant amounts of HETEs. LOX enzymes 
are known to operate through free radical mechanisms. The free radical nature of this 
HETE synthesis is also suggested by the product pattern (5-HETE + 9-HETE > 11-HETE 
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+ 15-HETE > 8-HETE + 12-HETE) that is consistent with the preference of this enzyme 
in hydrogen atom abstraction (H-7 > H-13 > H-10) (135). Thus, it seems paradoxical that 
the HETEs generated in a free radical reaction derive the hydroxyl group from water, 
which is often considered as evidence for an ionic mechanism.  
We suspect that what is actually incorporated into the HETE products is the 
hydroxide ligand of the non-heme ferric iron in the enzyme active site rather than water 
in the bulk solvent. The hydroxide ligand of the non-heme iron can be conceived as a 
trapped hydroxyl radical, and its combination with an arachidonate carbon radical to give 
HETEs seems feasible on chemical grounds. (In fact it mimics the rebound hydroxylation 
step in the hydroperoxide isomerase cycle producing epoxyalcohols (37).) Notably, for 
HETE synthesis this mechanism necessitates two molecules of the ferric enzyme to 
generate one molecule of HETE: the first molecule of ferric enzyme abstracts a hydrogen 
from arachidonic acid to generate the corresponding carbon radical and then releases it 
into the solution; this released arachidonic acid radical then fetches the trapped hydroxyl 
radical from a second molecule of ferric enzyme and becomes the final HETE product. In 
addition, this mechanism assumes that the hydroxide ligand of the non-heme iron readily 
exchanges with water in the bulk solvent. It would be of interest to further investigate the 
mechanism of this unusual HETE synthesis. Also, it remains to be ascertained whether 
this type of HETE synthesis is unique to Ala451Gly eLOX3 or is general among LOX 
enzymes. In the anaerobic reaction of soybean LOX-1 with arachidonic acid and 13S-
HPODE, 15-HETE and 11-HETE were also observed among the minor products, but the 
origin of the hydroxyl group in these HETE products was not investigated here due to 
their minute amounts.  
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Conclusions 
In the present study, we have established the role of O2 in LOX activation and 
elucidated the chemistry involved (Figure 43). The key event leading to LOX activation 
is dissociation of a ferric LOX-radical intermediate complex. O2 facilitates this 
dissociation and arrests the competing hydroperoxide isomerase cycling pathway by 
reacting with the epoxyallylic radical intermediate to give an epoxyallylic peroxyl 
radical, which, due to its limited reactivity within the enzyme active site, will leave the 
enzyme resulting in enzyme activation. 
 
Figure 43 Proposed model explaining the role of O2 in promoting LOX activation and 
inhibiting hydroperoxide isomerase activity. 
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CHAPTER IV 
 
ESSENTIAL FATTY ACIDS, 12R-LOX AND ELOX3, AND EPIDERMAL 
BARRIER FORMATION 
 
Introduction 
 In 1929, Burr & Burr famously reported the existence of essential fatty acids 
(EFA), and noted the most obvious symptom of EFA deficiency as “an abnormal scaly 
condition of the skin” (49). This phenotype is associated with defects in barrier function 
and trans-epidermal water loss (51,52), and thus resembles the human genetic disorders 
of ichthyosis, diseases with a dry, thickened, scaly skin. Linoleate is by far the most 
abundant EFA in the epidermis, being mainly esterified to the omega hydroxyl of the 
very long chain FA in two classes of sphingolipids unique to the epidermis, namely 
acylceramides and acylglucosylceramides. The most abundant subclass of these are 
esterified omega-hydroxyacyl-sphingosine (EOS) and Gluc-EOS, respectively (Scheme) 
(150). Acylglucosylceramides are the precursor of acylceramides (75) and a portion of 
acylceramides will be further converted to ω-hydroxyceramides (mainly omega-
hydroxyacyl-sphingosine, OS) that will then be covalently attached to the cross-linked 
proteins in the cornified cell envelope (CE) (69,70). These covalently bound ω-
hydroxyceramides are the main component of the corneocyte lipid envelope (CLE), and 
together with the underlying CE, constitute a specialized structure indispensable for the 
integrity of the water barrier (72,150,151). 
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 ALOX12B and ALOXE3 are the only human lipoxygenase genes that, if mutated 
to inactive forms, will cause a disease (86,100). The disease, autosomal recessive 
congenitial ichthyosis (ARCI), occurs in response to a defective skin barrier, and exhibits 
a typical ichthyosiform scaly skin. Because the same phenotype is caused by mutation of 
either gene, the encoded proteins, 12R-lipoxygenase (12R-LOX) and epidermal 
lipoxygenase-3 (eLOX3), are proposed to function in the same pathway during epidermal 
barrier formation. The recent 12R-LOX-/- and eLOX3-/- mouse models confirm their 
importance in epidermal barrier formation; indeed, deletion of either alox12b or aloxe3 is 
neonatal lethal, the pups dying of dehydration within hours of birth (89-91). Biochemical 
studies also suggest that the two enzymes act in tandem: 12R-LOX first makes a specific 
hydroperoxide from a fatty acid substrate, and eLOX3 in turn converts the 12R-LOX 
product into a specific epoxyalcohol (37). The physiological substrate of 12R-LOX and 
eLOX3 in the epidermis, however, remains to be identified. And why does the lack of 
LOX products lead to an impaired barrier function? 
 Two further observations led me to propose a model that may explain 
simultaneously the role of 12R-LOX and eLOX3 and the role of EFA in the epidermis. In 
essential fatty acid deficient epidermis, where the linoleate moiety of acylceramides and 
acylglucosylceramides is replaced by oleate, the covalently bound ω-ceramides are 
significantly decreased (78). In 12R-LOX-/- mouse epidermis, the covalently bound ω-
ceramides, as detected by thin layer chromatography, are greatly depleted (89). Putting 
all this information together, I propose that the two LOX enzymes oxygenate the linoleate 
esterified in acylglucosylceramdes or acylceramides. I further propose, in turn, that this 
LOX-catalyzed oxygenation is required to facilitate hydrolysis of the (oxidized) linoleate 
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moiety and leave free the very long chain FA omega hydroxyl for coupling to the CE 
proteins. To test this hypothesis, I first examined the proposed reactions in vitro, then 
looked for LOX metabolites in both pig and mouse epidermis, and finally with the aid of 
a 12R-LOX-/- mouse model, evaluated the impact of the putative 12R-LOX-eLOX3 
pathway on the profiles of both free and covalently bound ceramides, and on the CLE 
structure in the stratum corneum of mouse epidermis. 
Experimental Procedures 
Materials 
HODE methyl ester standards were synthesized by autoxidation of methyl 
linoleate (NuChek Prep Inc.) followed by triphenylphosphine reduction and HPLC 
purification. HODE free acid standards were generated by alkaline hydrolysis of the 
corresponding methyl esters or by reacting soybean LOX-1 (Sigma-Aldrich) or Anabaena 
LOX (16) with linoleic acid (NuChek Prep Inc.). Epoxyalcohol standards were 
synthesized by reacting hematin with 9S-HPODE. 4-Hydroxy-TEMPO and CHAPS were 
purchased from Sigma-Aldrich. Generation of 12R-LOX-deficient mice via N-ethyl-N-
nitrosourea mutagenesis has been described previously (91). Human 12R-LOX and 
human eLOX3 were expressed and purified as described previously (14).  
Preparation of epidermis 
Sections of pig skin (ca. 10 cm × 10 cm) were immersed in 65 °C water for 2 min, 
and then the epidermis was separated from the dermis using a razor blade. Mouse 
epidermis was isolated after treating the skin with 1.5 mg/ml Dispase II (Roche) in 
phosphate buffered saline at 4°C overnight.  
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Lipid extraction  
The epidermis was homogenized in chloroform-methanol mixtures (1:1 and 2:1, 
v/v). The organic layer was separated from the protein pellet by centrifugation. This was 
repeated four times. The lipids were extracted by the Bligh and Dyer method (152). The 
lipid extract was dried using a rotary evaporator or under a stream of N2 and then 
redissolved in chloroform-hexane (1:1, v/v). The lipid extract was then loaded onto a pre-
equilibrated solid phase silica column (Bond Elut, Varian, Inc.), washed with chloroform-
hexane (1:1, v/v), and eluted with chloroform and chloroform-methanol (2:1, v/v). 
Recovery of ester-linked protein-bound lipids 
After removal of free (and reversibly bound) lipids, protein pellets were incubated 
in 1M KOH in 95% methanol at room temperature overnight. The methanolic layer was 
removed after centrifugation, neutralized with 1N HCl, and then extracted by the Bligh & 
Dyer method. The protein pellet was washed by chloroform-methanol (1:1, v/v), which 
was then extracted by the Bligh & Dyer method. The organic phases were combined, 
dried, and redissolved in the LC solvent.  
Isolation of glucosyl-Cer[EOS] and Cer[EOS] from pig epidermis 
Glucosyl-Cer[EOS] and Cer[EOS] were isolated from the lipid extract by SP-
HPLC with APCI-MS detection (153). SP-HPLC used a Waters 2695 pump, a Beckman 
Silica Ultrasphere column (5 µm, 10 mm × 25 cm), a gradient program from chloroform 
to chloroform-isopropanol (1:1, v/v) in 15 min, and a flow rate of 5 ml/min. An Upchurch 
Scientific TEE was used to split the flow between the fraction collector and the mass 
spectrometer, a Finnigan LCQ deca XP or a Finnigan LTQ instrument (Thermo 
Electron). The APCI vaporizer temperature was set to 500 °C and the capillary 
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temperature to 150 °C. The spectra were obtained in full scan mode monitoring positive 
ions between m/z 400 and m/z 1500.  
Reaction of 12R-LOX and eLOX3 with glucosyl-Cer[EOS] or Cer[EOS].  
Isolated glucosyl-Cer[EOS] (final concentration: 60 µM) or Cer[EOS] (final 
concentration: 40 µM), together with the antioxidant 4-hydroxy-TEMPO (final 
concentration: 1 mM), was taken to dryness under a stream of N2. The lipids were 
dispersed in 2 ml of sodium phosphate pH 6.0 with 10 mM CHAPS by sonication on ice 
and then incubated with 12R-LOX (final concentration: 5 µM) at room temperature for 2 
h. To study the reaction of eLOX3, HPLC-purified 12R-LOX products (final 
concentration: 10-15 µM) were dispersed in 1 ml of sodium phosphate pH 6.0 with 10 
mM CHAPS by sonication on ice, and then incubated with eLOX3 (final concentration: 5 
µM) at room temperature for 2h. Both 12R-LOX and eLOX3 products were extracted by 
the Bligh and Dyer method.  
 
HPLC-UV and LC-MS analysis of 12R-LOX and eLOX3 reactions  
All HPLC-UV analyses used an Agilent 1100 or 1200 system with diode array 
detection. Reactions with glucosyl-Cer[EOS] were analyzed by RP-HPLC-UV analysis 
using a Zorbax Eclipase XDB-C8 column (5 µm, 4.6 mm × 15 cm), an isocratic solvent 
system of methanol/hexane (10:1, v/v) for 12R-LOX reaction or methanol/water (100:2, 
v/v) for eLOX3 reaction, and a flow rate of 1 ml/min. For reactions with Cer[EOS], we 
used SP-HPLC analysis instead, as described in the next section. Prior to LC-MS 
analysis, 12R-LOX products were reduced with excess triphenylphosphine, because 
hydroperoxides were not stable under the used APCI conditions. LC-MS analysis used 
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the same chromatography conditions as the corresponding HPLC-UV analysis, and the 
same APCI-MS conditions as described above.  
HPLC-UV and LC-MS analysis of epidermal ceramides 
SP-HPLC-UV analysis used a Beckman Silica Ultrasphere column (5 µm, 4.6 mm 
× 25 cm), a solvent system of hexane/isopropanol/acetic acid (90:10:0.1, v/v/v), and a 
flow rate of 1 ml/min. LC-MS analysis used the same chromatography conditions. For 
MS analysis of free and reversibly protein-bound ceramides, we used the same APCI 
conditions as described above. For analysis of ester-linked protein-bound ω-
hydroxyceramides, the APCI vaporizer temperature was set to 275 °C and the capillary 
temperature to 250 °C.  
Transesterification of oxygenated acyl(glucosyl)ceramides and HPLC-UV analysis of the 
methyl esters 
HPLC-purified samples were incubated with 0.16 M sodium methoxide in 
chloroform-methanol (2:1, v/v) at room temperature for 1h. After the reaction, the 
mixture was acidified by 1M KH2PO4 and the organic phase was washed with water 
before being dried and redissolved in the HPLC solvent. SP-HPLC-UV analysis of 
HODE methyl esters used a Beckman Silica Ultrasphere column (5 µm, 4.6 mm × 25 
cm), a solvent system of hexane/isopropanol (100:2, v/v), and a flow rate of 1 ml/min. 
Chiral HPLC-UV analysis of HODE methyl esters used a solvent system of 
hexane/methanol/ethanol (100:5:5, v/v/v), with either a Chiralpak AD column (5 µm, 4.6 
mm × 25 cm) eluted at 1 ml/min, or a Chiralpak AD column (5 µm, 2.1 mm × 15 cm) 
eluted at 0.2 ml/min. SP-HPLC-UV analysis of epoxyalcohol methyl esters used a 
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Beckman Silica Ultrasphere column (5 µm, 4.6 mm × 25 cm), a solvent system of 
hexane/isopropanol (100:2 or 100:1.5, v/v), and a flow rate of 1 ml/min. 
 
GC-MS analysis 
Derivatization and GC-MS analysis of epoxyalchols were performed as described 
previously (138). 
 
 
Results 
 
12R-LOX and eLOX3 react with glucosyl-EOS or EOS in vitro 
The species of glucosyl-EOS purified from pig skin were detected by RP-HPLC 
with UV absorbance at 205 nm as a series of structural analogues eluting at 7-11 min 
(Figure 44a, lower panel) and by RP-HPLC-APCI-MS with major ions m/z 1175, 1201, 
1203, and 1229, corresponding to very long-chain acyl fatty acid components of C30:0, 
C32:1, C32:0 and C34:1 respectively, as reported (61,154). Incubation with human 12R-
LOX at pH 6 led to the formation of a similar pattern of more polar products eluting at 
3.5 – 5 min and displaying UV absorbance at 235 nm (Figure 44a, upper panel). The UV 
spectrum of these products was characteristic of conjugated dienes (λmax = 235 nm), and 
was very subtly altered upon triphenylphosphine treatment (λmax = 234 nm), consistent 
with the reduction of the original hydroperoxy product to hydroxy. The pattern of ions of 
the reduced product on APCI-MS was also very similar to the substrate, except that the 
major ions were observed at 2 a.m.u. (atomic mass units) lower, at m/z 1173, 1199, 1201, 
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and 1227 (Figure 44b, upper panel); whereas the substrate exhibits major ions at 
[M+H]+, the hydroxy product readily ionizes with loss of H2O, giving ions corresponding 
to [M-H2O+H]+, an apparent loss of 2 a.m.u. compared to the substrate. 
To ascertain the position and stereo-configuration of the hydro(pero)xyl group 
introduced by 12R-LOX in the linoleate moiety, I transesterified the reduced products 
into hydroxyoctadecadienoate (HODE) methyl esters, which could then be conveniently 
analyzed by SP-HPLC and chiral-HPLC in comparison with authentic standards. As 
shown in Figure 44c, 9-HODE methyl ester was predominantly formed over 13-HODE 
methyl ester, and showed almost exclusively the 9R chirality. Thus, the linoleate in 
glucosyl-EOS was specifically oxygenated by 12R-LOX in vitro to the 9R-hydroperoxide 
(9R-HPODE). Incubations with 12R-LOX using non-glucosylated EOS as substrate were 
also carried out, and the same 9R-hydroperoxide was produced. 
Next, I incubated the 9R-HPODE-glucosyl-EOS produced from the 12R-LOX 
reaction with eLOX3. RP-HPLC-APCI-MS analysis identified a group of products with 
retention times shorter than those of the 9R-HPODE-glucosyl-EOS substrate and 
molecular masses 32 a.m.u. (i.e., the mass of two oxygen atoms) higher than glucosyl-
EOS. When transesterified into the methyl esters, these compounds gave rise to a single 
epoxyalcohol methyl ester as the major product, which was identified by SP-HPLC and 
GC-MS analysis in comparison with authentic standards (and assuming a 9R 
configuration) as methyl 13R-hydroxy-9R,10R-epoxyoctadeca-11E-enoate (Figure 44d 
and 44e). In addition, the 9-keto derivative, 9-KODE-glucosyl-EOS, was also formed in 
the reaction as a minor product. Non-glucosylated 9R-HPODE-EOS reacted similarly 
with eLOX3. Thus, these results together suggested an in vitro pathway in which 12R-
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LOX and eLOX3 act in tandem on the linoleate moiety of glucosyl-EOS or EOS with 
remarkable regio- and stereospecificity to give the 13R-hydroxy, 9R,10R-epoxy 
derivative (Figure 44f).  
Figure 44 
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Figure 44: Reaction of 12R-LOX and epidermal LOX-3 with glucosyl-EOS. (a) 
Reversed-phase HPLC analysis of the oxygenation of glucosyl-EOS by 12R-LOX. Inset: 
UV spectrum of the products. (b) Combined mass spectra of the substrates (lower) and 
products (upper). (c) SP-HPLC (left panel) and chiral HPLC (right) of the reduced and 
transesterified 12R-LOX products as methyl esters. (d) Analysis of the eLOX3 reaction 
with the hydroperoxy products of the 12R-LOX reaction with glucosyl-EOS. (e) GC-MS 
analysis of the main eLOX3 product as the methyl ester trimethylsilyl (TMS) ether 
derivative. The retention time on GC and the mass spectrum (electron impact, positive 
ion), in comparison with authentic standards identifies the product as the epoxyalcohol, 
9R,10R-epoxy-13R-hydroxy-octadeca-11E-enoate. (f) Scheme showing reaction of 12R-
LOX and eLOX3 with glucosyl-EOS. 
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Occurrence of 12R-LOX and eLOX3 metabolites of acylceramides in pig epidermis 
Having observed the reaction of 12R-LOX and eLOX3 with the 
acylglucosylceramides in vitro, I then went on to search for potential metabolites of the 
two enzymes in vivo, first in pig epidermis. Considering that the LOX metabolites, if 
present, might exist in minor amounts, I developed a sensitive method for ceramide 
analysis involving an isocratic SP-HPLC elution followed by either diode array or APCI-
MS detection. Using this method, I detected in pig epidermis three groups of novel 
ceramides with UV spectra and SP-HPLC mobility suggestive of LOX metabolites of the 
acylceramides EOS (Figure 45a). Subsequent LC-MS analysis confirmed that these three 
groups of compounds were, on the order of elution, keto, hydroxy, and epoxyalcohol 
derivatives of EOS (abbreviated to KODE-EOS, HODE-EOS, and epOH-EOS 
respectively). For example, the molecular masses of epOH-EOS differed from those of 
EOS by +32 amu, corresponding to the two incorporated oxygen atoms in epOH-EOS 
(Figure 45b). Upon transesterification with sodium methoxide, analysis of the methyl 
esters revealed a specificity reminiscent of the in vitro reactions of 12R-LOX and 
eLOX3: predominantly 9-HODE was recovered from the EOS ceramides in pig 
epidermis, and it was almost purely 9R in chirality (Figure 45c). Similarly, the single 
prominent epoxyalcohol recovered from epOH-EOS in pig epidermis was identified in 
comparison to synthetic standards as 13R-hydroxy-9R,10R-epoxy (making the 
assumption of the R chirality at C-9) (Figure 45d), and in KODE-EOS the 9-keto-
linoleate was the major species. This remarkable specificity suggested an enzymatic 
origin of these oxygenated metabolites of EOS, and, as it matches well to the specificity 
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of 12R-LOX and eLOX3 in vitro, it also points to a likely involvement of the two LOX 
enzymes.  
 
 
Figure 45 
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Figure 45: Natural occurrence of specifically oxygenated EOS ceramides in pig 
epidermis. (a) SP-HPLC analysis with diode-array UV detection reveals oxygenated 
species of EOS in pig epidermal extracts. KODE-EOS, containing a keto derivative of 
linoleate is detected at 270 nm (black trace). HODE-EOS, containing hydroxy-linoleate is 
detected at 235 nm (red trace). At 205 nm (blue trace), unmodified EOS and other known 
ceramides elute at 5-7 min, with a later peak of epOH-EOS eluting at 8-9 min. (b) Mass 
spectra of unmodified EOS (top) and epOH-EOS (below). (c) Following 
transesterification of the ceramides from panel a to the methyl ester derivatives, SP-
HPLC with UV detection at 235nm in comparison to authentic standards identifies the 
main oxygenated product as 9-hydroxy-linoleate (9-HODE), and chiral HPLC reveals 
this is predominantly 9R-HODE. (d) SP-HPLC analysis of the transesterified epOH-EOS 
peak from panel a shows a single peak (top panel) corresponding to 9R,10R-epoxy-13R-
hydroxy-octadeca-11E-enoate, the first of a mixture of authentic standards (lower panel). 
 
 
LOX metabolites of acylceramides in mouse epidermis 
Using similar analytical approaches, I also analyzed the epidermal ceramides 
from mouse neonates. As noted by others, the epidermal ceramide composition varies 
from species to species; not surprisingly, the HPLC profile of the epidermal ceramides 
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from mouse epidermis was markedly different from that from pig epidermis (cf. Figure 
45a and Figure 46a).  
Comparison of the ceramide profiles from wild-type and 12R-LOX-/- mouse 
epidermis immediately revealed two dramatic differences. First, the level of EOS in 12R-
LOX-/- mice was at least twice as much as in wild-type mice, whereas other known 
epidermal ceramides were present at similar or slightly reduced levels in 12R-LOX-/- 
mice. This selective accumulation of EOS in 12R-LOX-/- mice is expected if EOS is to 
be metabolized by 12R-LOX and eLOX3 as suggested in our hypothesis. Second, a novel 
class of ceramides was found in wild type mice but not in 12R-LOX-/- mice, and thus 
was likely to be the metabolites of 12R-LOX and/or eLOX3 in mouse epidermis (Figure 
46a). The UV spectrum of these compounds, although showing λmax at ~230 nm, was 
clearly distinct from that of HODE-EOS, and similar instead to the UV spectra of 
authentic standards with an epoxyenone structure (i.e., an epoxide group adjacent to a 
double bond adjacent to a keto group) (155). On LC-MS, the prominent ions in these 
compounds had m/z values 30 a.m.u. higher than in EOS, also consistent with an 
epoxyenone derivative of EOS (Figure 46b). To define the precise structure, an HPLC 
fraction containing these compounds was reduced with sodium borohydride followed by 
transesterification using sodium methoxide. The methyl esters thus formed consisted of 
two diastereomers in ~50:50 ratio, identified by SP-HPLC (Figure 46c) and GC-MS in 
comparison to authentic standards as methyl 13R-hydroxy-9,10-trans-epoxyoctadeca-
11E-enoate and methyl 13S-hydroxy-9,10-trans-epoxyoctadeca-11E-enoate. Thus, prior 
to the borohydride reduction these putative LOX metabolites were deduced to be the 13-
keto, 9,10-trans-epoxy derivative of EOS (Figure 46d). I have often observed such 
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epoxyenone derivatives as a minor product in reactions of eLOX3 with fatty acid 
hydroperoxides.  
Although not as prominent as the epoxyenone-EOS, KODE-EOS and HODE-
EOS were also present in wild type mouse epidermis. Whereas KODE-EOS seemed to be 
a mixture of 9-keto and 13-keto isomers, the remarkable 9R specificity seen both in vitro 
and in pig epidermis recurred in the HODE-EOS isolated from wild-type mouse 
epidermis. In 12R-LOX-/- mouse epidermis, KODE-EOS and HODE-EOS amounted to 
less than 25% and 30% respectively of the wild-type level, and HODE-EOS were ~50:50 
mixture of 9- and 13 isomers. Due to their relatively small quantities, the stereospecificity 
of KODE-EOS or HODE-EOS from 12R-LOX-/- mouse epidermis was not analyzed. 
Their presence in 12R-LOX-/- mouse epidermis might be partly attributed to non-
enzymatic oxygenation or to one of the additional LOX enzymes that are detectable in 
mouse epidermis, none of which, it should be noted, produce the 9R enantiomer of 9-
HPODE as product (97).  
In addition to the noted differences between wild-type and 12R-LOX-/- mice in 
the ceramide fraction of the epidermal lipid extract, a difference was also seen in the free 
(unoxidized and oxidized) fatty acid fraction (Figure 47). In wild-type mouse epidermis, 
HODE free acid existed predominantly as the 9R isomer, whereas in 12R-LOX-/- mouse 
epidermis, it occurred at ~ 15% of the wild-type level and was a mixture of 13-HODE 
and 9-HODE in a ratio of ~ 60:40. Since mouse 12R-LOX has been shown to be inactive 
towards free linoleic acid (97,115), the observed concurrence of 9R-HODE free acid and 
12R-LOX activity is best explained by a sequence of events in which linoleic acid is first 
incorporated into acylceramides such as EOS, then converted by 12R-LOX and a 
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peroxidase to the 9R-HODE derivative, and finally hydrolyzed by an esterase to yield 9R-
HODE free acid.  
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Figure 46: Occurrence of LOX metabolites in wild-type mouse epidermis, and absence 
in 12R-LOX-/- mouse epidermis. (a) SP-HPLC analysis of ceramides from wild-type 
(top) and from 12R-LOX-/- (bottom) mouse epidermis. (b) SP-HPLC-APCI-MS analysis 
of EOS (top) and LOX product (bottom) from wild-type mouse epidermis. (c) SP-HPLC 
analysis of the methyl esters transesterified from NaBH4-reduced LOX product. (d) 
Scheme of LOX product indentification.  
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Figure 47: Comparison of free oxidized fatty acids from wild-type and 12R-LOX-/- 
mouse epidermis. (A) SP- and chiral HPLC analysis of HODE free acid from wild-type 
mouse epidermis. (B) SP-HPLC analysis of HODE free acid from 12R-LOX-/- mouse 
epidermis. 
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Covalently bound lipids in mouse epidermis 
Central to our hypothesis is that the ester-linked protein bound ω-
hydroxyceramides and ω-hydroxy VLFA, which constitute the corneocyte lipid envelope, 
should be reduced in 12R-LOX-/- mice. Although this has been indicated by thin layer 
chromatography in the study by Krieg and colleagues (89), definitive evidence is lacking 
as the multiple spots on the TLC were not characterized. Therefore, here using LC-MS 
we analyzed and compared the levels of the ester-linked protein-bound ω-
hydroxyceramides and ω-hydroxy VLFA in wild-type and 12R-LOX-/- mouse epidermis. 
These ester-linked lipids were obtained by mild-alkaline hydrolysis of the protein pellet 
extensively extracted so as to be devoid of any free or reversibly bound lipids (Figure 
48a). Using SP-HPLC-APCI-MS analysis, we were able to discern two classes of 
covalently bound ω-hydroxyceramides in wild-type mouse epidermis, namely OS 
(Figure 48b, c) and OH, the latter of which as a minor component has not been 
previously recognized in mouse epidermis. Using RP-HPLC-ESI-MS analysis, covalently 
bound ω-hydroxy VLFA was also detected in wild-type mouse epidermis. It is 
noteworthy that similar to the reversibly bound lipids (vide infra), the principal VLFA in 
these irreversibly ester-linked lipids differed from the composition of the free lipids, the 
most abundant species being 34:1. 
In sharp contrast to wild-type epidermis, the level of covalently bound OS or OH 
in 12R-LOX-/- mice was less than 2% of the wild-type level (Figure 48d). Similarly, 
covalently bound ω-hydroxy VLFA was reduced by more than 100 fold in 12R-LOX-/- 
mice. Consistent with these biochemical results, examination of the stratum corneum by 
electron microscopy revealed that the CLE was virtually absent in 12R-LOX-/- mice 
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(Results of Debra Crumrine and Peter Elias, UCSF). These results prove unambiguously 
that 12R-LOX and eLOX3 are indispensably involved in the metabolic pathway of EOS 
that leads to the formation of covalently bound ω-hydroxy-ceramides and ω-hydroxy 
VLFA. As noted previously (89,91), additional structural abnormalities are evident in the 
12R-LOX-/- epidermis, including malformed lamellar granules (89), and their relative 
absence in our samples, indicating either that compensatory responses feedback to early 
steps in the epidermal barrier formation, or indeed that production of the oxygenated 
ceramides may be initiated prior to fusion of lamellar granules with the plasma 
membrane and extrusion of their contents. 
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Figure 48 
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Figure 48: Analysis of covalently bound ceramides in mouse skin. (a) Protein-bound 
ceramide species are released by mild alkaline hydrolysis of the ester linkage and 
identified by LC-MS mainly as OS, omega-hydroxy-acyl sphingosine. (b) Combined 
mass spectra of the OS species from wild-type mouse skin. (c) Analysis of bound 
ceramides from wild-type mouse epidermis showing LC-MS recordings of total ion 
current (top) and m/z 805, corresponding to the most prominent of the OS species. (d) 
Analysis of bound ceramides from 12R-LOX-/- epidermis. 
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LOX metabolites reversibly coupled to protein in mouse epidermis 
A surprising observation was made during our procedures to exhaustively extract 
the free lipids from mouse epidermis. Following 4-5 cycles of sonication and extraction 
with chloroform/methanol (1:1 or 2:1) for 1-2 hours at 0 °C, HPLC analysis indicated no 
further detectable free lipid in the later extracts. However, upon a further soak of the 
sonicated protein pellet in chloroform/methanol (1:1) at room temperature overnight, a 
specific pair of SP-HPLC peaks showing the UV absorbance profile of epoxyenone 
derivatives were evident (denoted as I and II in Figure 49, upper panel). To completely 
extract this pool of lipids, 6-7 cycles of such prolonged incubations at room temperature 
were required. Notably, these products were completely absent in the extracts of protein 
from 12R-LOX-/- mice (Figure 49, lower panel). LC-MS analysis indicated that the 
early eluting peak I comprised very long-chain omega-hydroxy fatty acids containing 
esterified epoxyenone (an acyl acid derivative), and peak II as EOS esterified with 
epoxyenone (an acyl ceramide). Compared to the unbound epoxyenones, for both I and 
II, mass spectrometry revealed a bias towards the longer 34:1 species in the ω-hydroxy 
VLFA component  (Figure 49). The esterified epoxyenone in I and II was further 
characterized following NaBH4 reduction and transesterification as already described 
above for analysis of the free ceramides, and the identical epoxyenone structure was 
revealed, i.e. 9,10-trans-epoxy, 11-trans, 13-keto-linoleate. Based on the SP-HPLC 
analysis, I estimated that the ratio of free over reversibly protein-bound epoxyenone-EOS 
in the wild-type was approximately 1:1. 
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To explain this unusual observation of slowly releasable lipids, I suspect that 
these products are covalently bound to proteins, yet the linkage must be slowly reversible 
so that they would partition into the organic phase on prolonged incubations. Michael 
addition of the enone moiety to histidine might account for the coupling and slow release. 
These novel observations indicate an additional mode of linking the lipids and proteins in 
the neonatal mouse epidermis, perhaps preceding or concurrent with the ester linkage 
through the omega-hydroxyl that is already established (156). 
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Figure 49 
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Figure 49: Identification of epoxy-enone fatty acid bound to protein. (a) SP-HPLC 
analysis of wild-type (top panel) and 12R-LOX-/- (lower panel) neonatal mouse 
epidermal lipids recovered from a final soak for 24 hr at room temperature following 
prior MeOH/CHCl3 extractions. Top panel inset, UV spectrum of products I and II. (b) 
Mass spectral analysis of I (top panel) and II (lower panel). (c) Potential binding of I and 
II to protein as a slowly reversible covalent Michael adduct, and structures of the major 
species of the free products I and II. 
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Discussion 
Our study provides a model that explains the role of 12R-LOX and eLOX3 in skin 
barrier formation, and ties this together with the long-known and not well-understood 
need for an EFA in the skin ceramides (Figure 50). We have demonstrated both in vitro 
and in vivo the existence of a novel metabolic pathway, where 12R-LOX oxygenates the 
linoleate-containing acyl(glucosyl)ceramides to give the 9R hydroperoxide, and eLOX3 
in turn converts the 12R-LOX product to the specific 9R,10R-epoxy-13R-hydroxy-
epoxyalcohol. We have further deduced, from our biochemical and EM evidence that the 
CLE is missing in 12R-LOX-/- mice in correlation with a complete absence of LOX 
metabolites, that this LOX-catalyzed oxygenation is required to facilitate hydrolysis of 
the (oxidized) linoleate moiety and leave free the ω-hydroxyl on the ceramides for 
coupling to the cross-linked proteins of CE. This covalent coupling is an important step 
in sealing the water barrier (47,150). If EFA are deficient, there is no LOX substrate 
available and thus the fatty acid cannot be cleaved. Absence of one or the other of the 
LOX enzymes has a similar effect. Thus in both cases, the CLE is either missing or 
defective, leading to a skin barrier defect.  
Our model linking EFA with the action of 12R-LOX and eLOX3 also provides a 
simple explanation on the finding by Houtsmuller and colleagues that for a fatty acid 
(natural or synthetic) to be an EFA in the skin, it has to have at least two cis double bonds 
in the arrangement of bond-CH2-bond and placed at about the ω6 position from the end 
of the carbon chain (54), which fits perfectly with the structural requirement of LOX 
substrates. Thus, although other fatty acids such as 9trans,12cis-18:2ω6 or 9trans,12cis-
18:2ω6 (which differs from linoleic acid only in the configuration of one double bond) 
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will be incorporated into acylceramides if topically applied to essential fatty acid 
deficient skin, they invariably fail to cure the skin defects because they are not LOX 
substrates (80).  
It was once assumed that arachidonic acid is the natural substrate of the putative 
12R-LOX-eLOX3 pathway in the epidermis, being converted via 12R-HPETE to 8R-
hydroxy-11R,12R-epoxyeicosa-5Z,9E,14Z-trienoic acid (37). A major problem for this 
assumption was that arachidonic acid is not a substrate of mouse 12R-LOX (97). Instead, 
the enzyme prefers to use fatty acid esters such as methyl arachidonate as substrate. This 
no longer presents as a problem, as we now suggest in this study that arachidonic acid 
oxygenation by 12R-LOX and eLOX3 is probably of little relevance in the physiological 
setting of skin barrier formation. Nonetheless, the 12R-LOX products of arachidonic acid 
do occur in the inflammatory skin disease of psoriasis (96), and may have a separate role 
in that condition. 
It is worth mentioning at this point that acylceramides were proposed to be LOX 
substrates 25 years ago (80), at a time when this class of ceramides was newly discovered 
(58), the potential role of prostaglandins in mediating the effect of EFA in the epidermis 
just ruled out (54), and 12R-LOX and eLOX3 to be discovered more than ten years later 
(83,101). In this study by Nugteren and colleagues, [14C-1]linoleic acid was topically 
applied to rat skin and some of the radioactivity was found two or three days later in a 
group of oxidized acylceramides that were suggested to be LOX metabolites. 
Unfortunately, due to technical limitations at that time, these putative LOX metabolites 
were not structurally defined. Our present study extended this finding by demonstrating 
that the oxygenated metabolites of EOS found in vivo exhibit the same remarkably high 
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regio- and stereospecificity as the LOX products in vitro, thus having definitively 
resolved the arguments (81) over whether the oxygenated metabolites were truly of 
enzymatic origin. Moreover, we have advanced a further step in rationalizing the 
functions these LOX metabolites may serve in the skin, i.e., to help build the CLE.  
Confusion may arise as to which of the two, acylceramides or 
acylglucosylceramides, are the LOX substrates. We have shown in our in vitro 
experiment that acylglucosylceramides are substrates of 12R-LOX and eLOX3, yet the 
LOX metabolites we have detected in vivo are oxygenated derivatives of acylceramides. 
Biochemical studies on LOX reactions with large esters suggest that the polar groups on a 
large ester substrate, such as the glucose in acylglucosylceramide does not directly 
interact with the enzyme active site and thus will play no major effect on LOX catalysis 
(106). Moreover, studies on mice deficient in β-glucocerebrosidase or the activator 
proteins indicate that deglycosylation is not a requisite step for formation of the CLE 
(although the CLE will remain glycosylated and thus defective) (73,74). Accordingly, we 
suggest that both acylceramide and acylglucosylceramide are accepted by 12R-LOX and 
eLOX3 as substrates. Within the context of our model (Figure 50), the 
acylglucosylceramide newly delivered to the plasma membrane is demanded by its own 
structure to span the entire membrane bilayer, with the glucose group protruding into the 
extracellular space where β-glucocerebrosidase resides and the linoleate moiety placed 
instead at inner leaflet of plasma membrane where the two LOX enzymes should reside. 
Thus, our model predicts that cleavage of the glucose group and cleavage of oxidized 
linoleate moiety may be two independent events separated by membrane 
compartmentation.  
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The LOX metabolites we have detected in vivo are at low levels, those in pig 
epidermis amounting in all to ~5% of the acylceramide substrate, EOS. Of note, despite 
numerous studies of epidermal ceramide composition in the past, the specific derivatives 
we have identified have not been previously characterized. In our case, the application of 
multiple wavelength UV detection on HPLC provided crucial insights that are absent in 
the forest of products detectable on thin layer chromatography and upon mass spectral 
analysis. The low abundance of these oxidized ceramides in fact consistent with our 
hypothesis that these LOX metabolites are obligatory intermediates rather than the end 
products of the pathway, being selectively subject to ester-bond cleavage with 
concomitant formation of ω-hydroxyceramides that will be covalently coupled to 
proteins. As noted earlier, such a hydrolysis event is strongly suggested by the 
observation in 12R-LOX-/- mice that the CLE is missing in correlation with a complete 
absence of LOX metabolites. In addition, since linoleic acid, similar to arachidonic acid, 
is not a substrate of mouse 12R-LOX, the 9R-HODE free acid present in wild-type and 
absent in 12R-LOX-/- mouse epidermis must stem from hydrolysis of the 9R-HODE-
acylceramide products. Further supporting our hypothesis, there accumulated many 
papers over the years showing that oxidized polyunsaturated fatty acid esters are more 
susceptible to hydrolysis, and indeed nowadays it is generally accepted that oxidation 
disrupts membranes and provokes clearance of oxidized lipids. It is also possible that the 
specific oxygenation pattern brought by 12R-LOX and eLOX3 may be stringently 
required by the downstream esterase for hydrolysis to occur.  
We have noted considerable differences in the pattern of LOX products between 
those from the in vitro reactions, those detected in pig epidermis and those detected in 
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mouse epidermis, although the specificity of the individual products is strikingly similar. 
For example, in the eLOX3 reaction with glucosyl-EOS in vitro, the epoxyalcohol 
derivative is the major product and the 9-KODE derivative is a minor product, whereas in 
pig epidermis, this relationship is reversed. In mouse epidermis, the epoxyalcohol 
derivative was not detected at all and instead the major LOX metabolite identified is 
9,10-epoxy-13-keto-EOS. Such epoxyenone compounds are often formed as byproducts 
in the reactions of eLOX3. Since the detected LOX metabolites in vivo are likely to be 
“leftovers” from the downstream hydrolysis, the emerging picture seems to be one in 
which the epoxyalcohol derivative is preferentially hydrolyzed, whereas the byproducts 
are hydrolyzed to a less extent and thus accumulate.   
An intriguing result of this study is that in mouse epidermis some epoxyenone-
EOS ceramides, together with epoxyenone-acyl acids, are directly coupled to proteins 
through a reversible linkage. Most likely, the chemistry involves Michael addition of the 
α,β-unsaturated ketone to His on proteins (155). Notably, the CE protein Involucrin is 
enriched in His (72). We have estimated that this type of covalently bound epoxyenone-
EOS products account for ~ 8% of total covalently bound ceramides. The physiological 
relevance of this reversible covalent coupling remains to be determined. 
Finally, it should be emphasized that the model proposed here is by no means all-
inclusive. We note the special physical properties brought by linoleate itself in 
acylceramides that may contribute to the proper phase behavior of intercellular lamellar 
membranes (68). Also, the unexpected finding of protein-bound epoxyenone-EOS 
products in mouse epidermis opens up the possibilities that LOX products may be 
directly attached to proteins. For example, both the epoxide group with an adjacent 
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double bond and the α,β-unsaturated keto group in the epoxyalcohol-EOS or ketone-EOS 
products are excellent electrophiles, naturally prone to attack by nucleophilic amino acid 
residues such as His, Cys and Lys. Notably, these potential non-ester-bound species 
cannot be distinguished from the ester-bound ω-hydroxyceramides using mild alkaline 
hydrolysis, since free ω-hydroxyceramides will also be recovered while the oxidized 
linoleate will remain attached to proteins even if the actual bound species are LOX 
products themselves.  
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Figure 50: A model connecting ceramides, EFA and LOX in the Stratum Corneum. (1) 
Lamellar granules containing lamellar lipid discs have Gluc-EOS (with linoleate coupled 
to the omega-hydroxyl) in the limiting membrane. (2) Fusion extrudes the lamellar 
contents extracellularly and combines the lamellar limiting membrane with the cell 
plasma membrane, initiating formation of the cornified lipid envelope (CLE, shown 
greatly expanded). (3) Progression towards the mature barrier entails LOX-catalyzed 
oxygenation of the linoleate, the resultant “oxygen signal” permits esterase-catalyzed 
hydrolysis of the oxidized linoleate, freeing the ceramide omega-hydroxyl for (4) 
transglutaminase-catalyzed covalent coupling of the CLE to the cross-linked proteins of 
the CE, thus helping to seal the barrier. Lipoxygenase-catalyzed oxygenation of (Gluc)-
EOS may be initiated earlier in the process than illustrated here. 
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CHAPTER V 
 
AN UNEXPECTED FINDING IN THE DISSERTATION RESEARCH: 
FORMATION OF A CYCLOPROPYL EPOXIDE VIA A LEUKOTRIENE A 
SYNTHASE-RELATED PATHWAY IN AN ANAEROBIC REACTION OF 
SOYBEAN LOX-1 WITH 15S-HPETE  
 
Introduction 
 
 Lipoxygenases (LOX) are named for their oxygenase activity with 
polyunsaturated fatty acids yet they also catalyze other types of reaction. One of the most 
important in a biological context is leukocyte 5-LOX-catalyzed further conversion of the 
hydroperoxide product 5S-HPETE to leukotriene A4 (LTA4) (157). LTA4, an unstable 
epoxide, will then be subject to metabolism of downstream enzymes in the pathway to 
more stable and biologically active LTs including the dihydroxy LTB4 and the peptidyl 
LTC4, D4 and E4 (2). Parallels of the LTA synthase activity of 5-LOX also exist in some 
other LOX enzymes. Mammalian 15-LOX-1, for example, can further convert 15S-
HPETE to a structural analogue of LTA4, named 14,15-LTA4 based on the position of the 
epoxide group between C-14 and C-15 . This 14,15-epoxide was recently given the name 
of eoxin A4 on account of its production by eosinophils and its further transformation, 
analogous to LTA4, to a series of biologically active peptidyl derivatives, 14,15-LTC4, D4 
and E4 (eoxins C4, D4, E4) ((158).  
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Despite the general parallels between leukocyte 5-LOX and mammalian 15-LOX-
1 within the physiological context, the two enzymes exhibit notable differences in their 
reactions towards 5S-HPETE and 15S-HPETE respectively. Leukocyte 5-LOX gives 
almost exclusively LTA4 from 5S-HPETE, whereas the reaction of mammalian 15-LOX-
1 with 15S-HPETE leads, in addition to 14,15-LTA4, to several other products including 
two fatty acid dihydroperoxides, 8S,15S-diHPETE and 5S,15S-diHPETE (159). On the 
other end of the spectrum of reactivity compared to leukocyte 5-LOX is the prototypical 
plant lipoxygenase, soybean LOX-1. It converts 15S-HPETE exclusively to 8S,15S-
diHPETE and 5S,15S-diHPETE (160). These diHPETEs are often referred to as “double 
oxygenation” products, since they are formed, in essence, by oxygenation of arachidonic 
acid twice in succession at two different positions.  
In the present study, I aimed to understand the mechanistic basis for the different 
preferences of LOX enzymes for LTA synthesis or double oxygenation. Some clues can 
be gleaned from the literature. Rabbit reticulocyte 15-LOX or porcine leukocyte 12-LOX 
(both being homologs of human 15-LOX-1), when incubated with 15S-HPETE under 
anaerobic reactions, gives a higher yield of 14,15-LTA4 at the expense of the double 
oxygenation products (159,161). Conversely, under higher than normal oxygen pressures, 
potato 5-LOX can be forced to perform double oxygenation on 5S-HPETE (162). These 
studies imply that LTA synthesis and double oxygenation are in competition, and the 
concentration of molecular oxygen is a critical determinant on which process dominates. 
The latter point can be better understood when one considers that LTA synthesis does not 
involve molecular oxygen whereas the double oxygenation reaction uses molecular 
oxygen as one of the two substrates. Since the catalysis should be influenced by oxygen 
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concentrations in the enzyme active site, rather than in the atmosphere per se, I 
hypothesized that the different preferences of LOX isoenzymes for LTA synthesis or 
double oxygenation stem from different oxygen concentrations in their active sites.  
With this hypothesis, I reasoned that soybean LOX-1, which catalyzes only 
double oxygenation with 15S-HPETE under usual aerobic conditions, might show 14,15-
LTA4 synthase activity when molecular oxygen is excluded. In this paper, I described 
such an anaerobic reaction of soybean LOX-1 with 15S-HPETE. As anticipated, I 
observed the formation of the hydrolysis products of the putative 14,15-LTA4. Moreover, 
as a mechanistically informative finding, I identified among the reaction products two 
novel 5,15-dihydroxy compounds and their δ-lactone derivatives. Based on their 
chemical structures, conditions of formation, and evidence from H218O incubations, I 
suggested that the 5,15-dihydroxy compounds and their δ-lactone derivatives result from 
nucleophilic attack by water (hydrolysis) and by the terminal carboxylate anion 
(lactonization) respectively of a novel cyclopropyl epoxide formed via a LTA-synthase 
related mechanism.  
 
EXPERIMENTAL PROCEDURES 
 
Materials 
Soybean LOX-1 (soybean P1, purified) and nordihydroguaiaretic acid (NDGA) 
were purchased from Cayman Chemical, Co Inc (Ann Arbor, MI). We determined that 
the purified soybean LOX-1 employed in this work was of 10-fold lower specific activity 
than advertised (possibly due to two cycles of freeze-thawing), ~20 µmol/min/mg using 
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the Axelrod assay with sodium linoleate (127). Linoleic and arachidonic acids were 
purchased from NuChek Prep Inc. (Elysian, MN). [1-14C]Arachidonic acid was 
purchased from PerkinElmer Life Sciences. 15S-HPETE and 13S-HPODE were 
synthesized by reacting soybean LOX-1 with arachidonic acid at pH 9 under the normal 
aerobic conditions followed by SP-HPLC purification (103). 5(RS)-HETE was 
chemically synthesized from arachidonic acid (163) and the enantiomers resolved by 
chiral column HPLC as described (164). 5,15-diHETE was prepared similarly using 5S-
HETE and/or 5R-HETE as substrate for soybean LOX-1, followed by reduction using 
NaBH4 and SP-HPLC purification. The Aldrich Atmosbag used for conducting the 
anaerobic incubations was purchased from Sigma-Aldrich (St. Louis, MO).  
Reaction incubations and extraction 
The initial anaerobic reactions on an analytical scale were conducted inside a N2-
inflated Aldrich Atmosbag. First, placed into the Aldrich Atmosbag were an open vial 
containing the enzyme solution (0.76 µM  soybean LOX-1 in 1 ml of sodium phosphate 
pH 7.5), an open vial containing the substrate solution (20 µM to 440 µM 15S-HPETE in 
1 ml of sodium phosphate pH 7.5), syringes, vial caps and a bottle of methanol. The 
Atmosbag was then sealed, and subjected to vacuuming and N2 inflation for three cycles. 
Twenty minutes was given for the enzyme and substrate solutions to reach equilibrium 
with the N2 atmosphere. Then the reaction was started by mixing the enzyme and the 
substrate. Reaction was stopped by addition of an equal volume of methanol, followed by 
extraction using an Oasis HLB cartridge (Waters Corp.).  
For the reactions in the presence of NDGA or 13S-HPODE, 80 µM NDGA or 
13S-HPODE was included in the substrate solution. For structural analysis of the 
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products, the incubations were scaled up to a volume of 20 ml using otherwise the same 
conditions. For incubations in 18O-enriched buffer, a volume of 0.5 ml was used, which is 
comprised of 0.4 ml of 96% H218O and 0.1 ml of 500 mM sodium phosphate pH 7.5.  
Kinetic measurements 
For kinetic measurements, the anaerobic reaction of soybean LOX-1 (usually 0.2 
µM unless noted otherwise) with 15S-HPETE (50 µM to 500 µM) was monitored at 280 
nm in an enclosed quartz cuvette using a Perkin-Elmer Lambda-35 spectrophotometer. N2 
saturated sodium phosphate buffer (pH 7.5), glucose oxidase, glucose and catalase were 
used to achieve the anaerobic conditions; subsequently, HPLC analyses verified that no 
oxygenation products were formed. The reaction volume is usually 1.1 ml. To avoid 
potential inhibition of alcohols on the enzyme activity, 15S-HPETE originally dissolved 
in methanol was first added to the quartz cuvette and then taken to dryness under a stream 
of N2. The cuvette was then placed to the bottom of a plastic bag filled with argon. 1 ml 
of N2 saturated buffer, 25 µl of glucose oxidase (stock concentration: 827 sigma 
units/ml), 1 µl of catalase (the stock solution was 5X diluted from the commercial 
solution of bovine liver catalase purchased from Sigma-Aldrich, C3155, 
≥35,000 units/mg protein), and 50 µl of glucose (2 M stock, N2 saturated) were then 
added to the cuvette. The cuvette was then capped, taken out of the bag, shaken for a few 
seconds and let stand for about 1 minute. Reaction was started by quick addition of 6 µl 
of soybean LOX-1 stock solution (final concentration: 0.38 µM). 
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HPLC analysis and purification 
The extracted products were analyzed by RP-HPLC and SP-HPLC using an 
Agilent 1100 HPLC system equipped with a diode array detector. The products from [1-
14C]15S-HPETE were analyzed simultaneously by the diode array detector and by a Flo-
One A-100 radioactive detector (Radiomatic Instruments and Chemical, Meridian, CT). 
The RP-HPLC analysis used a Waters Symmetry C18 column (5 µm, 0.46 × 25 cm), an 
isocratic solvent system of methanol/water/acetic acid (80:20:0.01 by volume) and a flow 
rate of 1 ml/min. The SP-HPLC analysis used a Beckman Ultrasphere Silica column (5 
µm, 0.46 × 25 cm), an isocratic solvent system of hexane/isopropanol/acetic acid 
(100:2:0.1 by volume for less polar products followed by a strong solvent wash, or 
100:5:0.1 for polar products), and a flow rate of 1 ml/min. Products 2, 3, 4 and 5 were 
purified by SP-HPLC. Products 1, 6, 7 were purified by SP-HPLC followed by RP-
HPLC. Separation of the two diastereomers of product 4 was achieved using a Chiralpak 
AD-RH column (5 µm, 0.46 × 15 cm), an isocratic solvent system of 
methanol/water/acetic acid (95:5:0.01 by volume) and a flow rate of 0.5 ml/min. For 
analysis of product 5, we used the same column, methanol/acetic acid (100:0.01, by 
volume) and a flow rate of 1 ml/min.  
Synthesis of HETEs and diHETE with trans-trans conjugated dienes  
Thiyl radical induced isomerization (mercaptoethanol, UV light, room 
temperature (165,166)), was used to convert cis-trans to trans-trans conjugated dienes. 
Reaction conditions had the starting material (2.5 mg, methyl ester of HETE or diHETE) 
in 0.5 ml isopropanol containing 0.5 µl mercaptoethanol in a quartz UV cuvette with 
telfon cap. The cuvette was submerged in a solution of aqueous 1M NaCl that served 
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both to stabilize the temperature at <25°C and absorb UV radiation below 220 nm. A low 
pressure immersion UV lamp rated with 3.5 Watts output at 254 nm (part no. 12128-15, 
Ace Glass Inc., Vineland, NJ) [caution: harmful UV radiation] was placed about 15 cm 
above the cuvette. Aliquots of the reaction were analyzed at 30 min intervals by 
argentation HPLC using a cation exchange column (Sepralyte SCX 5-µm, 25 x 0.46 cm, 
originally purchased from Analytichem International, later owned by Varian) in the silver 
form (167,168) with a solvent of hexane/isopropanol/acetic acid in the proportions 
70:30:0.1 (by volume) for mono-HETE methyl esters and 5,15-diHETE methyl ester, a 
flow rate of 1 ml/min, and with UV monitoring using an Agilent 1100 series diode array 
detector. 5-HETE and 15-HETE were isomerized in the conjugated diene, leading to 
accumulation of the trans,trans-HETEs (with two trans and two cis double bonds) with 
very minor peaks for the more highly isomerized derivatives. 5,15-diHETE was 
isomerized in one conjugated diene and, after 2-3 hours irradiation in both, giving the all-
trans derivative as the major product. 
Derivatization and GC-MS analysis 
Catalytic hydrogenations were performed in 100 µl of ethanol using about 1 mg 
of palladium on alumina and bubbling with hydrogen for 2 min at room temperature. The 
hydrogenated products were recovered by the addition of water and extraction with ethyl 
acetate. TMS ester TMS ether derivatives were prepared by treatment with 
bis(trimethylsilyl)-trifluoracetamide (10 µl) and pyridine (2 µl) at room temperature for 2 
h. Subsequently, the reagents were evaporated under a stream of nitrogen and the samples 
were dissolved in hexane for GC-MS.  
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Analysis of the methyl ester trimethylsilyl ether derivatives of the products was 
carried out in the positive ion electron impact mode (70 eV) using a Thermo Finnigan 
Trace DSQ ion trap GC-MS with the Xcalibur data system. Samples were injected at 150 
°C, and after 1 min the temperature was programmed to 300 °C at 20 °C/min. Spectra 
collected during elution of the GC peak (typically about 20 spectra) were averaged for 
calculation of the isotopic compositions. 
ESI-LC-MS 
ESI-LC-MS of purified product 4 and product 5 was performed using a Thermo 
Finnigan LC Quantum instrument. A Waters Symmetry C18 column (0.2 × 15 cm) was 
eluted with acetonitrile/water/ammonium acetate (50:50:10 mM) at 0.2 ml/min. The 
heated capillary ion lens was operated at 220 °C. Nitrogen was used as a nebulization and 
desolvation gas. The electrospray potential was held at 4 kV. Source-induced dissociation 
was set – 10 eV. Mass spectra were acquired over the mass range m/z 100-500 at 2 s per 
scan under the negative ion mode.  
NMR 
1H and 1H,1H-COSY NMR spectra were recorded on a Bruker DXR 600 MHz 
spectrometer at 298K. The ppm values are reported relative to residual non-deuterated 
solvent (δ = 7.16 ppm for C6H6). 
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RESULTS 
 
An anaerobic reaction of soybean LOX-1 with 15S-HPETE 
To test the hypothesis that soybean LOX-1 is capable of catalyzing LTA synthesis 
in the absence of oxygen, initially we incubated the enzyme (0.38 µM) with various 
concentrations of 15S-HPETE (20 µM to 440 µM) at pH 7.5 under N2 for two hours. 
[Although analysis of reaction rates is complicated by the mixture of products formed 
(see below), subsequent analyses indicated that, for example, 100 µM 15S-HPETE is 
fully consumed within 10 min. Observed rates are presented in the Supplemental data]. 
Reactions were stopped by addition of an equal volume of methanol, followed by 
extraction using an Oasis HLB cartridge. RP-HPLC analysis revealed that the substrate 
15S-HPETE, at all concentrations tested, was completely converted to seven new 
compounds, designated 1-7 based on the order of elution (Figure 51). We also examined 
the reaction carefully for the production of fatty acid dimers, as their formation would be 
predicted if this reaction follows the same mechanism as the well-studied anaerobic 
reaction of soybean LOX-1 with linoleic acid and 13S-HPODE (30,31,125). However, 
SP-HPLC and RP-HPLC analyses showed that this reaction gave no appreciable amounts 
of C-C linked dimers and confirmed that products 1-7 constitute the main products.  
Contribution of the Fe(II) enzyme to the anaerobic reaction with 15S-HPETE 
Since soybean LOX-1 exists in two oxidation states, Fe(II) and Fe(III), we next 
questioned which enzyme form is responsible for the formation of the products. NDGA, 
as a redox-based LOX inhibitor, inhibits the oxygenase activity of LOX by reduction of  
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Figure 51: RP-HPLC analysis of products from the anaerobic reaction of soybean LOX-1 
(0.38 µM) with 15S-HPETE (40 µM). The products were eluted using a Waters 
Symmetry C18 column (0.46 × 25 cm), a solvent system of methanol/water/acetic acid 
(80:20:0.01 by volume) and a flow rate of 1 ml/min. Shown are the UV traces at 205 nm, 
235 nm and 270 nm monitored by an Agilent diode array detector. The products are 
designated 1-7 based on the order of elution.  
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Fe(III) LOX to Fe(II) LOX (27); therefore, in the presence of NDGA, soybean LOX-1 
would be kept in the Fe(II) state and only the products from the Fe(II) enzyme would be 
observed.  
The anaerobic reaction of soybean LOX-1 (0.38 µM) with 15S-HPETE (40 µM) 
was performed in the presence of NDGA (80 µM) and subsequently analyzed by RP-
HPLC. As shown in Figure 52, only products 1, 6, 7 were formed in the presence of 
NDGA, indicating that these are the products from the Fe(II) enzyme. In addition, we 
noted that NDGA significantly accelerated the rate of reaction, especially at substrate 
concentrations lower than 100 µM.   
Under anaerobic conditions, linoleic acid also reduces Fe(III) soybean LOX-1 to 
Fe(II) soybean LOX-1, with itself being converted to a carbon-centered radical and then 
released from the enzyme active site (28). Accordingly, linoleic acid should have the 
same effect as NDGA does on the anaerobic reaction of soybean LOX-1 with 15S-
HPETE. Indeed, in the presence of linoleic acid (150 µM), 15S-HPETE was converted to 
essentially the same set of products as in the presence of NDGA (data not shown).  
Identification of the Fe(II) enzyme products 1, 6 and 7 
Products 1, 6 and 7 were identified by UV, LC-MS, and NMR. Product 1 is the 
C15 aldehyde 15-oxopentadeca-5Z,8Z,11Z,13E-tetraenoic acid, product 6 is 13R-hydroxy-
14S,15S-epoxyeicosa-5Z,8Z,11Z-trienoic acid, and product 7 is 15-oxoeicosa-
5Z,8Z,11Z,13E-tetraenoic acid (15-KETE) (Figure 53). Formation of the C15 aldehyde 
(product 1) and 15-KETE (product 7) is expected, as they are structural analogues of the 
major C13 aldehyde and 13-KETE formed in the anaerobic reaction of the Fe(II) enzyme 
with 13S-HPODE (30). Product 7 is a direct analogue of threo-11-hydroxy-12,13S-trans-
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epoxyoctadec-9Z-enoic acid, another known compound derived from 13S-HPODE by 
soybean LOX-1 (34), and this threo-13-hydroxy-14,15-trans-epoxyalcohol was originally 
identified by Corey and Mehrotra in 1983 (169). 
Contribution of the Fe(III) enzyme to the anaerobic reaction with 15S-HPETE 
To examine the products from the Fe(III) enzyme, we took advantage of the fact 
that 13S-HPODE reacts with Fe(II) soybean LOX-1 stoichiometrically to give Fe(III) 
soybean LOX-1 (18). Thus, soybean LOX-1 (0.2 µM) was reacted with [1-14C]-15S-
HPETE (40 µM) in the presence 13S-HPODE (80 µM). SP-HPLC with both UV and 
radioactivity detection revealed that 2, 3, 4 and 5 were the main products from the Fe(III) 
enzyme reaction (Figure 54), the complementary set of products compared to those 
formed from reactions of the Fe(II) enzyme in the presence of NDGA or linoleic acid. 
Identification of the Fe(III) enzyme products 2 and 3 
Products 2 and 3 were identified as 8R,15S-dihydroxyeicosa-5Z,9E,11E,13E-
tetraenoic acid (8R,15S-Z,E,E,E-diHETE) and 8S,15S-dihydroxyeicosa-5Z,9E,11E,13E-
tetraenoic acid (8S,15S-Z,E,E,E-diHETE) respectively, based on the same UV, mass 
spectra (Figure 55 and Figure 56), and chromatographic properties they exhibited as the 
authentic standards. These 8,15-diols with an all-trans conjugated triene are characteristic 
hydrolysis products of the unstable allylic epoxide, 14,15-LTA4. 
Identification of the Fe(III) enzyme products 4 and 5 
Products 4 and 5 display unusual UV spectra similar to, yet distinguishable from, 
that of the well-known double oxygenation product 5,15-dihydroxyeicosa-
6E,8Z,11Z,13E-tetraenoic acid (5,15-diHETE). In SP-HPLC solvents, the differences are 
the more striking (cf. Figure 57A, 57B). LC-ESI-MS (negative ion mode) showed that  
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Figure 52: RP-HPLC analysis of products from the anaerobic reaction of soybean LOX-
1 (0.38 µM) with 15S-HPETE (40 µM) in the presence of NDGA (80 µM). As in Fig. 51, 
the products were eluted using a Waters Symmetry C18 column (0.46 × 25 cm), a solvent 
system of methanol/water/acetic acid (80:20:0.01 by volume) and a flow rate of 1 
ml/min. Shown are the UV traces at 205 nm, 235 nm and 270 nm monitored by an 
Agilent diode array detector. 
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Figure 53: Chemical structures of product 1, 6, and 7.  
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Figure 54: SP-HPLC analysis of products from the anaerobic reaction of soybean LOX-1 
(0.38 µM) with [1-14C]15S-HPETE (40 µM) in the presence of 13S-HPODE (80 µM). 
(A) The 14C radiochromatogram recorded by a radioactive detector. (B) The UV 
chromatogram at 235 nm and 270 nm recorded by a diode array detector. The products 
were eluted using a Beckman Silica Ultrasphere column (0.46 × 25 cm), a solvent system 
of hexane/isopropanol/acetic acid (100:5:0.1 by volume) and a flow rate of 1 ml/min.  
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Figure 55: GC-MS analysis of the TMS ether TMS ester of hydrogenated product 2 
 
 
Figure 56: GC-MS analysis of the TMS ether TMS ester of hydrogenated product 3 
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Figure 57: Comparison of the UV spectra of product 4 and 5 with that of 5,15-(E,Z,Z,E)-
diHETE. (A) The spectra in RP-HPLC solvent, methanol/water/acetic acid (80:20:0.01 
by volume). (B) The spectra in SP-HPLC solvent, hexane/isopropanol/acetic acid 
(100:5:0.1 by volume). 
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product 4 has the same molecular mass, 336, as 5,15-diHETE (whereas under the same 
conditions, product 5 was not detected, see below). GC-MS analysis of the TMS ester 
TMS ether derivative of hydrogenated product 4 established the 5,15-dihydroxy structure 
(Figure 58): the prominent ions at m/z 401 and 261 arise from α-cleavage at the 5-
hydroxyl, and m/z 173 and 489 come from α-cleavage at the 15-hydroxyl. Thus, product 
4 is a geometric isomer of 5,15-diHETE. Unlike the well-known 5,15-diHETE containing 
two cis-trans conjugated diene chromophores (160), product 4 contains four double 
bonds, all in the trans configuration as indicated by the coupling constants (J ≈ 15 Hz) 
obtained from 1H NMR (Figure 59A) and 1H,1H-COSY NMR analysis. 
To confirm the structure of product 4, we synthesized all-trans-5,15-diHETE by 
thiyl radical-induced isomerization of the cis double bonds in 5,15-diHETE (See 
Experimental Procedures). The UV, chromatographic, and NMR properties of the 
synthetic compound were identical to product 4. In addition, comparison of the olefin 
regions of the NMR spectra of synthetic 6E,8E-5-HETE and 11E,13E-15-HETE helped 
with assignment of the individual olefin protons in all-trans-diHETE, in particular 
confirming that the H-6 signal is more upfield of H-14, and thus allowing assignment of 
the rest of the double bond proton signals from the COSY analysis.  
Unlike product 4, product 5 had eluded detection by ESI-MS, suggesting the lack 
of ionizable groups in the structure (e.g., as esters, including lactones). This was 
confirmed by GC-MS analysis of the TMS ether derivative of hydrogenated product 5, 
which gave a spectrum identical to that published for the TMS ether derivative of 
hydrogenated δ-lactone of 5,15-diHETE (170) (Figure 60). Diagnostic ions include m/z 
99, 173 and 327. 1H NMR and 1H,1H-COSY NMR analysis of product 5 determined the  
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Figure 58: GC-MS analysis of the TMS ether TMS ester of hydrogenated product 4. 
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Figure 59: 1H-NMR analysis of product 4 (panel A) and 5 (panel B) in d6-benzene. 
Shown is an expanded view of the region corresponding to olefinic protons. The splitting 
pattern of each olefinic proton is also illustrated. The proton signals are assigned with aid 
of 1H1H-COSY NMR. 
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Figure 60: GC-MS analysis of the TMS ether of hydrogenated product 5. 
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configurations of the four double bonds to be all trans (Figure 59B, Figure 61). Thus, 
product 4 is 5,15-dihydroxyeicosa-6E,8E,11E,13E-tetraenoic acid (5,15-all trans-
diHETE) and product 5 is the corresponding δ-lactone. 
Products 4 and 5 are each a mixture of diastereomers 
Although each appeared as a single peak on RP-HPLC and SP-HPLC, each could 
be further resolved using a chiral HPLC column into a 50:50 mixture of two peaks with 
identical UV spectra.  (Their NMR spectra are also identical, since there were no 
indications of a mixture of two sets of signals in the spectra of products 4 or 5). Based on 
the reasonable assumption that the original S configuration of the substrate 15S-HPETE is 
retained in the 15-hydroxyl, we conclude that the peaks resolved on the chiral column are 
diastereomers rather than enantiomers, epimeric at C-5. This was confirmed using 
synthetic all-trans-diHETE prepared from a 2:1 mixture of 5S,15S- and 5R,15S-diHETE 
diastereomers. Similar to product 4, this synthetic all-trans-diHETE chromatographed as 
a single peak on RP- and SP-HPLC. On the Chiralpak AD-RH column it resolved into the 
larger, earlier-eluting peak of 5S,15S followed by the later-eluting 5R,15S diastereomer. 
Mechanistic considerations that follow from the H218O experiments further support the 
conclusion that products 4 and 5 are each a mixture of diastereomers. 
The anaerobic reaction in H218O  
To understand the origin of the hydroxyls in products 2, 3, 4 and 5, we conducted 
the anaerobic reaction of soybean LOX-1 with 15S-HPETE in 18O-enriched water (80% 
H218O), followed by HPLC purification of the individual products, catalytic 
hydrogenation, TMS ether TMS ester derivatization, and GC-MS analysis.  
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Figure 61: 1H,1H-COSY NMR analysis of product 5 in d6-benzene. Shown is an 
expanded view of the region corresponding to olefinic protons and protons on 
hydroxylated carbons. Assignment of H-6 and H-5 has been aided by comparison with 
the NMR spectra of chemically synthesized 5-trans,trans-HETE lactone (data not shown).  
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In the mass spectrum of the derivatized pair of 8,15-diols with all-trans 
conjugated trienes (products 2 and 3) from the H218O reaction, the ions containing the 8-
hydroxyl were all shifted by +2 mass units (i.e., ions at m/z 303 to 305, 359 to 361 and 
489 to 491), while the m/z 173 fragment containing the 15-hydroxyl remained unchanged 
(Figure 62, 63). Quantitative analysis of the isotopic ratios revealed that the 8-hydroxyl 
derives exclusively from water, while the 15-hydroxyl derives from the 15-hydroperoxyl 
of the substrate. 
In accord with the results on the 8,15-diols, and in sharp contrast to the known 
mechanisms of formation of 5,15-diHETE via double oxygenation, GC-MS analysis of 
derivatized all-trans 5,15-diHETE (product 4), established that the 5-hydroxyl comes 
from water and the 15-hydroxyl from 15-hydroperoxyl group in the substrate, Figure 
64A. Ions containing the 5-hydroxyl were shifted by +2 mass units (to m/z 263, 313 and 
491), while m/z 173, the characteristic fragment ion of the 15-hydroxyl, remained 
unchanged.  
By contrast, GC-MS analysis of the derivatized product 5, the δ-lactone of all-
trans 5,15-diHETE, indicated no 18O incorporation in the molecule, Figure 64B. (The 
mass spectrum is identical to that of product 5 from H216O incubations). The lack of 18O 
in the δ-lactone ring clearly demonstrated that product 5 was not formed by lactonization 
of product 4. Instead, we surmise that the C-5 oxygen in the δ-lactone ring of product 5 
must derive from the free carboxylate group in the substrate. 
A cyclopropyl epoxide as the enzymatic product  
The formation of products 4 and 5 can be explained if the true enzymatic product 
is an allylic 14,15-epoxide with a cyclopropane ring (Figure 66, Discussion). This  
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Figure 62: GC-MS analysis of the TMS ether TMS ester of hydrogenated product 2 from 
the H218O incubation. 
 
 
Figure 63: GC-MS analysis of the TMS ether TMS ester of hydrogenated product 3 from 
the H218O incubation. 
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Figure 64: GC-MS analysis of TMS derivatized products 4 and 5 from the anaerobic 
reaction in H218O. (A) The mass spectrum of the TMS ether TMS ester derivative of 
product 4. (B) The mass spectrum of the TMS ether derivative of product 5. 
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epoxide is opened up in one of two ways. Either water reacts at the end of the conjugated 
system to yield product 4 (with corresponding incorporation of 18O from H218O at C-5), 
or nucleophilic attack by the free carboxylate yields the δ-lactone derivative with no 
involvement of water in the transformation. 
 
DISCUSSION 
 
Background of this study 
Soybean LOX-1 was the first LOX to be discovered and has since received the 
most extensive mechanistic studies among the LOX enzymes (5,171). Typically, the 
hallmarks of LOX catalysis, such as the antarafacial relationship between hydrogen 
abstraction and oxygen insertion, were first demonstrated for soybean LOX-1 and then 
recapitulated in studies on other LOX enzymes. One notable exception, however, is the 
LTA synthase-type activity. From a historical point of view, because no such chemistry 
had been described for soybean LOX-1, it was not immediately recognized at the time of 
the discovery of LTA4 that the same enzyme, 5-LOX, catalyzes the formation of 5S-
HPETE and LTA4. The recognition came a number of years later when it was 
demonstrated that both 5-LOX and LTA4 synthase activities involve stereoselective 
hydrogen abstraction as the initial step, always co-elute during purification, and are 
inhibited to similar extents by LOX inhibitors (172,173).   
LTA synthase activity and LOX dual specificity 
Both the primary LOX activity and the secondary LTA synthase activity start with 
hydrogen abstraction, yet at two different positions. Therefore, it has been suggested that 
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LTA synthase activity is a consequence of dual specificity, i.e., the ability of the enzyme 
to abstract hydrogens from two different positions and thus make two distinct 
hydroperoxides (173). Consistent with this suggestion, leukocyte 5-LOX gives the 8S-
hydroperoxide from 8,11,14-eicosatrienoic acid (compared with the 5S-hydroperoxide 
from arachidonic acid) (174,175). Similarly, mammalian 15-LOX-1 usually gives a 
mixture of 15S-HPETE and 12S-HPETE from arachidonic acid (176). However, dual 
specificity alone does not ensure LTA synthase type activity; for instance, the dual 
specificity of soybean LOX-1 is evidenced by the formation of 8S,15S-diHPETE and 
5S,15S-diHPETE in its double oxygenation reaction with 15S-HPETE (160), yet no LTA 
synthase type activity has ever been detected for this enzyme under the usual aerobic 
conditions.  
LTA synthase activity and active site oxygen  
We hypothesize that oxygen concentration in the enzyme active site is an 
additional factor that determines whether LTA synthase type activity will be present in a 
LOX or not, through influence on the rate of the competing process, double oxygenation. 
When oxygen concentration is low, as we would propose in the 5-LOX active site, double 
oxygenation barely occurs due to deprivation of oxygen co-substrate, so LTA synthase 
activity will occur without interference. By contrast, at high active site oxygen 
concentrations, as in soybean LOX-1, double oxygenation occurs so fast that LTA 
synthase type activity will be fully suppressed. To relieve this potential suppression of 
LTA synthase type activity imposed by molecular oxygen, here we performed the 
reaction of soybean LOX-1 with 15S-HPETE under anaerobic conditions. Consistent 
with our hypothesis, we observed under these conditions the formation of 8(RS),15S-
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Z,E,E,E-diHETEs, the expected hydrolysis products from 14,15-LTA4 (or the cis epoxide 
isomer, see below). This result strongly supports our view that the soybean LOX-1 has all 
the essential elements to fulfill the role of a LTA synthase, yet this potential has been 
obscured by the presence of high concentrations of oxygen in the active site, which 
favors the double oxygenation reaction.  
An oxygen channel in the LOX protein might normally target O2 to the correct 
position on the reacting substrate (10,177), or alternatively there could be an 
appropriately positioned oxygen pocket in the active site (11). Either way, oxygen could 
be well positioned for one substrate (e.g. arachidonic acid in mammalian 5-LOX) and out 
of place for another (5S-HPETE in 5-LOX), while adequately positioned for either 
arachidonic acid or 15S-HPETE in soybean LOX. It is expected that the Km(O2) for 
soybean LOX-1 using 15S-HPETE as substrate would be considerably lower than the 
Km(O2) for mammalian 15-LOX using the same substrate, or the Km(O2) for 5-LOX using 
5S-HPETE. These values for fatty acid hydroperoxide substrates remain to be 
determined. Yet, evidence does exist that suggests a high Km(O2) for LOX that normally 
exhibit LTA synthase activity; for example, a large Km(O2) can be deduced from the 
observation that potato 5-LOX shows double oxygenation activity with 5S-HPETE only 
under high oxygen pressures (162).  It would be of interest to test whether a similar 
switch occurs with mammalian 5-LOX or 15-LOX under hyperbaric conditions. 
The oxidation state of the enzyme involved in LTA synthesis  
Next, we questioned which enzyme form, Fe(III) or Fe(II) soybean LOX-1, is 
responsible for the formation of 8(RS),15S-Z,E,E,E-diHETEs. Although it is widely 
accepted that the Fe(III) LOX accounts for LTA synthesis, an alternative Fe(II) LOX 
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pathway, originally proposed for LT formation in fatty acid autoxidation (178) and in 
hemoglobin-catalyzed transformation of fatty acid hydroperoxides (179,180), is also 
feasible on purely chemical grounds (Figure 65). The key difference of the two pathways 
is the order of the two chemical steps, hydrogen abstraction and peroxide bond cleavage; 
while the Fe(III) LOX pathway involves hydrogen abstraction followed by peroxide bond 
cleavage, the Fe(II) LOX pathway employs the same two steps in the reverse order. To 
clarify this issue in the present case, we dissected the anaerobic reaction of soybean 
LOX-1 with 15S-HPETE into two components: one catalyzed by the Fe(II) enzyme and 
the other by the Fe(III) enzyme, using NDGA and 13S-HPODE to keep the enzyme 
ferrous and ferric, respectively. We found that 8(RS),15S-Z,E,E,E-diHETEs are formed in 
the presence of 13S-HPODE but not in the presence of NDGA, thus determining 
unambiguously that the Fe(III) enzyme is the catalytic species in the soybean LOX-1 
catalyzed formation of 14,15-LTA4 and the corresponding 8,15-diol hydrolysis products. 
Our result agrees well with the early studies using stereospecifically tritium-labeled 
arachidonic acid that established hydrogen abstraction as the first irreversible step in LT 
synthesis (172), and also agrees with the studies using LOX inhibitors that demonstrated 
the inhibitory effect of NDGA on LT formation from HPETEs, although at these early 
times the mechanism of inhibition of NDGA (159,173), i.e., by reduction of Fe(III) LOX 
to Fe(II) LOX,  had yet to be clarified (27). 
The proposed cyclopropyl epoxide intermediate leading to 5(RS),15S-all trans-diHETEs 
and the δ--lactone derivatives  
The most intriguing finding in the present study is probably the detection of the 
novel compounds, 5(RS),15S-all trans-diHETEs and the δ--lactone derivatives. Inspired 
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by the structural similarities of 5(RS),15S-all trans-diHETEs to 8(RS),15S-Z,E,E,E-
diHETEs, the shared involvement of the Fe(III) enzyme in the formation of both, and 
similar incorporations of H218O, we propose that the 5(RS),15S-all trans-diHETEs are 
also hydrolysis products of an unstable intermediate, formed in a mechanism with 
parallels to the synthesis of 14,15-LTA4. A feature of our proposal is involvement of first 
the ferric enzyme and then the ferrous species in activation at the two pentadiene units, 
followed by intramolecular coupling of two radicals to give un unstable epoxide which, 
upon hydrolysis, gives the 5,15-diols containing four trans double bonds. Notably, a 
directly analogous mechanism can explain LTA4 or 14,15-LTA4 synthesis. 
As illustrated in Figure 66, similar to 14,15-LTA4 formation, hydrogen 
abstraction by the Fe(III) enzyme is the initial step, but it occurs at C-7 rather than C-10 
to form a carbon-centered radical delocalized over the C5-C9 pentadiene. This initial step 
produces the Fe(II) enzyme which then induces homolytic cleavage of the O-O bond of 
the 15-hydroperoxide group to give an alkoxyl radical at the C11-C15 pentadiene. At this 
stage the reacting intermediate exists as an oxygen-centered and carbon-centered 
biradical. Due to its intrinsic instability, this biradical would rearrange, by reacting the 
oxygen-centered radical with the nearby double bonds to form an epoxide group and a 
second carbon- centered radical, followed by combination of the two carbon-centered 
radicals to form a new C-C bond, to give a covalently complete compound, an allylic 
14,15-epoxide with a cyclopropane ring comprised of C-9, C-10, and C-11, namely 
14,15-epoxy-[9,10,11-cyclopropyl]- eicosa-5Z,7E,13E-trienoic acid. 
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Figure 65: Two possible pathways of LTA formation on purely chemical grounds. 
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Figure 66: Proposed mechanism of formation of products 4 and 5. 
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Similar to other allylic epoxides, at non-alkaline pHs this cyclopropyl epoxide 
may react with even the weakest nucleophiles, such as water in aqueous solutions to give 
5(RS),15S-all trans-diHETEs, or the carboxylate group in the molecule itself to give the 
corresponding δ--lactones. As water is involved in the former but not the latter process, 
only the 5(RS),15S-diols and not the δ--lactones incorporate water at C-5, exactly what 
we found using H218O. Finally, as a subtle point of the proposed mechanism, the 
cyclopropane ring is formed only in the covalently complete final product, as opposed to 
in any radical intermediates, because such radical intermediates containing a 
cyclopropane ring and an adjacent radical would be highly energetically unfavorable 
(181).  
The stereochemistry of the epoxide group in the putative 14,15-LTA4 and the 
cyclopropyl epoxide intermediates cannot be determined based on the analysis of the 
hydrolysis products in the present study. Although perhaps not widely recognized, LOX-
catalyzed formation of the cis epoxy isomer of allylic epoxides has been documented and 
the cis epoxy isomer would hydrolyze to the same set of products as the trans epoxide 
isomer, with only a subtle difference in the product ratios (162).  
Concluding remarks 
In summary, our study demonstrates the competition between dioxygenation, 
which requires the presence of appropriately positioned molecular oxygen in the LOX 
active site, and leukotriene biosynthesis, which proceeds anaerobically. For an enzyme 
such as soybean LOX-1 in which O2 is readily available for dioxygenation reactions, 
leukotriene biosynthesis is not observed until the enzyme is placed in an anaerobic 
environment. Conversely, we surmise that in LOX enzymes in which leukotriene 
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synthesis occurs under aerobic conditions, molecular oxygen is less readily available in 
the active site. In the case of soybean LOX-1, the dioxygenase reactions on 15S-HPETE 
are initiated via hydrogen abstractions at C-7 and C-10, giving 5S,15S-diHETE and 
8S,15S-diHETE respectively, and the LTA synthase type of reactions are initiated in the 
same way under anaerobic conditions (Figure 67). The hydrogen abstraction at C-7 leads 
to formation of the novel cyclopropyl-containing epoxide, which in turn gives the 5,15-
diols with all-trans double bonds and the corresponding δ-lactones. 
In addition to driving reaction reaction initiated by the Fe(III) enzyme down the 
LT synthase pathway, a lack of active site oxygen may play a role in other non-canonical 
reactions of lipoxygenases. An example from the present study is formation by the Fe(II) 
enzyme of the threo-13-hydroxy-14,15-trans-epoxyalcohol, the 15-ketone and C15 
aldehyde. These reactions strongly resemble those of two unusual lipoxygenases that 
appear to be structurally intact and yet catalyze no detectable formation of fatty acid 
hydroperoxides with any natural polyunsaturated fatty acid. One of these, a specific LOX 
enzyme in maize (ZmLOX6) acts as a hydroperoxide lyase (129), forming aldehydes of 
the type found with the anaerobic soybean LOX-1. The other is the epidermal LOX-3 of 
mammalian skin, known from genetic studies to be required for proper differentiation in 
the epidermis and which displays hydroperoxide isomerase activity (37,96), forming 
epoxyalcohols and ketones, again similarly to the anaerobic soybean LOX-1. In both 
cases, a lack of available oxygen within the active site may contribute to both the lack of 
activity with natural fatty acids and the acquisition of new activities with fatty acid 
hydroperoxides. The concept of a limited access to oxygen within the lipoxygenase active 
site as a basis for new activities might also be extended to include the plant “type-II” 
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LOX enzymes such as soybean LOX-3 that catalyze mainly non-specific peroxidation of 
fatty acids and their esters and further conversion of the hydroperoxide products to 
ketones (127,128). In their case it appears that hydrogen abstraction is followed by 
release of the fatty acid radical and that reaction with oxygen occurs outside the LOX 
active site.  The enzyme, being left in the ferrous state, would in turn react with fatty acid 
hydroperoxides to give alkoxyl radicals that lead eventually to ketones. A lack of access 
to oxygen within the active site may prompt this outcome. 
Finally, we note the implications for the mechanism of leukotriene A4 synthesis 
based on the proposed mechanism of formation of the epoxy-cyclopropyl fatty acid. The 
involvement of both the ferric and ferrous iron and the production of a fleeting biradical 
species in both types of reaction are strongly implied. 
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Figure 67: Comparison of the aerobic and anaerobic reactions of soybean LOX-1 with 
15S-HPETE. Aerobic reaction is initiated by the H-7 and H-10 hydrogen abstractions 
(pro-R hydrogens, designated as in arachidonic acid rather than 15S-HPETE) with 15S-
HPETE in the reversed orientation, antarafacial oxygenation giving the 5S,15S-diHPETE 
and 8S,15S-diHPETE products, respectively (1,160,182). Anaerobically, analogous 
hydrogen abstractions can account for formation of the cyclopropyl epoxide and 14,15-
LTA4, respectively, followed by non-enzymatic hydrolysis to give the stable diol end 
products. 
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CHAPTER VI 
 
PARTIALLY RESOLVED ISSUES, OPEN QUESTIONS, AND FUTURE 
DIRECTIONS 
 
1. Why does not eLOX3 make a single product? In its classical reaction with 12R-
HPETE, the epoxyalcohol and 12-KETE are formed in a ratio of 60:40. Both derive from 
a common alkoxyl/epoxyallylic radical intermediate. Ketone is formed by loss of a 
hydrogen atom, whereas epoxyalcohol is formed via “oxygen rebound”. One is 
dehydration, the other isomerization. (A similar problem exists for allene oxide synthase, 
see ref. (183)) One possible explanation is that two orientations can be used by eLOX3 
with the same substrate. Consistent with this, I found that 9R-HPODE or 11R-HPETE is 
by eLOX3 converted to a mixture of a type A epoxyalcohol and 9-KODE, but 9R-
HPODE/lyso PC or 11R-HPETE/lyso PA (a large ester, head-first orientation prohibited) 
is converted by the enzyme nearly exclusively to the epoxyalcohol derivative (Figure 
68).  
Interestingly, I also found that Ala451Gly or Phe409Leu mutations in eLOX3 
specifically diminished type-A epoxyalcohol products while retaining type-B 
epoxyalcohol and ketone products from the reactions of eLOX3 with all fatty acid 
hydroperoxides tested, including 12R-HPETE, 15S-HPETE, 12S-HPETE, 8R-HPETE 
(methyl ester), 11R-HPETE and 9R-HPODE. (Although Ala451Gly eLOX3 converts 
15S-HPETE to mostly epoxyallylic hydroperoxides under aerobic conditions, its ability 
to make type-B epoxyalcohol and 15-KETE as the wild-type enzyme is revealed under 
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anaerobic conditions, Chapter II.) This suggests that formation of type-A epoxyalcohol is 
an event independent of formation of type-B epoxyalcohol and ketone, and the former is 
more readily perturbed by active site mutations.  
Finally, I noted that with the exception of 12S-HPETE, every R-hydroperoxide is 
transformed by eLOX3 to type-A epoxyalcohol, and every S-hydroperoxide to type-B 
epoxyalcohol. The mechanistic basis for this remains to be explored.  
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Figure 68: Reaction of human eLOX3 with 11R-HPETE/lyso PA. (A) UV scans. The 
reaction was carried out in 0.5 ml of 50 mM sodium phosphate pH 7.5. 11R-HPETE/lyso 
PA was synthesized by reacting Anabaena LOX with AA/lyso PA. After adding the 
enzyme, a scan was immediately taken (t ~ 15 s). The subsequent scans were taken every 
2 min. (B) RP-HPLC analysis. The reaction products were hydrolyzed to free acids by 
mild alkaline hydrolysis. Similar results were obtained using 9R-HPODE/lyso PC as 
substrate.  
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2. While the influence of substrate orientation on product specificity of eLOX3 is 
largely unexplored (Future Direction 1, above), the influence of substrate orientation on 
product specificity of conventional LOX enzymes has been studied extensively. From 
these and other studies, Dr. Coffa and Dr. Brash in this group have proposed a general 
model to explain the regio- and stereospecificity of most LOX enzymes (12). This model 
predicts that 9S-HPODE/lyso PC will not made by any LOX in reacting with LA/lyso 
PA, because “9S” specificity is associated with “head-first” substrate orientation, which 
is strongly disfavored by LA/lyso PA due to its bulky polar head group. In contrast to this 
prediction, in the reaction of Arabidopsis 9S-LOX with LA/lyso PA, I identified 9S-
HPODE/lyso PA as a major product (9S:9R~ 63:37) (Figure 69). Does this imply that at 
least some LOX enzymes have a U-shaped substrate channel with both ends open (17)?  
 
Figure 69A 
 
 
 
 
 178 
B 
 
C  
 
 
Figure 69: Reaction of Arabidopsis LOX with LA/lyso PC in the presence of 4-hydroxy-
TEMPO. The products were reduced with TPP and then hydrolyzed to free acids by mild 
alkaline hydrolysis. (A) SP-HPLC analysis. (B)&(C) Chiral HPLC analysis of 9-HODE 
and 13-HODE products respectively.  
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3. One finding that has intrigued me is that a specific epoxyalcohol is formed in the so-
called purple enzyme degradation (Purple enzyme refers to the complex between ferric 
soybean LOX-1 and 13S-HPODE, see Chapter I). Related to this reaction is the not well-
known linoleic acid-independent anaerobic reaction of soybean LOX-1 with 13S-
HPODE, which was reported to give a specific epoxyalcohol. Because the purple enzyme 
is in the ferric state and the enzyme after the degradation remains ferric, I once 
considered that the epoxyalcohol is made by the ferric enzyme rather than the ferrous 
enzyme, via a mechanism similar to that of hematin, from non-heme Fe3+ to Fe4+-OH, 
then back to Fe3+. However, there is no indication in the literature that the non-heme iron 
in LOX enzymes could exist in higher oxidation states. My repeated attempts to 
reproduce the purple enzyme degradation and the related LA-independent anaerobic 
reactions proved to be futile, and it seemed that I always obtained a mixture of 
epoxyalcohols rather than a single one. Possibilities include: 1) my enzyme brought from 
Cayman Chemical was in bad shape – this is not entirely impossible since I have detected 
a “gain-of-function” activity in the Cayman enzyme, which I will describe later; 2) in the 
early days, the standard protocol often stated acidification to pH 2-3 before extraction, 
and this might have selectively retained one epoxyalcohol and destroyed others.  
One explanation for linoleic acid-independent anaerobic reaction of soybean 
LOX-1 with 13S-HPODE is that whereas the ferrous enzyme reacts with the fatty acid 
hydroperoxide to give an alkoxyl/epoxyallylic radical, the ferric enzyme reacts with the 
fatty acid hydroperoxide to give a peroxyl radical. This hypothesis predicts that the 
epoxyallylic radical should readily combine with the peroxyl radical to give peroxide-
linked dimers. Using Cayman soybean LOX-1 (Cayman Chemical Item Number 60700), 
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I was able to identify a group of peroxide-linked dimers as the major products in its 
reaction with 13S-HPODE methyl ester. Kinetic measurements clearly showed that this 
reaction was catalytic. Addition of NDGA to the incubation resulted instead in self-
combination of the epoxyallylic radical forming C-C linked dimers, further suggesting 
that the ferric enzyme was involved in making the peroxyl radical. This finding 
fascinated me and was thus followed by extensive analytical chemical work that 
culminated in unambiguous identification of the structure of the major dimer by GC-MS, 
LC-MS, and NMR (Figure 70, Figure 71, LC-MS analysis of the hydrolyzed sample 
showed m/z 605.5, not shown). However, it seems that this reaction could not be 
reproduced using Sigma soybean LOX. Thus questions remain as to whether this 
observation was an artifact brought by impurities/additives in the “purified” Cayman 
soybean LOX-1 or was a bona fide reaction readily inhibited by impurities in the Sigma 
soybean LOX preparation.  
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Figure 70A 
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Figure 70B 
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Figure 70C 
 
Figure 70: GC-MS analysis of the major peroxide-linked dimer after catalytic 
hydrogenation and TMS derivatization. The major dimer was purified by both RP- and 
SP-HPLC. Hydrogenation reduces peroxide bonds and double bonds, and opens up the 
epoxide group. (A) Top: total ion trace. Bottom: selective ion trace at m/z 73, showing 
compounds with TMS group. (B) Mass spectrum of the eluate at 7.51 min, which 
identified the peak as 18:0, 13-OTMS. (C) Mass spectrum of the eluate at 8.16 min, 
which identified the peak as 18:0, 9-OTMS, 13-OTMS.  
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Figure 71: (A) 1H,1H-COSY NMR spectrum of the major peroxide-linked dimer from 
the anaerobic reaction of Cayman soybean LOX-1 with 13S-HPODE methyl ester. (B) 
Chemical structure of the compound as established by GC-MS (after catalytic 
hydrogenation), LC-MS (after alkaline hydrolysis), and NMR.  
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4. Almost every conjugated HPETE or HPODE is an eLOX3 substrate, how about 
bisallylic hydroperoxides (e.g., 7-HPETE, a major oxygenation product of eLOX3)? 
Cumene hydroperoxide? The alkoxyl radicals derived from these hydroperoxides show 
different chemistry from those derived from conjugated HPETEs. These experiments 
were considered in 2007, but were not actually done.  
 
5. An incidental finding: conversion of 13-cis,trans-HPODE by sodium dithionite to 9-
trans,trans-HODE (Figure 72). Sodium dithionite was newly purchased from Sigma-
Aldrich. 13-cis,trans-HODE did not react with sodium dithionite. What surprised me was 
1) that very little, if any, 13-trans,trans-HODE was formed in this reaction; 2) using 
newly purified [1-13C]-13S-HPODE, I found that ~ 50% radioactivity remained in the 
aqueous phase after acidification to pH 3 and extraction by methylene chloride. Control 
experiments showed that no radioactivity remained in the aqueous phase if sodium 
dithionite was omitted. The radioactive metabolite in the aqueous phase seemed not to be 
volatile and remains to be identified.  
 
 186 
 
Figure 72: SP-HPLC analysis of the reaction of 13-HPODE (100 µM) and sodium 
dithionite (1 mM) in 50 mM sodium phosphate pH 7.5. Incubation time was 30 min.  
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